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GENERAL INTRODUCTION  
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INTRODUCTION
Renal disease and the immune system
Chronic kidney disease (CKD) is a global problem with a worldwide prevalence of 
approximately 13% (1). The major causes of CKD are hypertension and diabetes (2). 
According to the ‘Kidney Disease, Improving Global Outcomes’ (KDIGO) guidelines, CKD 
is defined as a glomerular filtration rate (GFR) below 60 ml/min/1.73m2 for ≥3 months 
(3). Based upon the GFR, CKD is divided into 5 stages (3). When the GFR drops <15 ml/
min/1.73m2, also known as end-stage renal disease (ESRD), this is defined as renal failure 
(3). Patients with ESRD need renal replacement therapy (RRT) in the form of dialysis or 
renal transplantation, with the latter being the best option for RRT because it is associated 
with a better survival and quality of life compared with dialysis (4-6). Renal failure is 
associated with an impaired immune system and ESRD patients are known to be more 
susceptible to infections and show lower vaccination responses to vaccinations when 
compared with healthy individuals (7-10). Next to this, recent studies show that patients 
with ESRD show a prematurely aged T-cell immune system when compared with healthy 
individuals (11-13). 
Ageing of the circulatory T-cell compartment
With increasing age, there are several changes that occur in the (T-cell) immune system. 
Firstly, hematopoietic stem cells shift towards the myeloid progenitor line, which causes 
a decline in the lymphoid progenitor cells (14). Next to this, the thymus involutes, which 
leads to a decline in functional tissue and a decline in newly formed naive T cells (15). 
These newly formed naive T cells, also called recent thymic emigrants (RTEs), can be 
recognized by their expression of CD31 on their surface (16, 17). RTEs are also high in 
T-cell receptor excision circle (TREC) content (16, 18). TRECs arise during T-cell receptor 
(TCR) rearrangement in the thymus. During TCR rearrangement in the thymus, parts 
of DNA in the TCR loci will be deleted and circularized into these molecules (18). An 
interesting characteristic of these TRECs are that they are passed through to only 
one daughter cell during proliferation as they are located outside the nucleus and do 
not replicate during cell division (19) (Figure 1). Thus, dilution of the TREC content is 
informative about the proliferative history of T cells. This means that the frequency of 
RTEs and the TREC content give information about the thymic output and can be used as 
T-cell ageing parameters.
Furthermore, ageing also causes an increase in differentiation and proliferation of 
circulatory T cells. This will lead to phenotypical changes in T cells (Figure 2). Naive T cells 
will differentiate into memory T cells and these memory T cells will comprise the majority 
of the peripheral T-cell pool in the elderly (20, 21). This will eventually lead to the loss of 
the homing receptor CCR7, loss of CD27 and upregulation of PD-1 and CD57 (22-26). 
Next to this, it is also associated with the loss of the co-stimulatory molecule CD28 on 
the surface of (highly differentiated) memory T cells (27). This co-stimulatory molecule 
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binds to CD80/86 which is needed for a proper T-cell activation when the TCR binds to 
a major histocompatibility (MHC) peptide complex (28). When a T cell only binds to an 
antigen presented by an MHC molecule without the simultaneous stimulation of CD28, 
it will go into apoptosis or become anergic (28). These highly differentiated memory T 
cells, also defined as CD28null memory T cells, have a high cytotoxic potential and can 
already become activated by the recognition of an antigen without the need for co-
stimulation (27, 29). These T cells are present within both the CD4+ and CD8+ T-cell 
populations (23, 27, 29, 30). The CD4+CD28null T cells resemble CD8+CD28null T cells with 
regard to their properties. They are able to produce proinflammatory cytokines such as 
interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α), and have intracellular 
stores of granzyme B and perforin (23, 29-32). Circulatory CD4+CD28null T cells have 
been associated with various clinical outcomes. They are associated with unstable angina, 
atherosclerotic vascular events and risk for the development of (co-stimulatory blockade 
resistant) rejection after renal transplantation (29, 31, 33-36). Therefore, the presence of 
these cells plays an important role with regard to clinical outcomes in ageing individuals. 
Special attention needs to be given to infection with cytomegalovirus (CMV) with 
regard to the increased differentiation of T cells. CMV is a member of the herpesviridae 
family and has the largest genome of all the herpesviruses (37). The prevalence increases 
with age, which can be >60% among people who are over 40 years old (38). An infection 
is also influenced by ethnicity and wealth (38, 39). For example, the prevalence is higher 
in Hispanics and people with a low socioeconomic status (38, 39). An acute infection 
is usually asymptomatic, but might also be accompanied by symptoms that resemble 
infectious mononucleosis (40). After an acute infection, the virus remains latent within 
the body (41). CMV can lead to the appearance of late differentiated memory T cells, 
especially of memory T cells that lack the co-stimulatory molecule CD28 (21, 42, 43). 
Next to this, it has also been associated with an inversion of the CD4:CD8 ratio, lower 
relative telomere length of CD8+ T cells, and a decline in RTEs and TREC content 
(21, 44). Thus, CMV causes significant changes in the circulatory T-cell system that 
mimics ageing.
In addition to the increased differentiation, the increase in proliferation will also 
affect the telomere length of the circulatory T cells, leading to telomere attrition (45, 46) 
(Figure 3). 
Ageing of T cells within lymph nodes
Lymph nodes are oval shaped structures that are widely distributed throughout the human 
body and are connected with each other by lymphatic vessels. They are responsible for 
the circulation of lymph, which is a clear, plasma-like fluid that consists of leukocytes, 
bacteria, proteins and cellular waste products. Lymph enters the lymph node via afferent 
lymphatic vessels and leaves the lymph node via efferent lymphatic vessels. A lymph 
node is covered by a fibrous capsule. The tissue itself is further divided into a cortex 
and a medulla. The outer part of the cortex consists of lymphoid follicles, which mainly 
contain B cells. The deeper part of the cortex mainly consists of T cells and dendritic cells. 
The medulla consists of plasma cells that secrete antibodies and macrophages (47, 48). 
Lymph nodes are an important part of the immune system, as immune responses 
are initiated within lymph nodes. B cells will form germinal centers within the lymph 
node after recognizing an antigen via interaction with follicular dendritic cells. Dendritic 
cells in the deeper part of the cortex, will present antigens to naive T cells, which 
then will proliferate and differentiate into effector cells. Effector T cells will then leave 
the lymph node to migrate to the site of infection (47, 48). These responses can lead to 
an enlargement of the lymph node, which can be observed by the human eye. 
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Figure 1. The TRECs (indicated with the blue circles) are only passed through to one 
daughter cell after division.
Figure 2. Differentiation of T cells leads to loss of markers such as CCR7, CD28, CD27 and 
the upregulation of CD57 and PD-1. Figure 3. Every division leads to attrition of telomeres, which are located at each end of 
the chromatid.
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Until now, little is known about how ageing-related changes in circulatory T cells 
relate to changes within the lymph node (49, 50). Next to that, whether the circulatory 
changes in ESRD patients also occur within lymph nodes is unknown. Thus, an in depth 
analysis of these changes within lymph nodes is also needed for a more comprehensive 
understanding of the ageing T-cell immune system in ESRD patients.
THE AIM AND OUTLINE OF THIS THESIS
Patients need to use immunosuppressive agents after renal transplantation which has 
disadvantages. Immunosuppressive drugs will reduce the risk for rejection, but on 
the other hand will increase the risk for diabetes, hypertension, infections, and they 
can even be harmful for the renal allograft because of their nephrotoxicity (51, 52). 
Since ESRD patients show a prematurely aged, circulatory T-cell immune system (11, 12), 
the use of these agents will impair their immune system even more. Therefore, definition 
of predictive T-cell parameters with regard to the development of rejection and infection 
is needed for a more personalized immunosuppression. Next to this, the ageing-related 
changes in circulatory T cells need to be compared with the changes in lymph nodes, since 
immune responses are initiated within lymph nodes. Thus, the objective of this thesis 
is, to evaluate the predictive value of T-cell ageing parameters and clinical outcomes 
such as the development of rejection and infection, and also to compare the changes in 
circulatory T cells with changes in the lymph nodes.
Chapter 1 will introduce the premature ageing process in ESRD patients and the different 
T-cell ageing parameters that can be assessed from the blood and lymph nodes.
Chapter 2 will discuss the relationship between circulatory T-cell ageing parameters 
assessed prior to renal transplantation and the development of acute allograft rejection 
within three months after renal transplantation.
Chapter 3 will describe the alloreactive potential of CD4+CD28null T cells, as these cells 
were associated with a reduced risk for rejection after renal transplantation.
Chapter 4 will assess the relationship between circulatory T-cell ageing parameters and 
the development of opportunistic and serious infections after renal transplantation.
Chapter 5 will describe how ageing-related changes in circulatory T cells relate to changes 
in the T-cell composition of lymph nodes.
Chapter 6 will evaluate the relationship between the development of early acute rejection 
after renal transplantation and the T-cell composition of the lymph node prior to renal 
transplantation. Next to this the alloreactivity of T cells isolated from lymph nodes and 
peripheral blood were also evaluated and compared.
Chapter 7 will summarize and discuss all the obtained results
Chapter 8 will show a Dutch summary of the acquired results
Chapter  2
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ABSTRACT
Background
End-stage renal disease patients have a dysfunctional, prematurely aged peripheral T-cell 
system. Here we hypothesized that the degree of premature T-cell ageing before kidney 
transplantation predicts the risk for early acute allograft rejection (EAR).
Methods
222 living donor kidney transplant recipients were prospectively analyzed. EAR was defined 
as biopsy proven acute allograft rejection within 3 months after kidney transplantation. 
The differentiation status of circulating T cells, the relative telomere length and the number 
of CD31+ naive T cells were determined as T-cell ageing parameters.
Results
Of the 222 patients analyzed, 30 (14%) developed an EAR. The donor age and the historical 
panel reactive antibody score were significantly higher (p=0.024 and p=0.039 respectively) 
and the number of related donor kidney transplantation was significantly lower (p=0.018) 
in the EAR group. EAR-patients showed lower CD4+CD28null T-cell numbers (p<0.01) and 
the same trend was observed for CD8+CD28null T-cell numbers (p=0.08). No differences 
regarding the other ageing parameters were found. A multivariate Cox regression analysis 
showed that higher CD4+CD28null T-cell numbers were associated with a lower risk for 
EAR (HR: 0.65, p=0.028). In vitro, a significant lower percentage of alloreactive T cells was 
observed within CD28null T cells (p<0.001).
Conclusion
Immunological ageing-related expansion of highly differentiated CD28null T cells is 
associated with a lower risk for EAR.
INTRODUCTION
Loss of renal function leads to retention of uremic molecules and cytokines, which 
creates oxidative stress and inflammation (53). The resulting pro-inflammatory uremic 
environment underlies the dysfunctional T-cell immunity of end-stage renal disease (ESRD) 
patients (54). The major changes in the peripheral T-cell composition are T-lymphopenia, 
increased T-cell differentiation and loss of telomere length, the latter indicating a history 
of enhanced T-cell replication (55).
The T-lymphopenia is largely due to a loss of naive (antigen-inexperienced) T cells, 
which show signs of increased activation and are more prone to apoptosis (55). This loss 
of circulating naive T cells runs in parallel with a decrease in newly formed naive T cells, 
known as recent thymic emigrants (RTEs, indicating a premature involution of the thymus). 
In combination with an expanded, more differentiated memory T-cell compartment, 
this leads to a relatively large decrease in the percentage of circulating naive T cells 
(55, 56). The highly differentiated memory T cells are characterized by a loss of the co-
stimulatory molecule CD28, making them less dependent on co-stimulation to become 
activated (27). Moreover, these cells are known to have a reduced telomere length due to 
their numerous cell divisions (30, 55, 57).
The uremia-associated changes in the composition of the peripheral T-cell 
compartment resemble the physiological changes in the ageing immune system of elderly 
healthy individuals, (13, 20, 58) which leads to the concept of ESRD-related premature 
immunological ageing. This was confirmed when a combined analysis of the thymic 
output, differentiation status and the telomere length of T cells in ESRD patients was 
performed and the results were compared to healthy individuals over a wide age 
range (55). A consistent pattern of premature immunological ageing was observed with 
a discrepancy of 15-20 years between the immunological age of T cells of ESRD patients 
compared to their chronological age (12, 55). This prematurely aged T-cell system of 
ESRD patients offers at least a partial explanation for the increased susceptibility to 
infections (7), reduced vaccination response (8-10, 59), increased prevalence of 
malignancies (60, 61) and may also be a non-classical risk factor for cardiovascular 
diseases (62-65). 
A prematurely aged T-cell system leading to impaired T-cell immunity may also 
reduce the risk for acute rejection after kidney transplantation, but this has not been 
systematically studied. In addition, most studies that have assessed the circulating T-cell 
compartment in relation to acute rejection have only demonstrated percentages of cells 
(66, 67). This can lead to erroneous conclusions given the complex changes in all T-cell 
subsets and for example expansion of memory T cells may be interpreted as a reduction 
in the number of naive T cells and vice versa.
In this study, we hypothesized that the degree of premature T-cell ageing, based on 
the absolute number of differentiated T cells, thymic output and telomere length, prior 
to kidney transplantation (KT) is associated with the risk for early acute allograft rejection 
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(EAR) in kidney transplant recipients. Based upon our analyses we observed that T-cell 
differentiation status was associated with the risk for EAR after KT.
MATERIALS AND METHODS
Study population
All patients participated in a randomized-controlled clinical trial with the primary aim 
to study the efficacy of a genotype-based approach to tacrolimus dosing (Dutch trial 
registry number NTR 2226; http://www.trialregister.nl/trialreg/index.asp). All patients 
gave written informed consent to participate in the clinical trial, as well as for the sub-
study, which is presented here. None of the transplant donors were from a vulnerable 
population and all donors or next of kin provided written informed consent that was 
freely given. The study was approved by the Medical Ethical Committee of the Erasmus 
MC (MEC number 2010-080, EudraCT 2010-018917-30). This study was conducted in 
accordance with the Declaration of Helsinki.
All patients undergoing a living-donor KT in the period from 1 November 2010 to 1 
October 2013 were considered for participation in this study. This study included all ESRD 
patients with various causes of chronic kidney disease (CKD) (Table 1). Patients were 
excluded if they were younger than 18 years and if they received immunosuppressive 
medication (except for glucocorticoids) within 28 days prior to transplantation.
All patients received induction therapy with basiliximab (20 mg i.v. on day 0 and 
day 4), tacrolimus (aiming for predose concentrations of 10-15 ng/mL in weeks 1-2, 8-12 
ng/mL in weeks 3-4, and 5-10 ng/mL, thereafter), mycophenolate mofetil (starting dose 
of 1 g b.i.d., aiming for predose concentrations of 1.5 – 3.0 mg/L), and glucocorticoids. 
All patients received 50 mg prednisolone b.i.d. intravenously on days 0-3. Thereafter, 20 
mg oral prednisolone was started and subsequently tapered to 5 mg at month 3.
We determined clinical variables such as age at time of transplantation, gender, 
CMV-seropositivity, anti-CMV IgG titer, human leukocyte antigen (HLA) class I and 
class II mismatches, current and historical panel reactive antibody (PRA) score, warm 
ischemia time (WIT), number of previous kidney transplantations, preemptive KT (defined 
as receiving a kidney before the start of renal replacement therapy (RRT)) and related 
KT (defined as receiving a kidney from a genetically related donor) (Table 1). The HLA-
typing was assessed according to the international standards (American Society for 
Histocompatibility and Immunogenetics/the European Federation for Immunogenetics) 
using serologic and DNA-based techniques. The PRAs were determined at the laboratory 
of the blood bank in Leiden, the Netherlands. In all transplantations the complement 
dependent cross match was negative, but flowcytometry based cross matches were 
not performed.
We defined EAR as the development of biopsy-proven acute allograft rejection 
according to the Banff criteria (68) within 3 months after KT.
PBMCs isolation
By using Ficoll-Paque Plus (GE healthcare, Uppsala, Sweden), peripheral blood mononuclear 
cells (PBMCs) were isolated from heparinized blood samples drawn from KT-recipients 
the day before KT. The isolated PBMCs were stored at –150°C with a minimum amount 
of 10×106 cells per vial for further experiments.
Absolute numbers of CD4+ and CD8+ T cells and T-cell differentiation 
status by FACS analysis
To determine the absolute numbers of the different lymphocyte populations from blood, 
a Trucount staining was done. In this protocol, 20 µl of the 6-color TBNK reagent (BD 
Multitest™, BD, Erembodegem, Belgium) was used in combination with a BD Trucount™ 
tube (BD) and 50 µl of EDTA blood. This tube contains a number of beads (i.e. bead 
count; lot-specific) and enables calculation of absolute numbers of cells per µl of blood. 
The 6-color TBNK reagent contains phycoerythrin (PE)-labeled anti-CD45, AmCyan-
labeled anti-CD19, PE-Cy7-labeled anti-CD3, Peridinin chlorophyll (PerCP)-labeled 
anti-CD4, fluorescein isothiocyanate (FITC)-labeled anti-CD8 and allophycocyanin-Cy7 
(APC-Cy7)-labeled anti-CD16/CD56. 
In addition, a whole blood staining was performed to determine the T-cell 
differentiation status (55, 69). Briefly, whole blood was stained with AmCyan-labeled 
anti-CD3 (BD) in combination with pacific blue (PB)-labeled anti-CD4 (BD) and APC-Cy7-
labeled anti-CD8 (BD). T cells were defined as CD4+ or CD8+ and further defined into 
four different subsets based on their expression of CCR7 and CD45RO after staining 
using FITC-labeled anti-CCR7 (R&D systems, Uithoorn, The Netherlands) and APC-labeled 
anti-CD45RO (BD). Naive T cells were identified as CCR7+ and CD45RO–, central memory 
(CM) cells as CCR7+ and CD45RO+, effector memory (EM) cells as CCR7– and CD45RO+ 
and the highly differentiated effector memory CD45RA+ (EMRA) cells as CCR7– and 
CD45RO–. T-cell differentiation is associated with loss of CD28 expression on the cell 
surface. Numbers of CD28– (or CD28null) T cells within the T-cell subsets were determined 
by staining with PerCP-Cy5.5-labeled anti-CD28 (BD). Recent thymic emigrants (RTEs) 
were identified by the expression of CD31 within the naive T-cell pool upon staining with 
PE-labeled anti-CD31 (Biolegend, Europe BV, Uithoorn, the Netherlands). Samples were 
measured at the FACSCanto II (BD) acquiring at least 5x104 lymphocytes and analyzed 
using FACS Diva software version 6.1.2 (BD) (55, 69).
Telomere Length Assay
Flow fluorescent in situ hybridization (flow-FISH) was performed to determine the relative 
telomere length (RTL) of CD4+ and CD8+ T cells. PBMCs were isolated and stained with 
either CD4-biotin (Beckman-Coulter, BV, Woerden, the Netherlands) or CD8-biotin 
(Biolegend) followed by staining with streptavidin-Cy5 (Biolegend). The PBMCs were fixed 
and permeabilized (Invitrogen Life Technologies, Bleiswijk, the Netherlands) and by using 
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the telomere FITC-labeled PNA-kit (DakoCytomation, Heverle, Belgium) the telomere 
length was determined. The sub cell-line 1301 of CCRF-CEM (human T-cell leukemia, 
Sigma-Aldrich, Zwijndrecht, the Netherlands, ECACC catalogue number 85112105) 
known for its long telomeres, served as an internal positive control. After acquisition 
of the samples on the FACSCanto II (BD) and analysis using FACS Diva software version 
6.1.2 (BD), the RTL of the CD4+ and CD8+ T cells was calculated through the next 
formula (69, 70): 
Cytokine producing alloantigen-stimulated T cells
To determine frequencies of alloantigen-specific (cytokine-producing) T cells prior to 
transplantation, we used the CD137 multi-parameter flowcytometric assay as published 
recently (71). PBMCs of a kidney transplant recipient were stimulated in presence of 
co-stimulation (αCD49d, 1 µg/mL; BD) with or without T cell-depleted (>98% pure) 
donor PBMCs at a 1(5x106):1(5x106) ratio for 24 hours of which the last 12 hours were 
in presence of Brefeldin A (Golgiplug, BD) and monensin (Golgistop, BD). A distinction 
between donor and recipient’s cells is enabled by depleting the donor PBMC for CD3+ T 
cells, i.e. CD3+ T cells are derived from the recipient. Subsequently, the cell surface was 
stained using AmCyan-labeled anti-CD3 (BD), APC-Cy7-labeled anti-CD8 (BD) and PerCP-
Cy5.5-labeled anti-CD28 (BD) in order to visualize where the cytokine producing T cells 
are located. Following fixation and permeabilization, CD137 and cytokines were stained 
intracellular using APC-labeled anti-CD137 (BD), PE-labeled anti-interferon (IFN)-γ (BD) 
and FITC-labeled anti-interleukin (IL)-2 (BD). At least 0.5-1×106 viable CD3+ T cells were 
acquired on the FACS Canto II. Alloantigen-specific cytokine producing T cells were 
corrected for the cytokine signal observed in the absence of donor T-cell-depleted PBMC 
stimulation. Samples were measured on the FACSCanto II (BD) and analyzed using FACS 
Diva software version 6.1.2 (BD).
Statistical analysis
All variables are presented as medians with interquartile ranges. The difference between 
continuous variables was analyzed with the Mann–Whitney U test. The difference 
between categorical variables was analyzed either with the Pearson’s chi-squared test 
or with the Fisher’s exact test depending on the expected values in any of the cells of 
a contingency table. The latter was used when the expected values were lower than 5 
in any of the cells. For the assessment of an association between clinical/immunological 
variables and the presence of EAR, the Cox proportional hazards model was used. Next 
to this, a Kaplan-Meier curve was created for the assessment of EAR free survival rate 
stratified for one of the T-cell ageing parameters. The significance level (p-value) was 
determined.  The  sub  cell‐line  1301  of  CCRF‐CEM  (human  T‐cell  leukemia,  Sigma‐Aldrich, 
Zwijndrecht,  the  Netherlands,  ECACC  catalogue  number  85112105)  known  for  its  long 
telomeres,  served  as  an  internal  positive  control.  After  acquisition  of  the  samples  on  the 
FACSCanto II (BD) and analysis using FACS Diva software version 6.1.2 (BD), the RTL of the CD4+ 
and CD8+ T cells was calculated through the next formula (69, 70):  
 
��� � �median	FL1	sample	cells	with	probe	 � median	FL1	sample	cells	without	probe� � ���	�����	��	�������	�� ��������median	FL1	control	cells	with	probe	 � median	FL1	control	cells	without	probe� 	� ���	�����	��	������	�� 1������ 	� 1�� 
 
Cytokine producing alloantigen‐stimulated T cells 
To  determine  frequencies  of  alloantigen‐specific  (cytokine‐producing)  T  cells  prior  to 
transplantation, we used the CD137 multi‐parameter flowcytometric assay as published recently 
(71).  PBMCs  of  a  kidney  transplant  recipient were  stimulated  in  presence  of  co‐stimulation 
(αCD49d,  1  µg/mL;  BD)  with  or  without  T  cell‐depleted  (>98%  pure)  donor  PBMCs  at  a 
1(5x106):1(5x106) ratio for 24 hours of which the last 12 hours were in presence of Brefeldin A 
(Golgiplug, BD) and monensin (Golgistop, BD). A distinction between donor and recipient’s cells 
is enabled by depleting the donor PBMC for CD3+ T cells,  i.e. CD3+ T cells are derived from the 
recipient. Subsequently, the cell surface was stained using AmCyan‐labeled anti‐CD3 (BD), APC‐
Cy7‐labeled anti‐CD8  (BD) and PerCP‐Cy5.5‐labeled anti‐CD28  (BD)  in order  to visualize where 
the cytokine producing T cells are  located. Following fixation and permeabilization, CD137 and 
cytokines  were  stained  intracellular  using  APC‐labeled  anti‐CD137  (BD),  PE‐labeled  anti‐
interferon  (IFN)‐γ  (BD)  and  FITC‐l beled  anti‐interleukin  (IL)‐2  (BD).  At  least  0.5‐1×106  viable 
CD3+ T cells were acquired on the FACS Canto II. Alloantigen‐specific cytokine producing T cells 
were corrected for the cytokine s gnal observed  in the absence of donor T‐cell‐depl ted PBMC 
stimulation. Samples were measured on  the FACSCanto  II  (BD) and analyzed using FACS Diva 
software version 6.1.2 (BD). 
 
Statistical analysis 
All  variables  are  presented  as  medians  with  interquartile  ranges.  The  difference  between 
continuous  variables was  analyzed with  the Mann–Whitney  U  test.  The  difference  between 
categorical variables was analyzed either with the Pearson’s chi‐squared test or with the Fisher’s 
exact test depending on the expected values in any of the cells of a contingency table. The latter 
was used when the expected values were lower than 5 in any of the cells. For the assessment of 
an  association  between  clinical/immunological  variables  and  the  presence  of  EAR,  the  Cox 
proportional hazards model was used. Next  to this, a Kaplan‐Meier curve was created  for  the 
assessment  of  EAR  free  survival  rate  stratified  for  one  of  the  T‐cell  ageing  parameters.  The 
significance level (p‐value) was two‐tailed and 0.05 was used for all analyses. Statistical analyses 
two-tailed and 0.05 was used for all analyses. Statistical analyses were performed using 
SPSS® version 21.0 for Windows® (SPSS Inc., IL, USA). T-cell subset graphs were created 
using GraphPad Prism 5 (CA, USA).
RESULTS
Patient characteristics
We enrolled 222 consecutive patients who received a kidney transplant from a living 
donor. Patient characteristics are shown in Table 1. Of the 222 patients analyzed, 30 
(14%) had an EAR. The majority of the rejections were classified as grade II (67%), 30% 
were classified as grade I and only one rejection was classified as grade III. The median 
age of the patients was 57 years and the median donor age was 53 years. The donors 
were significantly older in the EAR group with a median age of 58 years compared to 
a median age of 52 years in the no rejection group (p=0.024). The majority of the patients 
(92%) received a donor kidney for the first time, 14 patients (6%) for the second time and 
three patients (1%) for the third time. Of the 30 patients who developed EAR, 11 (37%) 
received T-cell depletion therapy consisting of either alemtuzumab subcutaneously or 
rabbit anti-thymocyte globulin (rATG) intravenously. Four patients had a transplantectomy 
within the first 3 months after transplantation. Two of these patients had a therapy-
resistant cellular acute rejection within the first week after KT. The other two patients 
were in the no rejection group and the graft was removed due to vascular problems that 
occurred during the transplantation procedure. 
The historical PRA score was significantly higher in the EAR group compared with 
the no rejection group (p=0.039). The relative number of genetically related KT was 
significantly lower in the EAR group (20% vs 43%, p=0.018). Other potential risk factors 
for acute rejection, like number of HLA mismatches or previous kidney transplantation, 
did not associate with EAR in this patient group.
Patients with EAR have a lower number of CD4+CD28null T cells prior to KT
The CD4+ and CD8+ T-cell differentiation status of both patient groups was determined 
prior to KT (Figure 1). In S1 Figure, typical examples of the gating strategy are depicted 
for the flowcytometric analysis of the CD4+ and CD8+ T-cell population, respectively. No 
significant differences were found in the number of CD4+ T cells (Figure 1A) between 
the EAR group and no rejection group. Moreover, the number of naive, memory, CM 
and EM (Figure 1B-1E) was not significantly different. Interestingly, compared to the no 
rejection group, the EAR group had significant lower number of CD28null T cells within 
the CD4+ T-compartment (21 cells/µl vs. 7 cells/µl, p<0.01, Figure 1F).
The total number of CD8+ was not significantly different between the two patient 
groups (Figure 2A). The number of naive, memory and CM, EM and EMRA (Figure 2B-2F) 
CD8+ T cells did also not show any significant differences between the two groups. 
Furthermore, the EAR group tended to have a lower number of CD28null CD8+ T cells 
(p=0.08, Figure 1G) compared to the no rejection group.
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Even though we mainly focused on absolute cell numbers, we also analyzed 
percentages of the different T cell subsets to provide a better comparison with previous 
studies. These analyses showed similar findings (S1 Table). Again, significant higher 
percentages of CD4+CD28null T cells were seen in the no rejection group (p=0.011). Next 
to this, (a tendency for) higher percentages of CD4+ and CD8+ CM T cells were seen in 
the EAR group (p=0.055 and p=0.005 respectively).
Table 1. Patient characteristics
KT Patients (n=222)
No Rejection 
(n=92) (86%)
Early Rejection 
(n=30) (14%) P
Age recipient 57 (46 – 64) 55 (47 – 63) 0.60
Age Donor 52 (40 – 62) 58 (50 – 65) 0.024
Male gender recipient 118 (61%) 14 (63%) 0.84
Male gender donor 94 (49%) 13 (43%) 0.57
CMV-seropositivity recipient 118 (61%) 15 (50%) 0.23
CMV-serostatus donor/recipient
-/- 42 (22%) 10 (33%) 0.17
-/+ 38 (20%) 5 (17%) 0.69
+/- 32 (17%) 5 (17%) 1.00
+/+ 80 (42%) 10 (33%) 0.39
Anti-CMV IgG titer recipient (AU/mL) 65 (42 – 105) 58 (47 – 86) 0.75
Mismatch HLA class I 2 (2 – 3) 3 (2 – 3) 0.15
Mismatch HLA class II 1 (1 – 2) 1 (1 – 2) 0.31
Mismatch HLA class I and II 4 (3 – 5) 4 (3 – 5) 0.11
PRA current (%) 0 (0 – 4) 0 (0 – 4) 0.52
PRA historic (%) 4 (0 – 4) 4 (0 – 29) 0.039
Amount of KT 1 (1 – 1) 1 (1 – 1) 0.63
Warm ischemia time 20 (16 – 24) 21 (16 – 25) 0.69
Cause of CKD
Nephrosclerosis/atherosclerosis/hypertension 44 (23%) 7 (23%) 0.96
Primary glomerulopathies 26 (14%) 4 (13%) 1.00
Diabetes 41 (21%) 2 (7%) 0.06
Urinary tract infections/stones 5 (3%) 1 (3%) 0.59
Reflux nephropathy 9 (5%) 1 (0%) 1.00
Polycystic Kidney Disease 33 (17%) 7 (23%) 0.42
Other 26 (14%) 5 (17%) 0.58
Unknown 8 (4%) 3 (10%) 0.17
Pre-emptive KT 75 (39%) 17 (57%) 0.07
Genetically-related KT 82 (43%) 6 (20%) 0.018
Acute rejection type
Cellular rejection 25 (83%)
Antibody-mediated rejection 1 (3%)
Mixed rejection 4 (13%)
Data are presented as medians (interquartile range).
No differences in relative telomere length and RTEs between the EAR 
group and no rejection group prior to KT
As a marker for the proliferative history, the RTL of the CD4+ and CD8+ T cells was 
determined. For both T-cell subsets no significant differences were found between 
the EAR group and the no rejection group regarding the RTL (Table 2). 
The number and percentages of RTEs were identified by the expression of CD31 
within the naive T-cell pool. No significant differences for CD4+ or CD8+ T cells were found 
between the two groups prior to KT (Table 2).
Donor age, historical PRA, a related kidney donation and absolute 
numbers of CD4+CD28null T cells are related with the risk for EAR
The results of the univariate Cox regression analysis of the patient characteristics are 
presented in Table 3. This analysis showed that receiving an older donor kidney was 
associated with a higher risk for EAR (HR: 1.41, p=0.011). Besides this, a higher historical 
PRA score was also associated with a higher risk for EAR (HR:1.11, p=0.001). Receiving 
a donor kidney from a relative reduced the risk for EAR (HR: 0.36, p=0.025).
The univariate Cox regression analysis of the T-cell subsets showed that a higher 
number of absolute CD4+CD28null T cells, i.e. having a more differentiated CD4+ T-cell 
compartment, was associated with a lower risk for EAR (HR: 0.65, p=0.025). In contrast, 
the number of CD8+CD28null T cells was not associated with the risk for EAR (HR: 0.98, 
p=0.420). Furthermore, higher percentages of CD4+CD28null T cells were also associated 
with a lower risk for rejection (HR: 0.92; p=0.047). However, higher percentages of CD8+ 
CM T cells, representative of having a less differentiated memory compartment, were 
associated with a higher risk for EAR (HR: 1.05; p=0.035).
A multivariate Cox regression analysis was performed with the three aforementioned 
clinical characteristics (i.e. donor age, historical PRA and a related kidney donation) 
as covariates (Table 4). In accordance with the univariate analysis, a higher absolute 
number of CD4+CD28null T cells was associated with a lower risk for EAR (HR: 
0.65, p=0.028). Again, no association could be observed between the number 
CD8+CD28null T cells and the risk for EAR (HR: 0.99, p=0.415). Next to this, only 
the percentages of CD4+CD28null T cells were associated with the risk for EAR (S2 Table). 
Higher percentages of these cells were also associated with a lower risk for EAR 
(HR: 0.91; p=0.036).
Furthermore, we generated a Kaplan-Meier curve with the EAR free survival stratified 
for the tertiles of CD4+CD28null T cells (Figure 3). This analysis showed that high numbers 
of these cells were correlated with a significant higher EAR free survival rate compared 
with intermediate and low numbers of these cells (p=0.008 and p=0.009 respectively).
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Figure 1. CD4+ T-cell differentiation status prior to KT. Absolute numbers of (A) total, (B) 
naive, (C) memory, (D) CM, (E) EM and (F) CD28null CD4+ T cells are shown for the no rejection 
(white boxplot, n=192) and EAR (red boxplot, n=30) group of patients. Significant differences were 
calculated and shown (*p<0.05, **p<0.01, **p<0.001).
Figure 2. CD8+ T-cell differentiation status prior to KT. Absolute numbers of (A) total, (B) naive, 
(C) memory, (D) CM, (E) EM, (F) EMRA and (G) CD28null CD8+ T cells are shown for the no rejection 
(white boxplot, n=192) and EAR (red boxplot, n=30) group of patients. Significant differences were 
calculated and shown (*p<0.05, **p<0.01, **p<0.001).
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Table 2. RTL and RTEs content before kidney transplantation in patients with or without rejection 
within the first 3 months
KT Patients (n=222)
No Rejection (n=92) 
(86%)
Early Rejection (n=30) 
(14%) P
RTL of CD4+ T cells 12.1 (9.1 – 15.0) 11.5 (10.0 – 13.3) 0.90
RTL of CD8+ T cells 11.4 (9.2 – 15.3) 11.1 (10.4 – 14.4) 0.83
CD31+CD4+ naive T-cell numbers (/µl) 106.5 (56.7 – 207.4) 104.3 (77.0 – 192.9) 0.99
CD31+ within CD4+ naive T-cells (%) 66.4 (55.1 – 75.1) 62.2 (53.7 – 76.8) 0.69
CD31+CD8+ naive T-cell numbers (/µl) 55.4 (24.1 – 566.3) 65.0 (12.8 – 203.9) 0.80
CD31+ within CD8+ naive T-cells (%) 97.7 (94.4 – 98.9) 97.9 (93.9 – 99.5) 0.41
Data are presented as medians (interquartile range). RTL: Relative Telomere Length, RTEs: Recent 
thymic emigrants.
Table 3. Hazard ratios for the clinical characteristics in relation to early acute allograft rejection 
(univariate analysis).
HR 95%CI P
Age donor (decades) 1.41 1.09 – 1.85 0.011
PRA historic (%) 1.11 1.04 – 1.18 0.001
Genetically related KT 0.36 0.15 – 0.88 0.025
CD4 positive CD28null T cells (cells/µL) 0.65 0.45 – 0.95 0.025
CD8 positive CD28null T cells (cells/µL) 0.98 0.94 – 1.03 0.420
CD4 positive central memory T cells (%) 1.02 1.00 – 1.04 0.124
*P<0.05, **P<0.01, ***P<0.001. CI: confidence interval, HR: hazard ratio. Age of the donor is presented 
in decades, PRA historic is presented with steps of 5%, and the CD4 positive and the CD8 positive 
CD28null cells are presented with steps of 20 cells/μL.
Table 4. HRs for the T-cell parameters in relation to early acute allograft rejection (multivariate analysis).
HR 95%CI P
Age donor (decades) 1.40 1.06 – 1.84 0.016
PRA historic (%) 1.13 1.06 – 1.21 <0.001
Genetically related KT 0.47 0.19 – 1.17 0.102
CD4 positive CD28null T cells (cells/µL) 0.65 0.45 – 0.96 0.028
*P<0.05, **P<0.01, ***P<0.001. CI: confidence interval, HR: hazard ratio. The CD4 positive and 
the CD8 positive CD28null cells are presented with steps of 20 cells/μL. Covariates: age donor, PRA historic, 
related KT.
Alloantigen-specific T cells predominantly co-express CD28
To obtain more insight between the association of highly differentiated T cells and the risk 
for EAR, a multiparameter flowcytometric assay (i.e. combining intracellular cytokine 
staining with cell surface markers) (72) was performed upon alloantigen stimulation 
of PBMCs obtained from kidney transplant recipients prior to kidney transplantation 
(Figure 4). In S2 Figure a representative example of the gating strategy is shown of 
the dissection of alloantigen-specific (CD137+ and CD137+ IL-2+ or IFN-γ+) CD4+ T cells 
into a CD28null or CD28+ T-cell compartment. A similar FACS-analysis was performed for 
the CD8+ T-cell population. All CD3+ T cells are of patient’s origin, as the donor cells were 
depleted of T cells prior to stimulation.
First, the frequency of alloantigen-specific CD137-expressing T cells was determined 
in the CD4+ T-cell compartment and these were mainly CD28+ (i.e. 72.4% vs 27.6%, 
p<0.001, Figure 4A). In addition, the CD28+ T cells contained more IL-2 (86.9% vs 13.1%, 
p<0.001) and IFN-γ (i.e. 65.1% vs. 34.9%, p<0.001) producing alloantigen-specific T 
cells compared to the CD28null fraction (Figure 4B and 4C) upon alloantigen-stimulation.
Similar results were found for the CD8+ T cells. Upon alloantigen-stimulation, 
the CD137+CD8+ T-cells were mainly located within the CD28+ T cells (i.e. 60.4% vs 
39.6%, p<0.001, Figure 4D). A higher proportion of these cells were also able to produce 
more IL-2 compared to their CD28null counterparts (i.e. 72.4% vs 27.6%, p<0.001) and 
IFN-γ (i.e. 57.4% vs 42.6%, p<0.01) (Figure 4E and 4F).
Figure 3. Tertiles of CD4+CD28null T cells and EAR free survival. Kaplan-Meier curve representing 
EAR free survival rate against time after kidney transplantation in days. The curves represent 
the tertiles of CD4+CD28null T cells. Low represents <4.33 cells/μl, intermediate represents 4.33–36.67 
cells/μl and high represents >36.67 cells/μl. These groups were created based upon the frequencies 
of the cell numbers in our cohort and were divided into three equal groups.
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Figure 4. Cytokine producing alloantigen-stimulated T cells. First, the frequency of CD137+ 
cells within CD4+ T-cell population was determined (blue boxplot) in ESRD patients. These cells were 
divided into (A) a CD28+ (light green boxplot) and a CD28null subset (dark green boxplot). Next, 
the frequency of IL-2+ cells within the CD137+CD4+ was determined (blue boxplot). Furthermore, 
these cells were divided into (B) a CD28+ (light green boxplot) and a CD28null subset (dark green 
boxplot). Also the frequency of IFN-γ+ CD137+CD4+ T cells was determined (blue boxplot) and also 
these cells were divided into (C) a CD28+ (light green boxplot) and a CD28null subset (dark green 
boxplot). Next to the CD4+, the frequency of CD137+ cells within the CD8+ T-cell population was 
determined (blue boxplot) and divided into a CD28+ (light green boxplot) and a CD28null subset 
(dark green boxplot) (D). Within these CD137+CD8+ T cells, the frequency of IL-2 (F) and IFN-γ+ 
(G) was determined (blue boxplots) and divided into a CD28+ (light green boxplots) and a CD28null 
subset (dark green boxplots) (E+F). Significant differences were calculated and shown (*p<0.05, 
**p<0.01, **p<0.001).
DISCUSSION
In this study we analyzed within a large homogenous cohort of patients whether the degree 
of premature T-cell ageing prior to KT is associated with the risk for EAR post-KT. Of 
the three T-cell ageing parameters (thymic output, differentiation status and telomere 
length) used for the assessment of an immunological T-cell age, only the differentiation 
status was associated with the risk for EAR. A higher number as well as percentage of 
CD28null T cells, mainly within the CD4+ T-cell population, is associated with a lower risk 
for EAR. The number of RTEs or the relative telomere length of CD4+ and CD8+ T cells 
were both not associated with the risk for rejection.
CD28null T cells are predominantly located within the (antigen-experienced) memory 
population and in particular within the more differentiated T cells (73). Loss of CD28 
on the cell surface of (CD4+) T cells is one of the features of T-cell ageing as CD28null T 
cells are present at a low frequency and rarely found in young individuals. Moreover, 
CD4+CD28null T cells are highly associated with seropositivity for cytomegalovirus (CMV) 
(74-76). However, in this study we did not observe a significant difference with respect 
to frequencies of CMV-seropositive individuals between the EAR group and the no 
rejection group. 
The majority of CD28null T cells lack the expression of CCR7. This is important for 
homing to secondary lymphoid organs (31) where (naive) T cells are activated by antigen-
presenting cells presenting alloantigens in a direct or indirect manner. In addition to 
the lack of CD28, they are less able to provide co-stimulation through the CD40L-CD40 
pathway contributing to defective helper function (77).
A characteristic feature of CD4+CD28null T cells is their restricted T-cell receptor profile 
(34, 78) compared to the CD28+ T-cell population. This may compromise their reactivity 
to foreign antigens like for example alloantigens. Thus, theoretically higher numbers of 
CD28null T cells might result in lower alloreactivity. This hypothesis is supported by our 
finding that IL-2 and IFN-γ producing alloantigen-specific T cells were predominately 
located within the CD28+ T-cell population, both within the CD4+ and the CD8+ T-cell 
compartment. In addition, in liver transplant recipients, higher frequencies of CD4+CD28+ 
T cells were found in allograft rejecting patients (79). Next to this, the higher percentages 
of CD4+ and CD8+ CM T cells in the EAR group, supports this finding by suggesting that 
the less differentiated cells are more present in patients who develop an acute rejection.
The finding that high CD28null T-cell numbers are associated with a lower risk 
for allograft rejection is in line with an earlier small study in which these cells were 
shown to have an exhausted phenotype (67). Furthermore, several studies support 
the senescent character of these CD28null T cells. A study by Nunes et al. showed that 
highly differentiated CD8+ T cells were accompanied by an increase of CD28null and CD27– 
T cells (80). In line with this, the highly differentiated CD8+ T cells were also associated 
with PD-1 positivity, which was in accordance with replicative senescence of these T 
cells (80). Next to this, a study by Dirks et al. showed that CMV viremia was associated 
with increased PD-1 expression on CD4+CD28nullCD27– T cells in transplant recipients 
(81). Furthermore, a study by Koch et al. showed that the expression of the senescence 
markers CD57 and KLRG-1 were more present in the highly differentiated CD4+ and 
CD8+ T cells, and were almost absent in the naive T-cell populations (26). Our group also 
showed that the percentage of CD57+ cells was significantly higher in CD4+ memory T 
cells (11). In a recent study, a lower frequency of CD4+CD28null T cells was also observed in 
relation to acute rejection within the first year after kidney transplantation but statistical 
significance was lost in the multivariate analysis (66). The patient population in that study 
was much more heterogeneous, including post-mortal kidney transplantations, more re-
transplantations and a higher number of CMV-seropositive patients which could at least 
in part explain the difference in findings between both studies (66). The higher number 
of CMV-seropositive patients in that study might also explain why we could not find 
relations between CD8+ EMRA T-cells and the development of EAR in our current study.
Compared to the CD28+ T-cell population, the CD28null T cells are known to have 
shorter telomeres (74). The fact that we could not detect a correlation between the overall 
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telomere length and the risk for EAR, might be explained by the relatively low frequency 
of CD28null T cells within the CD4+ T-cell population in which the relative telomere length 
was assessed. In line with our findings, a study by Oetting et al. could also not find an 
association between the RTL and the risk for acute rejection (82).
In this study we could not find an association between RTEs and the risk for EAR 
based on the expression of CD31. Since the thymus involutes rapidly after puberty, 
the contribution of the thymus to maintain the (naive) T-cell pool is relatively small in older 
individuals (83). Maintaining adequate numbers of naive T cells upon ageing mainly relies 
on homeostatic proliferation either through homeostatic cytokines like IL-7 or low-affinity 
T-cell receptor interactions with self-antigens being presented by antigen-presenting cells 
(84). Since the total number of naive T cells is not different between the two groups of 
patients, it is likely that the degree of homeostatic proliferation is similar. These findings 
suggest that the naive T-cell compartment is not of significant importance for alloreactivity 
within the first three months after KT and that the memory T-cell compartment is more 
relevant (85). 
Another interesting finding in this study was the higher risk for EAR in patients with 
a higher historical PRA score. Several other studies have shown that high levels of historical 
PRA scores are associated with rejection and graft failure (86-88). Our findings support 
the results of these studies with regard to rejection and suggest that a peak historical PRA 
score might also be an important contributor in the setting of EAR in KT.
 As the T-cell ageing parameters do not change post-KT (69), it is likely that at the time 
of rejection the composition of T cells including the frequency of CD28null T cells is similar 
to the pre-KT value. This means that allograft rejection risk assessment based on T-cell 
ageing prior to KT probably resembles the T-cell age prior to time of rejection. 
In conclusion, the T-cell ageing-related expansion of highly differentiated CD4+CD28null 
T cells in ESRD patients is associated with a lower risk for EAR. This may be related to 
a significantly lower percentage of alloreactive T cells within the CD28null T cell fraction. 
This study provides in depth analysis of the various T-cell subsets with regard to T-cell 
ageing in the setting of KT. To give a more accurate representation we mainly focused 
on absolute cell numbers instead of percentages. Furthermore proliferative history 
was also taken into account by the assessment of RTL. These characteristics were then 
combined with functional capacities of the highly differentiated CD28null T cells and 
associations were drawn with regard to EAR. The patient characteristics of the two 
patient groups are highly similar, which makes the study population homogenous. 
Next to this, only living-donor KT was considered. We believe that the combination of 
the aforementioned aspects contribute novel facets in the relationship between premature 
T-cell ageing and the risk for EAR after KT. Further analyses are needed to investigate 
the properties of these cells and to define cut-off values for the clinical practice. In 
the future this could possibly attribute to an optimal risk assessment for a personalized 
immunosuppressive regimen.
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this  could  possibly  attribute  to  an  optimal  risk  assessment  for  a  personalized 
immunosuppressive regimen. 
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Supplementary Figure 1. Gating strategy of (A) CD4+ and (B) CD8+ T cells. A typical example of the gating strategy 
is  shown.  Briefly,  lymphocytes were  identified  based  on  the  forward/sideward  characteristics  followed  by  the 
selection  of  the  CD3+CD4+  T  cells.  These  CD4+  T  cells  were  dissected  into  subsets  using  CCR7  and  CD45RO. 
Furthermore, the number of CD28null cells was examined within the (A) CD4+ T‐cell population. The same strategy 
was followed for (B) CD8+ T cells. 
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characteristics followed by the selection of the CD3+CD4+ T cells. These CD4+ T cells were dissected 
into subsets using CCR7 and CD45RO. Furthermore, the number of 28null cells was examined 
within the (A) CD4+ T-cell population. The same strategy was followed for (B) CD8+ T cells.
 
Supplementary  Figure  2.  Example of  the  gating  strategy of  cytokine producing  alloantigen‐stimulated  T  cells. 
Briefly, lymphocytes were identified based on the forward/sideward characteristics. Next the CD3+CD4+ (i.e. CD8‐) 
and CD3+CD8+ were selected and within these, the CD137+ were selected as shown for the CD4+ population. These 
cells were divided into a CD28+ and CD28null population. Furthermore the frequency of IL‐2+ and IFN‐γ+ CD137+CD4+ 
was determined and also dissected into a CD28+ and CD28null subset. A similar approach was applied for the CD8+ T‐
cell compartment. 
 
 
 
Suppl mentary Figure 2. Exampl  of the g ting strategy of cytokine producing alloantigen-
stimulated T c lls. Briefly, lymphocytes were identified base  on the forward/sideward characteristics. 
Next the CD3+CD4+ (i.e. CD8-) and CD3+CD8+ were selected and within these, the CD137+ were 
selected as shown for the CD4+ population. These cells were divided into a CD28+ and CD28null 
population. Furthermore the frequency of IL-2+ and IFN-γ+ CD137+CD4+ was determined and 
also dissected into a CD28+ and CD28null subset. A similar approach was applied for the CD8+ 
T-cell compartment.
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Supplementary Table 1. T-cell differentiation status before kidney transplantation in patients with 
or without rejection within the first 3 months
KT Patients (n=222)
No Rejection 
(n=192) (86%)
Early Rejection 
(n=30) (14%) P
CD4+ naive T cells (%) 29.4 (18.0 – 42.0) 29.7 (24.1 – 36.4) 0.905
CD4+ memory T cells (%) 70.6 (60.0 – 82.0) 70.3 (63.6 – 75.9) 0.905
CD4+ central memory T cells (%) 40.5 (31.3 – 50.6) 46.6 (37.3 – 54.6) 0.055
CD4+ effector memory T cells (%) 24.4 (16.5 – 32.5) 24.9 (14.6 – 27.7) 0.303
CD4+CD28null T cells (%) 3.0 (0.5 – 9.6) 1.0 (0.2 – 4.1) 0.011
CD8+ naive T cells (%) 18.1 (8.8 – 35.1) 22.8 (13.8 – 39.9) 0.323
CD8+ memory T cells (%) 81.9 (65.0 – 91.2) 77.3 (60.1 – 86.2) 0.323
CD8+ central memory T cells (%) 4.2 (2.3 – 7.9) 6.1 (4.1 - 13.6) 0.005
CD8+ effector memory T cells (%) 32.7 (20.3 – 45.4) 28.2 (23.8 - 41.6) 0.899
CD8+ EMRA T cells (%) 33.7 (18.5 - 52.1) 31.6 (16.9 - 50.3) 0.759
CD8+CD28null T cells (%) 40.5 (19.6 - 60.4) 27.6 (19.6 - 52.9) 0.190
Data are presented as medians (interquartile range).
Supplementary Table 2. Hazard ratios for the clinical characteristics in relation to early acute allograft 
rejection (multivariate analysis)
HR 95%CI P
Age donor (decades)
PRA historic (%)
Genetically related KT
CD4 positive CD28null T cells (%)
1.43
1.13
0.51
0.91
1.09 – 1.88
1.07 – 1.22
0.21 – 1.28
0.84 – 0.99
0.011
<0.001
0.152
0.036
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. CI: confidence interval, HR: hazard ratio. Age of the donor is 
presented in decades, PRA historic is presented with steps of 5%, the CD4 positive and the CD8 positive 
CD28null cells are presented with steps of 20 cells/µL, CD4 and CD8 positive central memory T cells are 
presented with steps of 1%, and the CD4 positive CD28 null T cells are presented with steps of 1%
Chapter  3
CD4+ CD28NULL T CELLS ARE NOT ALLOREACTIVE 
UNLESS STIMULATED BY IL-15
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INTRODUCTION
Patients with end-stage renal disease (ESRD) have a prematurely aged circulatory T-cell 
system (11, 13). The discrepancy between their chronological and their immunological 
T-cell age can be as much as 15-20 years (11, 13). A typical feature of an aged peripheral 
T-cell system is the increase in late differentiated memory T cells (20, 21, 89). A key 
characteristic of these cells is loss of the co-stimulatory molecule CD28 on their surface 
(20, 23, 27, 29). These CD28null T cells are mainly of effector memory (CCR7–CD45RO+) 
and EMRA phenotype (CCR7–CD45RO– but CD45RA+) (30, 90). CD4+ and CD8+ T cells can 
both lack CD28 (23, 27, 29, 30). In patients with ESRD, there is a significant expansion of 
the CD28null T-cell populations and the frequency of CD4+CD28null T cells may be as high 
as 65% (30). 
Continuous antigenic stimulation and/or a proinflammatory environment are probably 
the main drivers of CD28 loss (91). Increased CD28null T-cell frequencies are therefore 
found in patients with ESRD, HIV infection, rheumatoid arthritis and type 1 diabetes 
(27, 29, 30). Additionally, CMV infection causes a persistent expansion of terminally 
differentiated CD28null T cells (42, 43). 
CD4+CD28null T cells are actually not classical helper T cells but share many functional 
similarities with cytotoxic CD8+ T cells. CD4+CD28null T cells produce proinflammatory 
cytokines such as interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α), 
and contain cytotoxic molecules like granzyme B and perforin in intracellular stores 
(23, 29-32). 
Given the highly proinflammatory and cytotoxic profile of CD4+CD28null T cells, any 
alloreactivity of these cells may be particularly harmful for the transplanted organ. 
Indeed, the presence of these cells has been associated with the risk for development of 
(co-stimulatory blockade-resistant) rejection after renal transplantation (RT) (29, 34, 36, 
92). Association between increased numbers of these cells prior to RT and a reduced risk 
for early acute allograft rejection was also a part of these observations (36). However, in 
vitro studies about the alloreactivity of CD4+CD28null T cells are lacking, but are needed 
for a proper understanding of the role of these cells with regard to rejection. Therefore, 
in this study the alloreactive potential and immunomodulatory properties of CD4+CD28null 
T cells were examined.
MATERIALS AND METHODS
Study population
Samples were obtained from renal transplant recipients who received a renal allograft in 
the period from January 2011 to August 2013. All patients gave written informed consent 
to participate in this study. The study was approved by the Medical Ethical Committee 
of the Erasmus MC (MEC number 2012-022) and was conducted in accordance with 
the Declaration of Helsinki and the Declaration of Istanbul.
Clinical variables were determined as shown in Table 1. 
ABSTRACT
Background
Proinflammatory, cytotoxic CD4+CD28null T cells can be substantially expanded in patients 
with end-stage renal disease. These cells have been associated with the risk for rejection, 
but their alloreactive potential is unknown. 
Methods
CD4+CD28null T cells were stimulated with HLA-mismatched antigen presenting cells in 
the absence/presence of exogenous cytokines. Alloreactive potential was evaluated by 
proliferation, degranulation, cytotoxicity and cytokine production. Furthermore, their 
suppressive capacity was assessed by measuring inhibition of proliferating alloreactive 
CD28+ T cells.
Results
CD4+CD28null T cells contained alloreactive (CD137+) T cells but did not proliferate in 
response to allogeneic stimulation, unless IL-15 was added. However, they could 
proliferate upon stimulation with CMV-antigen without exogenous cytokines. IL-15 
increased the frequency of proliferating alloreactive CD4+CD28null T cells to 30.5% 
without inducing CD28 expression (p<0.05). After allogeneic stimulation together with 
IL-15 and IL-21, frequency of degranulating CD107a+CD4+CD28null T cells increased 
significantly from 0.6% to 5.8% (p<0.001). Granzyme B and perforin positivity remained 
similar, but production of IFN-γ and TNF-α increased by the combination of IL-15 and 
IL-21 (p<0.001 and p<0.05, respectively). Finally, CD4+CD28null T cells did not show 
significant suppression.
Conclusion
CD4+CD28null T cells represent a population with absent alloreactivity unless IL-15 
is present.
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Responder and stimulator PBMC isolation 
Blood was obtained from renal transplant recipients one day prior to RT and from healthy 
donors. Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized 
blood samples by using Ficoll-Paque Plus (GE healthcare, Uppsala, Sweden). Isolated 
PBMCs of responders were stored at –150oC with ≥10×106 cells/vial whereas stimulator 
PBMCs were further processed as described below.
Preparation of stimulator
Selection of healthy donors was based on ≥2 HLA-I mismatches and ≥1 HLA-II mismatches 
with the responder. PBMCs of these donors were labeled with CD3-microbeads (Miltenyi 
Biotec, Bergisch Gladbach, Germany) and subsequently depleted for T cells using 
the autoMACS® Pro (Miltenyi Biotec). Allogeneic stimuli were depleted for >95% of 
CD3+ T cells as assessed by flow cytometry upon staining the negative fraction with 
Amcyan-labeled anti-CD3 (BD, Erembodegem, Belgium). CD3-depleted cells (stimulator) 
were stored at –150oC at 5×106 cells/vial until further use.
Cell sorting of responder cells
PBMCs of 11 renal transplant recipients, with a frequency of ≥10% CD28null T cells 
within CD4+ T cells, were selected. These PBMCs were thawed and prepared for sorting 
experiments using the following antibodies: phycoerythrin-cyanine 7 (PE-Cy7)-labeled 
anti-CD3 (BD Pharmingen), brilliant violet 510 (BV510)-labeled anti-CD4 (Biolegend, 
San Diego, CA, USA), phycoerythrin (PE)-labeled anti CD28 (BD) and a live-dead marker 
7-amino-actinomycin D (7-AAD or ViaProbe, BD). After the staining procedure, cells were 
washed and resuspended at 20–25×106/ml and sorted on the FACSAria II SORP (BD) into 
CD4+CD28null and CD4+CD28+ T cells. Isolated T-cell fractions were used as responder cells 
and subjected to allogeneic stimulation. Median purities were 97.0% [94.9%–98.8%] for 
CD4+CD28null T cells.
Stimulation 
In each experiment two different allogeneic stimuli (≥2 HLA-I mismatches and ≥1 HLA-II 
mismatches) were included, and used in a one way mixed lymphocyte reaction (MLR). 
PBMC and sorted CD4+CD28+ and CD4+CD28null T cells (responders) were labeled 
with CFSE (Molecular Probes®, Leiden, the Netherlands) according to manufacturer’s 
instruction and stimulated in triplicate at 5×104/well with an allogeneic stimulus (40Gy-
irradiated) at a 1:1 ratio for 6 days. In a set of experiments, PBMCs of CMV-seropositive 
individuals were either not or pre-incubated with humanized anti-IL-15R antibody (5µg/
ml; Thermo Fisher, Bleiswijk, the Netherlands) and/or humanized anti-IL-21R antibody 
(10µg/ml; Pfizer, New York, USA) and subsequently stimulated with CMV-lysate (30 μg/ml; 
Microbix Biosystems Inc. Ontario, Canada). These concentrations are known to provide 
sufficient blockade of the receptors according to the certificate of analysis provided by 
Thermo Fisher (IL-15R blockade) and a study by de Leur et al. (93) (IL-21R blockade).
Allogeneic stimulation was performed with/without IL-15 (10 ng/ml, Peprotech Inc., 
London, UK) and/or IL-21 (10 ng/ml, Peprotech Inc.). These cytokines were based upon our 
experiments (see results) and studies showing the effect of IL-15 and IL-21 on memory T 
cells (94-96). Ten ng/ml was chosen, because no differences were seen between stimulation 
with 10 or 50 ng/ml (data not shown). As a negative control, responders were stimulated 
using only culture medium (RPMI-1640 (Lonza Group, Basel, Switzerland) with 10% heat-
inactivated pooled human serum). On day 5, wells of the same condition were pooled, 
supernatant stored at -80oC and 5 μg/mL monensin (Golgistop; BD Pharmingen) was 
added overnight. On day 6, alloreactive potential including proliferation, degranulation, 
cytotoxicity and cytokine production was analyzed as described in the sections below. 
Allogeneic proliferation
Proliferation was analyzed by measuring CFSE dilution and determining the frequency of 
CFSE– T cells. Cells were stained using the following antibodies; PE-Cy7-labeled anti-CD3 
(BD Pharmingen), BV510-labeled anti-CD4 (Biolegend) and PE-labeled anti-CD28 (BD). 
A dump-channel was employed, in order to exclude unwanted cells by co-staining the cells 
for the live-dead marker 7-AAD, peridin chlorophyll protein (PerCP)-labeled anti-CD19 
(BD), PerCP-Cy5.5-labeled anti-CD56 (Biolegend) and PerCP-labeled anti-CD14 (BD).
Samples were measured on the FACSCanto II (BD) and analyzed using FACS Diva 
software version 6.1.2 (BD).
CD137 expression
Alloantigen-specific T cells were determined by the CD137 multi-parameter flowcytometric 
assay as published previously (71). Briefly, PBMCs of 10 patients were stimulated with 
T-cell depleted donor or autologous PBMCs (control) at a 1:1 ratio in presence of αCD49d 
(as co-stimulation) at 1 µg/mL (BD) for 24 hours. During the last 12 hours, golgiplug 
(Brefeldin A; BD) and golgistop (Monensin; BD) were added. Cell surface was stained 
with the following antibodies; AmCyan-labeled anti-CD3 (BD), allophycocyanin (APC)-
Cy7-labeled anti-CD8 (BD) and PerCP-Cy5.5-labeled anti-CD28 (BD). After fixation and 
permeabilization, CD137 was stained intracellularly by using APC-labeled anti-CD137 
(BD). Samples were measured on the FACSCanto II (BD) and analyzed using FACS Diva 
software version 6.1.2 (BD). Allogeneic CD137-expressing CD4+CD28+ or CD4+CD28null T 
cells were corrected for CD137-expressing cells upon autologous stimulation.
Degranulation and cytotoxic potential upon allogeneic stimulation
Following 6 days of stimulation, cells were harvested and stained as described above, 
and combined with allophycocyanin (APC)-labeled anti-CD107a (BD Pharmingen). 
Degranulation was determined by analyzing the percentage of CD107a+CD4+CD28null T 
cells. In addition, a dissection was made in order to analyze CD107a within proliferating 
(CFSE–) as well as non-proliferating (CFSE+) CD4+ T cells. Samples were measured on 
the FACSCanto II (BD) analyzed using FACS Diva software version 6.1.2 (BD). 
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Cytotoxic potential was analyzed by measuring granzyme B+ and perforin+ 
CD4+CD28null T cells. Briefly, a one way MLR was performed with sorted CFSE-labeled 
CD4+CD28null T cells, stimulated with different HLA-mismatched irradiated (40Gy) CD3-
depleted cells alone or supplemented with exogenous IL-15 and IL-21. As a negative 
control, a stimulation using only culture medium was included. Upon cell surface staining 
as described earlier, cells were fixed and permeabilized. Subsequently, granzyme B 
and perforin were stained intracellularly using Alexa Fluor 647-labeled anti-granzyme 
B (Biolegend) and BV421-labeled anti-perforin (Biolegend). Samples were measured on 
the FACSCanto II (BD) and analyzed with FACS Diva software version 6.1.2 (BD).
Analysis of cytokine production
The concentration of cytokines, i.e. IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ and IL-17A, 
present within collected supernatants, was determined using the human Th1/Th2/Th17 
cytometric bead array (CBA) cytokine kit (BD) according to manufacturer’s instruction. 
Briefly, cytokine standards with fixed concentrations of each analyte were measured on 
the FACS Canto II (BD) and median fluorescence intensities (MFI) were used to generate 
a standard curve for each analyte, using a 4-parameter logistic regression analysis with 
GraphPad Prism 5 (CA, USA). MFI of the various analytes within the samples were 
transformed into concentrations (pg/mL) of a particular cytokine. For these experiments, 
we focused on production of proinflammatory cytokines TNF-α and IFN-γ.
Analysis of suppression
Patient PBMCs were sorted into CD4+CD28null T cells and T cells without CD4+CD28null 
(responders). CD4+CD28null T cells were evaluated for suppressive potential of allogeneic-
induced proliferation of the responder fraction consisting of CD8+ and CD4+CD28+ T cells. 
Suppressive capacity of CD4+CD28null T cells was either tested directly or upon allogeneic 
expansion in presence of both IL-15 (50 ng/mL) and IL-21 (50 ng/ml). Briefly, responders 
were CFSE-labeled, and either not or stimulated in triplicate at 5x104/well with irradiated 
allogeneic stimuli at a 1:1 ratio, in absence or presence of CD4+CD28null T cells (expanded 
using the same allogeneic stimulus). A 1:2 suppressor:responder ratio was used when 
CD4+CD28null T cells were not expanded. After 6 days, suppressive capacity was analyzed 
by evaluating percentages of CFSE– responders in presence or absence of CD4+CD28null 
T cells.
Statistical analysis
All variables are presented as medians (with interquartile ranges). Differences between 
two paired conditions were analyzed using the Wilcoxon signed rank test. Differences 
between two different fractions (e.g. divided vs undivided fractions) were analyzed 
using the Mann-Whitney U test. Differences between three or more paired conditions 
were analyzed using the Friedman test followed by a correction for multiple testing. 
The significance level (p-value) was two-tailed and an α of 0.05 was used for all analyses. 
Statistical analyses were performed using SPSS® version 21.0 for Windows® (SPSS Inc., 
IL, USA) and GraphPad Prism 5 (CA, USA). Figures were created with GraphPad Prism 5 
(CA, USA).
RESULTS
Study population
In total 11 patients were included (Table 1). Median patient age was 60 years. Seven patients 
were male and all patients were CMV IgG+. Cause of renal failure was nephrosclerosis/
atherosclerosis/hypertension (3 patients), focal segmental glomerulosclerosis (2 patients), 
diabetes mellitus type 2 (2 patients), vasculitis, polycystic kidney disease, hemolytic-uremic 
syndrome and one unknown. Six patients underwent dialysis prior to transplantation. 
Median frequency of CD4+CD28null T cells prior to RT was 31.3% (17.8%-36.4%).
CD4+CD28null T cells need exogenous cytokines to proliferate upon 
allogeneic stimulation
CD4+CD28null T cells showed no increase in proliferation upon allogeneic stimulation 
compared with CD4+CD28+ T cells (Figure 1A-B). Median percentage of proliferating 
CD4+CD28null T cells remained around 1.7% (Figure 1B), while this percentage rose 
significantly from 1.9% to 25.7% (p<0.001) for CD4+CD28+ T cells (Figure 1B). An obvious 
explanation for this difference could be that the sorting procedure had a deleterious 
effect on the proliferative capacity of CD4+CD28null T cells. Therefore, first we assessed 
CD28 expression on proliferating alloreactive CD28+ T cells. CD28 expression appeared 
to be slightly higher after allogeneic stimulation (p<0.05), without significant induction 
of CD28null T cells (Figure 1C). Then proliferation of CD28null T cells in the unsorted T-cell 
fraction was analyzed, which confirmed that CD28null T cells indeed do not proliferate 
in presence of allogeneic stimulator cells (Figure 1D). The CD28null T-cell population also 
harbors CMV-specific T cells. In presence of CMV-antigen, CD4+CD28null T cells showed 
significant proliferation (Figure 1E). Median percentage of proliferating CD4+CD28null 
T cells rose from 7.7% to 70.0% (p<0.05; n=8) upon stimulation with CMV-antigen. 
Blocking the IL-15R and/or IL-21R did not influence CMV-lysate-induced proliferation 
of CD4+CD28null T cells, indicating that it is independent from IL-15 or IL-21 (data not 
shown). Thus, CD4+CD28null T cells are not senescent and are able to proliferate vigorously 
upon recognition of a cognate antigen. 
CD137 expression is an early and sensitive marker of antigen-specific T-cell activation 
and can be used to identify the total pool of alloreactive T cells (71). Using this assay, 
presence of alloreactive CD137+ T cells was shown in both CD28null and CD28+ T cells 
(Figure 2A-B). Median percentage of cells within the CD28+ fraction was 0.36% and 
within the CD28null fraction 0.21% (n=10) (Figure 2B). As alloreactive T cells reside within 
CD4+CD28null T cells, we set out to evaluate whether exogenous cytokines could induce 
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Figure 1. Proliferative capacity of CD4+CD28null T cells. (A) An example of the absence 
of proliferation by CD4+CD28null T cells (upper histograms) and the presence of proliferation 
by CD4+CD28+ T cells (lower histograms) from the same patient upon allogeneic stimulation is 
shown. The histograms on the left represent the unstimulated condition, while the histograms 
on the right represent the allogeneic condition. (B) The frequency of proliferating cells within 
sorted CD4+CD28null T cells and sorted CD4+CD28+ T cells are shown after allogeneic stimulation. 
Nine patient samples were stimulated with 2 different allogeneic stimulators, but due to lack of 
material, only 12 tests could be analyzed pairwise for the CD4+CD28null T cells and only 16 tests 
for CD4+CD28+ T cells. Differences between the conditions were analyzed with a Wilcoxon signed 
rank test. (C) The frequencies of CD4+CD28+ T cells are represented immediately after the sorting 
procedure and after allogeneic stimulation. Nine patients were stimulated with 2 different allogeneic 
stimulators separately. This led to n=18 for the CD4+CD28+ T cells for a Wilcoxon signed rank 
test. (D) Frequencies of proliferating CD4+ T cells within PBMCs from 5 patients after allogeneic 
stimulation are shown. (E) An example of proliferation by CD4+CD28null T cells upon stimulation 
with CMV-antigen is shown. The histogram on the left represents the unstimulated condition, while 
the histogram on the left shows the CMV-antigen stimulated condition. Frequencies of cells are 
depicted as individual percentages as well as medians. Significant differences were calculated and 
shown (ns: not significant, *p<0.05, **p≤0.01, ***p≤0.001).
proliferation of alloreactive CD4+CD28null T cells. This showed that IL-15 and IL-21, which 
are cytokines known to stimulate memory T cells (94-96), provided the highest fold 
of increase of CD4+CD28null T-cell frequency (Figure 2C). Based upon these results we 
continued to analyze the effect of the cytokines IL-15 with/without IL-21 at 10 ng/ml.
In presence of IL-15 alone (p<0.05), and both IL-15 and IL-21 (p<0.001), percentage 
of proliferating CD4+CD28null T cells increased significantly upon allogeneic stimulation 
(Figure 2D). IL-15 increased the median percentage of proliferating CD4+CD28null T cells 
to 30.5%, while the combination of both cytokines increased this to 48.6%. Thus, 
CD4+CD28null T cells need primarily IL-15 to proliferate upon allogeneic stimulation. 
Increase in proliferation was due to a combination of allogeneic stimulation and 
the addition of exogenous cytokines. Stimulation with only IL-15 and IL-21 showed 
a significant lower proliferation than when an allogeneic stimulus was added. Median 
percentage of proliferating CD4+CD28null T cells with only IL-15 amounted to 9.1% while 
this was significantly higher when an allogeneic stimulus was added 
(30.5%, p<0.05; n=6). A similar result was found when IL-15 and IL-21 were 
combined. Median percentage of proliferating cells with only IL-15 and IL-21 amounted 
to 10.2%, while this was significantly higher when an allogeneic stimulus was present 
(30.0%, p<0.05; n=6).
Degranulation and upregulation of cytotoxic molecules by cytokines is 
limited
Degranulation was assessed by measuring CD107a expression. Median frequencies of 
CD107a+ T cells increased from 0.6% to 1.4% (p<0.05) after allogeneic stimulation. 
Adding only IL-15 or IL-21 to the culture did not have an effect on CD107a expression 
within CD4+CD28null T cells (Figure 3A), unless both cytokines were combined. This 
increased the median CD107a expression to 5.8% (2.7%–8.5%, p<0.001) (Figure 3A). 
Subsequently, we dissected CD107a-expressing cells into those proliferating or not 
in response to allogeneic stimulation (Figure 3B). In absence of exogenous cytokines, 
Table 1. Patient characteristics
RT Patients (n=11)
Age 60 (44 – 66) 
Male 7 (64%)
CMV-seropositivity 11 (100%)
Underlying disease
Nephrosclerosis/atherosclerosis/hypertension 3 (27%)
Focal segmental glomerulosclerosis 2 (18%)
Diabetes 2 (18%)
Vasculitis 1 (9%)
Polycystic Kidney Disease 1 (9%)
Hemolytic-uremic syndrome 1 (9%)
Unknown 1 (9%)
Dialysis prior to transplantation 6 (55%)
Data are presented as median (interquartile range) or as number (percentage).
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Figure 3. Degranulation and presence of cytotoxic molecules. (A) The effect of cytokines 
on CD4+CD28null T cells with regard to CD107a expression is analyzed in four different allogeneic 
conditions. Six patients were stimulated with 2 different allogeneic stimulators in most of the cases, 
which led to n=11 for a non-parametric repeated measures ANOVA (Friedman test) between 
the different allogeneic conditions. (B) The differences between the frequencies of dividing and 
not-dividing CD4+CD28null T cells with regard to CD107a expression are shown under two allogeneic 
conditions; allogeneic stimulation and allogeneic stimulation in combination with IL-15 and IL-21. (C) 
Frequencies of granzyme B and (D) perforin positive CD4+CD28null T cells are shown between three 
different conditions (i.e. medium, allogeneic stimulation and allogeneic stimulation in combination 
with IL-15 and IL-21). Three patients were stimulated with 2 different allogeneic stimulators separately 
in most of the cases, which led to n=5 for a non-parametric repeated measures ANOVA (Friedman 
test) between the different conditions. The differences between the frequencies of dividing and 
not-dividing CD4+CD28null T cells with regard to (E) granzyme B positivity and (F) perforin positivity 
are shown under two allogeneic conditions (i.e. allogeneic stimulation and allogeneic stimulation in 
combination with IL-15 and IL-21). Frequencies of cells are depicted as either individual percentages 
with medians or bars with medians. Significant differences were calculated and shown (ns: not 
significant, *p<0.05, **p≤0.01, ***p≤0.001).
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CD107a expression was higher in the non-proliferating fraction (p<0.05). Presence of 
both cytokines tended to show a higher frequency of CD107a-expressing cells within 
the proliferating fraction compared with the non-proliferating fraction (p=0.088). But 
compared with the allogeneic condition without cytokines, frequency of proliferating cells 
expressing CD107a increased significantly when IL-15 and IL-21 were added (p<0.001).
Figure 3C & 3D show that the cytotoxic molecules granzyme B and perforin are 
present within CD4+CD28null T cells in the unstimulated condition. Overall, frequency of 
granzyme B and perforin positive CD4+CD28null T cells did not increase significantly after 
allogeneic stimulation in presence of IL-15 and IL-21 (Figure 3C-D). However, frequency 
of granzyme B and perforin positive cells was mainly within the non-proliferating fraction 
of CD4+CD28null T cells, whether or not the cells were cultured in presence of IL-15/IL-21 
(p<0.01) (Figure 3E-F). 
In summary, CD107a expression can be upregulated by IL-15 and IL-21. Next to 
this, there is no significant upregulation of the frequency of granzyme B+ and perforin+ 
CD4+CD28null T cells in the proliferated cell fraction
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Figure 2. CD137 expression and effect of cytokines. (A) An example of CD137 expression 
by CD4+CD28+ T cells (dot plot on the left) and by CD4+CD28null T cells (dot plot on the right) 
upon allogeneic stimulation is shown. (B) The frequency of CD137 expressing CD4+CD28+ and 
CD4+CD28null T cells from 10 patients are shown after allogeneic stimulation. (C) The expansion of 
CD4+CD28null T cells is shown in response to IL-15 + IL-2, IL-15 + IL-7 and IL-15 + IL-21 at 50 ng/
ml (n=5). The Y-axis shows the expansion of CD4+CD28null T cells, which is represented as the fold 
increase of the frequency of these cells. (D) The effect of cytokines on CD4+CD28null T cells with regard 
to proliferation is analyzed in four different allogeneic conditions. The four allogeneic conditions 
are as follows; without cytokines, with IL-15, with IL-21 and with IL-15 + IL-21. Nine patients were 
stimulated with 2 different allogeneic stimulators, but due to lack of material, 11 samples could be 
analyzed with a non-parametric repeated measures ANOVA (Friedman test) between the different 
allogeneic conditions. 
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Cytokine production is enhanced by IL-15 and IL-21 in CD4+CD28null T cells
The concentration of IFN-γ present in the supernatant was similar for cell culture 
conditions in which CD4+CD28null T cells were co-cultured with or without allogeneic 
stimulator cells (Figure 4A). Only with addition of IL-15 and IL-21, production of IFN-γ by 
CD4+CD28null T cells significantly increased from 0.87 to 6.32 pg/ml (p<0.001) (Figure 4B).
Same was also true for the concentration of TNF-α. Again, no difference was observed 
in the concentration of TNF-α between the unstimulated and allogeneic condition (Figure 
4C). The concentration of TNF-α also showed a significant increase under influence of 
IL-15 (with/without IL-21) in CD4+CD28null T cells (p<0.05 for both conditions) (Figure 4D). 
Median TNF-α concentration increased from 0.54 (0.46–0.70) to 1.45 pg/ml (1.13–3.33) 
under influence of IL-15, and to 1.28 pg/ml (1.22–3.70) under influence of both cytokines.
In summary, cytokine production by CD4+CD28null T cells can, to a certain degree, be 
upregulated with IL-15 and IL-21.
CD4+CD28null T cells do not have suppressive properties
Directly upon isolation, CD4+CD28null T cells did not have suppressor activity on proliferating 
alloreactive T cells (data not shown). Analyzing the suppressive properties of allogeneic-
expanded CD4+CD28null T cells, showed no significant suppression of allogeneic-
induced proliferation by T cells depleted for CD4+CD28null T cells (data not shown). 
The suppressive potential of proliferating allogeneic CD4+CD28null T cells was addressed 
specifically for both cell populations. The results showed that sorted proliferating and 
non-proliferating CD4+CD28null T cells after allogeneic expansion were not displaying 
differences in suppressor activity (data not shown).
DISCUSSION
This study is the first in which pure fractions of CD4+CD28null T cells were used to 
investigate alloreactivity with/without exogenous cytokines. It is known that these cells 
can be drastically expanded and that they can comprise as much as 65% of the total 
CD4+ T-cell population in ESRD patients (30). CD4+CD28null T cells have also been shown 
to be associated with a higher as well as a decreased risk for rejection after RT (29, 
34, 36). However until now, studies looking into the alloreactive potential of these cells 
are lacking.
Our results demonstrated that CD4+CD28null T cells showed no proliferation upon 
allogeneic stimulation alone. This was not due to the sorting procedure, since it did not 
influence CD28 expression. Stability of the CD28 phenotype was also observed by a study 
of Alonso-Arias et al. (94). Next to this, even within unsorted cells, CD4+CD28null T cells 
showed no proliferation in response to allogeneic stimulation contrary to CD4+CD28+ 
T cells. This means that, lack of responsiveness to allogeneic stimulation is a trait of 
these CD4+CD28null T cells. This could be due to the highly differentiated state of these 
cells. Continuous antigenic stimulation, by for example chronic viral antigens, can lead to 
differentiation and expansion of cells directed against specific antigens (42, 43). Therefore, 
the provided antigen might differ in strength of stimulation for these cells to respond 
properly. This is further supported by our finding that CMV-antigen was sufficient enough 
for CD4+CD28null T cells to proliferate significantly compared with an allogeneic stimulus. 
However, alloantigen specific (CD137+)CD4+CD28null T cells did exist, but needed 
additional stimulation to become responsive. We found that proliferation upon allogeneic 
stimulation could be induced by IL-15. This is especially important as renal tubular epithelial 
cells, next to cells of the immune system, can also produce IL-15 (97, 98). Furthermore, 
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Figure 4. Cytokine production after allogeneic stimulation. (A) The concentration of IFN-γ 
production (pg/ml) by CD4+CD28null T cells are compared between negative control (medium) and 
allogeneic stimulation alone. (B) The effect of cytokines on CD4+CD28null T cells with regard to 
IFN-γ production is analyzed in four different allogeneic conditions. Four patients were stimulated 
with 2 different allogeneic stimulators separately in most of the cases, which led to n=6 for 
a paired analysis between the negative control and allogeneic condition (A) and n=7 for a non-
parametric repeated measures ANOVA (Friedman test) between the different allogeneic conditions 
(B). (C) The concentration of TNF-α production (pg/ml) by CD4+CD28null T cells are compared 
between negative control (medium) and allogeneic stimulation alone. (D) The effect of cytokines 
on CD4+CD28null T cells with regard to TNF-α production is analyzed in four different allogeneic 
conditions. The same sample size and statistical analyses apply also to these figures. Frequencies 
of cells are depicted as individual percentages as well as medians. Significant differences were 
calculated and shown (ns: not significant, *p<0.05, **p≤0.01, ***p≤0.001).
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IL-15 is also required for survival of CD4+CD28null T cells in the periphery (99, 100). IL-15 
did not upregulate the presence of granzyme B and perforin in CD4+CD28null T cells 
significantly, but positivity for cytotoxic molecules was mostly within the non-proliferating 
fraction, suggesting the release of these molecules by the proliferating fraction. This is 
further supported by our finding that, in presence of IL-15 and IL-21, CD107a+ proliferating 
CD4+CD28null T cells significantly increased in frequency. This means that IL-15 and IL-21 
could optimize the cytotoxic potential of these cells towards the renal allograft, especially 
when the significant amounts of granzyme B and perforin within these cells are taken 
into account. Presence of these intracellular cytotoxic molecules within the unstimulated 
condition was also shown by us, which is in accordance with previous studies (23, 29, 
30, 32). Next to this, we also observed that cytokine production by CD4+CD28null T 
cells was limited upon allogeneic stimulation, but that addition of exogenous IL-15 and 
IL-21 enhanced IFN-γ and TNF-α production. This supports the finding that allogeneic 
stimulation does not provide sufficient stimulation for CD4+CD28null T cells to produce 
cytokines unless supported by IL-15 together with IL-21.
Next to their reduced alloreactive potential, another mechanism contributing to their 
association with reduced risk for rejection, might involve suppressive properties. Several 
studies have shown that within CD8+ T cells, suppressive/regulatory cells are present that 
are more of an effector type and thus can lack CD28 (101-103). Since CD4+CD28null T cells 
resemble CD8+CD28null T cells, they might show similarities with regard to suppressive/
regulatory function. However, our results showed that these properties were not present 
in CD4+CD28null T cells. Even a functional division of CD4+CD28null T cells into dividing and 
non-dividing cells upon allogeneic stimulation, did not show any differences.
These mechanisms together suggest that these cells could be harmful for the renal 
allograft, if the optimal conditions are met. Whether these cells can be called exhausted is 
a matter of debate, since they are still able to proliferate and exert cytotoxic functions in 
multiple ways (94, 95). Their function seems also to be stimulus-dependent. For example, 
we showed that these cells were able to proliferate upon stimulation with CMV-antigen. 
This means that these cells are not exhausted and still harbor significant proliferative 
potential. But when an allogeneic stimulation was applied, no significant proliferation 
could be observed unless the latter was promoted by especially IL-15. This difference 
might be caused by the increased specificity of these cells for CMV, as discussed earlier. 
Infection with CMV can lead to expansion of T cells with an oligoclonal repertoire 
(104, 105). This diminished T-cell receptor repertoire diversity might impair the ability to 
recognize new antigens. Furthermore, it could be that the affinity/avidity of these T cells 
to alloantigen might not be as high as to CMV-antigen, and dependent on IL-15 and IL-21 
to respond. The additional requirement of IL-15 and in lesser extent of IL-21 in the setting 
of alloreactivity, might also explain the improved renal allograft survival and graft function 
in patients with co-stimulatory blockade therapy belatacept, compared with cyclosporine 
based regimens (106). Inhibition of the co-stimulatory pathway leads to anergy of CD28+ 
T cells by binding of CD80/86 on an antigen presenting cell, which on its turn usually 
binds to CD28 on T cells (107). Since CD4+CD28null T cells need additional cytokines next 
to allogeneic stimulation, inhibition of immune cells that can provide these cytokines 
will lead to a low alloresponsive state. In co-stimulatory blockade resistant rejections 
however, the severity of rejections are more serious compared with rejections under 
cyclosporine (108, 109). A study by de Graav et al. demonstrated the presence of CD86+ 
monocytes in the rejected allograft under belatacept treatment (109). This severity could 
be explained by the production of IL-15 by these monocytes and probably also the renal 
tubular epithelial cells, which might lead to activation of highly proinflammatory and 
cytotoxic CD28null T cells. 
In conclusion, CD4+CD28null T cells can become alloreactive when the proper conditions 
are met, especially in presence of IL-15. IL-21 can enhance the cytotoxic potential of 
CD4+CD28null T cells.
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INTRODUCTION
Patients with end-stage renal disease (ESRD) have a prematurely aged T-cell system. 
This process is likely induced by the pro-inflammatory uremic environment created by 
the loss of renal function (54) and is marked by lower thymic output, increased T-cell 
differentiation and telomere shortening (11).
The changes in the peripheral T-cell compartment of ESRD patients resemble 
the physiological changes in the immune systems of healthy elderly persons (13, 20, 58). 
Studies analyzing these T-cell ageing parameters in ESRD patients, using healthy elderly 
persons as a reference, showed a discrepancy of 15–20 years between the immunological 
and chronological ages of T cells of ESRD patients (11, 12).
A characteristic of this process is lower thymic output, noted by a decrease in newly 
formed naive T cells (i.e. recent thymic emigrants [RTE]) (11). In addition, increased 
T-cell differentiation leads to a more differentiated memory T-cell compartment. Both 
mechanisms together reduce the percentage of naive T cells in the circulation to 
a relatively high extent (11, 56). Another feature of T-cell differentiation is the loss 
of the costimulatory molecule CD28 on the surface of memory T cells (27), enabling 
these cells to become activated without costimulation. Furthermore, the increments of 
proliferation and differentiation reduce the telomere length (11, 30, 57).
The prematurely aged T-cell system of ESRD patients is associated with a reduced 
vaccination response (8-10, 59) and an increased susceptibility to infection (7). The latter 
is a major cause of mortality in ESRD patients, in addition to cardiovascular disease (7, 
110, 111). Immunosuppressive drugs given after renal transplantation (RTx) increase 
the risk of severe and opportunistic infections (OIs). Whether the degree of preexistent 
uremia-associated immunodeficiency adds to this increased susceptibility is unknown. In 
healthy elderly persons, an immunological risk profile (IRP) has been established (20, 112). 
Potentially, the identification of an IRP based on ageing parameters in patients eligible 
for RTx would allow for a more personalized regimen of immunosuppressive medication.
In this study, we investigated whether the degree of premature T-cell ageing prior to 
and within the first year after RTx is associated with the risk of infections after RTx.
MATERIALS AND METHODS
Study population
All ESRD patients who received a kidney from a living donor in the period from November 
1, 2010, to October 1, 2013, were considered for participation. We excluded patients if 
they were lost to follow-up (n=6) or received T-cell depletion therapy (n=17). The latter 
were excluded because these agents cause significant long-lasting T-cell depletion with 
a subsequent increased risk of severe infections (113, 114). All patients gave written 
informed consent to participate in the clinical trial and in the substudy, which is presented 
in this paper. The study was approved by the medical ethics committee of the Erasmus 
Medical Center (MEC number 2010-080, EudraCT 2010-018917-30) and was conducted 
in accordance with the Declaration of Helsinki and the Declaration of Istanbul.
ABSTRACT
Background
Patients with end-stage renal disease have prematurely aged T cell systems. We tested 
whether T-cell ageing parameters were associated with the risk of infections after renal 
transplantation (RTx). 
Methods
We studied 188 patients over 1 year. Peripheral T cells were analyzed before and at 3 and 
6 mo after RTx for frequency of recent thymic emigrants, relative telomere length and 
differentiation status. These parameters were related to the occurrence of opportunistic 
and serious infections. 
Results
Overall, 84 patients developed an infection. In this group, 50 developed an opportunistic 
infection and 53 developed a serious infection. T-cell ageing parameters assessed before 
RTx were not associated with infection risk. The memory T cells showed a decrease within 
the first 3 months in both groups (p<0.001). The CD4+ memory T cells increased between 
3 and 6 months within the infection group (p=0.015). The number of CD8+ memory T 
cells increased in both groups (p<0.001) but reached baseline levels only in the infection 
group. In the infection group, the CD8+CD28null T-cell percentage increased between 3 and 
6 months (p=0.024), tending to be higher than at baseline (p=0.061). These differences 
in post-RTx dynamics resulted from infections. 
Conclusion
Parameters of uremia-associated premature ageing of peripheral T cells do not predict 
posttransplant infections.
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All patients received similar immunosuppressive regimens. This included induction 
therapy with basiliximab (Simulect; Novartis, Basel, Switzerland) and maintenance 
therapy with tacrolimus (Prograf; Astellas Pharma, Tokyo, Japan), mycophenolate mofetil 
(Cellcept; Roche, Basel, Switzerland) and glucocorticoids.
Clinical variables were assessed, as shown in Table 1, including age, sex, cytomegalovirus 
(CMV) seropositivity, HLA mismatches, current and historical panel reactive antibody 
scores, number of previous RTx, warm ischemia time, underlying cause of renal failure, 
preemptive RTx and genetically related RTx. HLA typing was performed according to 
international standards (American Society for Histocompatibility and Immunogenetics, 
European Federation for Immunogenetics) using serological and DNA-based techniques. 
The panel reactive antibodies were determined at the laboratory of the blood bank in 
Leiden, the Netherlands.
The infections occurring within the first year after RTx were scored for type of 
infection (serious infection [SI] or OI), the causative microorganism (viruses, bacteria, 
fungi), the number of infections per patient and the time until infection development (in 
days) (Table 2). We defined an OI as an infection associated with cellular and humoral 
immunosuppression. These included viral infections such as CMV, Epstein-Barr virus 
(EBV), herpes simplex virus, varicella zoster virus and polyomavirus; bacterial infections 
such as typical and atypical mycobacteria, Listeria, Legionella and Nocardia; and fungal 
infections such as Pneumocystis jirovecii pneumonia (PCP), Aspergillus, Cryptococcus 
and Candida. CMV viremia was detected by viral genome quantification in blood by 
real-time polymerase chain reaction (PCR), and CMV disease was considered if this was 
accompanied by clinical signs and/or organ involvement. Quantification of EBV, varicella 
zoster virus, herpes simplex virus and polyomavirus DNA was assessed by real-time PCR 
assays. EBV infection was considered if there were clinical signs and/or organ involvement. 
BK nephropathy was diagnosed if histologically confirmed via a renal biopsy. We defined 
an SI as any infection requiring admission to the hospital. We excluded infections of 
iatrogenic cause, such as urinary tract infections due to catheterization. These SIs were 
categorized into four groups based on the tract that was involved (i.e. urinary tract, 
respiratory tract, gastrointestinal, and other) (Table 2).
Isolation of peripheral blood mononuclear cells
By using Ficoll-Paque Plus (GE Healthcare, Uppsala, Sweden), peripheral blood 
mononuclear cells were isolated from heparinized blood samples. Blood was drawn from 
RTx recipients the day before RTx (T=0), and at 3 months (T=3) and 6 months (T=6) 
after RTx. The isolated peripheral blood mononuclear cells were stored at -150°C with 
a minimum amount of 10×106 cells per vial.
T-cell differentiation status and absolute numbers of T-cell subsets
To determine T-cell differentiation status, whole-blood staining was performed based on 
a study by Sallusto et al. (22), as described in detail in a previous study (11). The absolute 
numbers of the different T-cell subsets were determined via Trucount staining (Becton 
Dickinson, Franklin Lakes, NJ), as described by Bouvy et al. (115). 
Relative telomere length
To determine the relative telomere length (RTL) of CD4+ and CD8+ T cells, flow fluorescent 
in situ hybridization was performed, as described in detail by a previous study (11).
Statistical analysis
All variables were presented as medians with interquartile ranges. The differences between 
continuous variables were assessed with the Mann–Whitney U test. The difference between 
categorical variables was analyzed with either the Pearson chi-square test or the Fisher 
exact test, depending on the expected values in any of the cells of a contingency table. In 
case of repeated measurements, a nonparametric repeated measures analysis of variance 
(Friedman test) was used, and a correction was made for multiple comparisons. When 
there was a significant difference between the two patient groups, a Cox regression 
analysis was used to assess whether an association could be observed between a variable 
and the development of infection after RTx. The significance level (p-value) was two-
tailed, and an α of 0.05 was used for all analyses. Statistical analyses were performed 
using SPSS version 21.0 for Windows (IBM Corp., Armonk, NY) and GraphPad Prism 5 
(GraphPad Software, La Jolla, CA). Figures were created with GraphPad Prism 5.
RESULTS
Patient and infection characteristics
Of the 211 eligible patients, six were lost to follow-up. Four of those patients underwent 
a transplantectomy due to therapy-resistant acute rejection or vascular problems shortly 
after RTx; the other two patients were referred to their own hospitals soon after RTx. Of 
the remaining 205 patients, 17 received T-cell depletion therapy. This led to 188 patients 
for further analysis. 
Patient characteristics are shown in Table 1. The median patient age was 57 years, 
and the median donor age was 53 years. The majority of patients (93%) underwent 
transplantation for the first time, 13 patients (7%) were transplanted for the second 
time, and one patient (1%) was transplanted for a third time. Of all analyzed patients, 
84 (45%) developed an infection within the first year after RTx. The CMV donor/recipient 
(D/R) serostatus was significantly more often a D+/R– configuration in the infection group 
(p=0.009). Furthermore, a D–/R+ configuration was more often observed in the group 
without infection (p=0.027). There were no other differences between the groups. 
Characteristics of the infections are shown in Table 2. Fifty patients developed an OI, 
and 53 developed an SI. The median time for development of an infection was 2.9 months 
to the first OI and 3.3 months to the first SI; the overall median time for development of 
an infection was 2.9 months. The majority of infections (85%) occurred within the first 6 
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months after RTx, and within this period, the majority (66%) occurred within the first 3 
months (Figure 1A). Most of the OIs were of viral origin, accounting for 96% of the cases. 
Approximately half of the SIs (49%) were urinary tract infections (Table 2 and Figure 1B).
Pretransplant T-cell ageing parameters
Prior to RTx, there was no difference in differentiation status or in numbers of CD4+ 
and CD8+ T cells or the various subsets between the groups with and without infection 
(Table 3). Moreover, the RTLs in both T-cell compartments were not discriminative between 
groups (Table 3). In addition, similar frequencies of RTE were detectable in both groups 
before transplant (Table 3).
Because a primary CMV infection has a significant impact on the T-cell differentiation 
status (27, 42) and more D+/R– RTxs were present in the infection group, we performed 
the same analyses without the D+/R– configuration. These analyses also showed no 
significant differences between groups (data not shown). Moreover, performing the same 
analyses without CMV viremia/disease showed no differences between groups (Table S1). 
Finally, we focused on the development of CMV viremia/disease separately. We divided 
these patients into two different risk groups. The D+/R+ and D–/R+ configurations were 
Table 1. Patient characteristics
RT Patients (n=188)
No Infection (n=104) 
(55%)
Infection (n=84) 
(45%) P
Age recipient 57 (48 – 63) 57 (46 – 65) 0.522
Age Donor 53 (43 – 61) 55 (39 – 63) 0.647
Male recipient 65 (63%) 50 (60%) 0.677
Male donor 50 (48%) 44 (52%) 0.557
CMV seropositivity recipient 67 (64%) 45 (54%) 0.132
CMV serostatus D/R
 -/- 26 (25%) 18 (21%) 0.565
 -/+ 24 (23%) 9 (7%) 0.027
 +/- 11 (11%) 21 (25%) 0.009
 +/+ 43 (41%) 36 (43%) 0.835
Mismatch HLA class I 2 (2 – 3) 2 (2 – 3) 0.622
Mismatch HLA class II 1 (1 – 2) 1 (1 – 2) 0.377
Mismatch HLA class I and II 4 (3 – 5) 4 (3 – 5) 0.924
Current PRA (%) 0 (0 – 4) 0 (0 – 4) 0.887
Historical PRA (%) 4 (0 – 4) 4 (0 – 5) 0.589
Amount of RTx 1 (1 – 1) 1 (1 – 1) 0.072
Warm ischemia time 20 (17 – 24) 19 (16 – 23) 0.177
Underlying disease
 Nephrosclerosis/atherosclerosis/ 
 hypertension
26 (25%) 19 (23%) 0.704
 Primary glomerulopathies 15 (14%) 11 (13%) 0.793
 Diabetes 18 (17%) 21 (25%) 0.196
 Urinary tract infections/stones 3 (3%) 2 (2%) >0.999
 Reflux nephropathy 7 (7%) 2 (2%) 0.303
 Polycystic Kidney Disease 17 (16%) 17 (20%) 0.491
 Other 12 (12%) 8 (10%) 0.656
 Unknown 6 (6%) 4 (5%) >0.999
Pre-emptive RTx 49 (47%) 30 (36%) 0.115
Genetically-related RTx 42 (40%) 32 (38%) 0.749
Data are presented as median (interquartile range) except as noted. Values in bold represent significant 
p-values (p<0.05). CMV, cytomegalovirus; D/R, donor/recipient; PRA, panel reactive antibody; RTx, renal 
transplantation.
Table 2. Infection characteristics
Opportunistic Infections 50 (60%)
 Viral infections 48 (96%)
  CMV viremia 13 (27%)
  CMV disease 12 (25%)
  BK viremia 17 (35%)
  BK nephropathy 2 (4%)
  EBV viremia 6 (13%)
  EBV infection 2 (4%)
  Herpes Simplex 1 (2%)
  Varicella Zoster 3 (6%)
 Bacterial Infections 0 (0%)
Fungal Infections 3 (6%)
Candida 3 (100%)
PCP pneumonia 0 (0%)
 Number of opportunistic infections per patient 1 (1 – 1)
 Days until first opportunistic infection 88 (70 – 185)
Serious Infections 53 (63%)
 Viral Infections 9 (32%)1
 Bacterial Infections 38 (91%)1
 Fungal infections 1 (4%)1
 Type of serious infections
Urinary tract infections 26 (49%)
 Respiratory tract infections 12 (23%)
 Gastrointestinal infections 18 (34%)
 Other infections 15 (28%)
 Number of serious infections per patient 2 (1 – 2)
 Days until first serious infection 99 (50 – 134)
Days until first infection 87 (55 – 140)
Data are presented as absolute number (percentage) or as median (interquartile range). CMV, 
cytomegalovirus; EBV, Epstein-Barr virus; PCP, Pneumocystis jirovecii pneumonia. 1The percentages were 
calculated via exclusion of missing values and refer to the 53 patients with a serious infection.
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defined as moderate-risk groups. From the 112 patients with these configurations, 67 
patients did not develop an infection and 8 developed a CMV viremia/disease. When 
we analyzed the differences between these two groups with regard to CD28null T 
cells, RTL and RTE, we did not observe any differences prior to RTx (Table S2). Patients 
with the D+/R– configuration were defined as high risk (n=32). Of these patients, 
16 developed CMV viremia/disease and 11 did not. The only difference we observed 
between these two groups was, that the percentage of CD8+CD28null T cells was higher 
in the group without infection (Table S3). Furthermore, a negative correlation between 
the frequency of CD8+CD28null T cells and the development of CMV viremia/disease (ρ= 
–0.424, p=0.031) was observed, and a linear regression analysis showed a similar result 
(B= –0.016, p=0.031). We then performed a Cox regression analysis to assess whether 
higher frequencies of these cells were associated with a lower risk of development of CMV 
viremia/disease. We defined time as days until the development of CMV viremia/disease. 
This analysis showed that the hazard ratio per percentage increase of CD8+CD28null T 
cells was equal to 0.95 (95% confidence interval 0.895–0.997, p=0.038). These results 
suggest that in patients with a D+/R– configuration, a higher frequency of CD8+CD28null 
T cells is associated with a lower risk of development of CMV viremia/disease.
Seventeen patients developed an acute rejection, for which they received 1000 mg 
methylprednisolone intravenously on 3 days consecutively. These patients were equally 
present within both groups (data not shown).
Immunological risk profile
Several studies have tried to assess an IRP in persons with immunological ageing 
(20, 112). In these studies, an inverted CD4/CD8 ratio was associated with poor survival 
(20, 112). An important contributor to this inverted ratio was CMV seropositivity 
(21, 58). Based on these findings, we assessed whether an inverted CD4/CD8 ratio and 
CMV seropositivity were able to discriminate between groups. Furthermore, having both 
of these characteristics was defined as a high-risk profile. Having only one or neither of 
these characteristics was defined as a low-risk profile. The results showed that none of 
these variables were able to predict the risk of an infection after RTx (Table 4), and none 
were able to discriminate between OIs and SIs (data not shown).
Posttransplant CD4+ T-cell subset dynamics
The absolute CD4+ T-cell numbers declined significantly between T=0 and T=3 (p < 
0.01) in both groups (Figure 2A). The CD4+ naive T-cell numbers were not affected after 
RTx in both groups (Figure 2B), but the absolute CD4+ memory T-cell numbers declined 
significantly between T=0 and T=3 (p < 0.001 for both groups) (Figure 2C). These numbers 
increased again between T=3 and T=6 and were significant only for the infection group 
(p=0.015). CD4+CD28null T-cell frequencies were not different after RTx between groups 
(Figure 2F). Exclusion of the D+/R– group for CMV did not affect the observed dynamics 
of the CD4+ T-cell compartment.
The different CD4+ T-cell subsets at T=3 were not associated with the development of 
an infection after this period (data not shown). Given the small number of infections after 
6 months (only 13 patients with an infection), T=6 was not considered as a time point for 
the prediction of infections thereafter in the CD4+ T-cell subsets. In contrast, exclusion of 
CMV viremia/disease showed some differences. The CD4+ memory T cells, CD8+ T cells 
and the CD8+ naive T cells seemed lower in the infection group (p=0.078, p=0.031 and 
p=0.053 respectively) (Table S4); however, further analyses showed that there were no 
correlations between these variables and the development of infections after 3 months 
(Table S5).
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Figure 1. Infection characteristics. (A) The amount of infections are represented in three groups 
at RTx and at 3 and 6 months after RTx. The light blue bar represents the number of OIs, the blue 
bar represents the number of SIs, and the green bar represents every infection. (B) The type of 
infections are presented. Among the OIs, the dark blue bar represents the number of viral OIs 
and the light blue bar represents the number of fungal OIs. Among the SIs, from dark green to 
light green, the bars represent the number of urinary tract infections, the number of respiratory 
tract infections, the number of gastrointestinal infections, and the number of other infections, 
respectively. OI, opportunistic infection; RTx, renal transplantation; SI, serious infection.
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Posttransplant CD8+ T-cell subset dynamics
Absolute CD8+ T-cell numbers declined significantly during the first 3 months in the groups 
without and with infection (p<0.001 and p=0.005, respectively) (Figure 3A). Between 
T=3 and T=6, CD8+ T-cell numbers increased again (p=0.009 and p=0.007, respectively), 
approaching baseline levels at T=6. Naive T-cell numbers were not affected after RTx in 
both groups (Figure 3B). The CD8+ memory T-cell numbers (Figure 3C) declined significantly 
during the first 3 months after RTx in both groups (p<0.001), with a significant increase 
thereafter (p<0.001), reaching baseline levels only in the infection group. For the group 
without infection, a shift was observed toward relatively more highly differentiated 
effector memory CD45RA+ T cells at T=6 (Figure 3D–F). The CD8+CD28null T-cell frequencies 
declined significantly between T=0 and T=3 (p<0.001) in the group without infection 
(Figure 3G), with a subsequent increase thereafter (p=0.007). In the infection group, 
the CD8+CD28null T-cell frequencies increased significantly (p=0.024) between T=3 and 
T=6, almost resulting in a larger value than at baseline (p=0.061).
The different CD8+ T-cell subsets at T=3 were not associated with the development of 
infections after this period (data not shown).
RTL and RTE after transplant
The RTL of the CD4+ T-cell population was not affected after RTx in both groups (Figure 
4A). The RTL of the CD8+ T-cell population increased only in the infection group between 
T=0 and T=3 (p=0.018) and remained similar thereafter (Figure 4B). The RTL of the CD8+ 
T-cell population in the group without infection did not change during the whole period 
(Figure 4B).
In the group without infection, the percentage of RTE within the naive CD4+ T-cell 
population declined between T=0 and T=3 (p=0.013) (Figure 4C), whereas the percentage 
of RTE within the naive CD8+ T-cell population showed no differences (Figure 4D). 
Frequencies of RTE remained similar during the rest of the period for naïve CD4+ T cells. 
In the infection group, the percentage of RTE within the naive CD4+ and CD8+ T-cell 
population remained similar (Figures 4C and D). 
Neither RTL nor the number of RTE at T=3 was associated with subsequent 
infections thereafter.
DISCUSSION
This prospective study tested the hypothesis that the degree of premature immunological 
ageing before and after transplant predicts the risk of infections after RTx. Furthermore, 
we compared our findings with immune risk parameters defined by other studies 
(20, 112). This study is the first in its field because of its prospective nature, clinical 
setting, well-defined parameters and large group of patients with the exclusion of those 
receiving T-cell depletion therapy.
The majority of infections occurred within the first 6 months after RTx, which 
is in accordance with the generally observed course of infections after solid organ 
Table 3. T-cell ageing parameters prior to renal transplantation
At T=0 (n=188) No Infection (n=104) (55%) Infection (n=84) (45%) P 
CD4 cells (cells/µL)
CD4 naïve (cells/µL)
CD4 memory (cells/µL)
Naïve/memory CD4 
CD4 CM of CD4 memory (%)
CD4 EM of CD4 memory (%)
CD4 EMRA of CD4 memory (%)
CD28null of CD4 (%)
CD8 cells (cells/µL)
CD8 naïve (cells/µL)
CD8 memory (cells/µL)
Naïve/memory CD8
CD8 CM of CD8 memory (%)
CD8 EM of CD8 memory (%)
CD8 EMRA of CD8 memory (%)
CD28null of CD8 (%)
RTL CD4 
RTL CD8 
CD31 of naive CD4 (%)
CD31 of naive CD8 (%)
688 (524 – 887) 
207 (102 – 336)
467 (357 – 573)
0.45 (0.23 – 0.70)
61.7 (49.8 – 73.5) 
35.4 (24.5 – 45.8)
1.9 (0.7 – 4.2)
3.0 (0.5 – 8.9)
390 (254 – 503)
64 (32 – 104)
283 (189 – 405)
0.20 (0.10 – 0.53)
6.3 (3.5 – 13.5)
45.1 (29.8 – 58.5)
44.4 (27.8 – 64.9) 
43.4 (23.8 – 61.2)
12.2 (9.8 – 14.7)
11.5 (9.5 – 14.6)
65.8 (55.8 – 75.4)
97.6 (94.5 – 98.8)
691 (441 – 913) 
170 (96 – 326)
456 (296 – 650)
0.40 (0.21 – 0.73)
60.6 (46.4 – 68.8)
36.3 (28.5 – 47.8)
2.1 (1.3 – 4.1)
2.5 (0.3 – 10.9)
328 (210 – 496)
53 (25 – 105)
251 (136 – 345)
0.24 (0.10 – 0.54)
7.0 (2.7 – 12.0)
47.1 (28.9 – 61.4)
44.1 (26.4 – 58.7) 
37.0 (17.6 – 59.6)
11.6 (8.9 – 15.1)
11.0 (8.9 – 15.8)
66.8 (52.9 – 72.8)
97.9 (94.4 – 99.2)
0.763
0.642
0.895
0.916
0.476
0.359
0.305
0.681
0.122
0.433
0.129
0.689
0.723
0.710
0.697
0.269
0.954
0.997
0.382
0.346
Data are presented as medians (interquartile range). EMRA, effector memory CD45RA+; RTL, relative 
telomere length; T=0, time of renal transplantation; TCM, central memory T cells; TEM, effector 
memory T cells.
Table 4. Immunological Risk Profile
RT Patients (n=188) No Infection (n=104) (55%) Infection (n=84) (45%) P
CMV seropositivity
 CMV negative
 CMV positive
CD4/CD8 ratio
 ≥ 1
 < 1
Immune Risk Profile
 Low Risk Profile
 High Risk Profile 
37 (36%)
67 (64%)
90 (87%)
13 (13%)
93 (89%)
10 (10%)
39 (46%)
45 (54%)
73 (87%)
11 (13%)
77 (92%)
7 (8%) 
0.132
0.923
0.745
Data are presented as absolute number (percentage). CMV, cytomegalovirus; RTx, renal transplantation.
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Figure 2. Dynamics of CD4+ T cells. The courses of (A) CD4+ T cells, (B) CD4+ TNAIVE, (C) CD4
+ TMEM, 
(D) CD4+ TCM within CD4
+ TMEM, (E) CD4
+ TEM within CD4
+ TMEM, and (F) CD4
+CD28null within CD4+ T 
cells at T=0, T=3, and T=6 are represented. The white bars represent the no-infection group, and 
the green bars represent the infection group. The bars represent the medians with interquartile 
ranges. Absolute numbers of cells are depicted (cells/µL) for graphs (A–C) and percentages are 
depicted for graphs (D–F). Significant differences were calculated and shown (*p<0.05, **p≤0.01, 
***p≤0.001). RTx, renal transplantation; T=0, time of RTx; T=3, 3 months after RTx; T=6, 6 months 
after RTx; TCM, central memory T cells; TEM, effector memory T cells; TMEM, memory T cells; TNAIVE, 
naive T cells.
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Figure 3. Dynamics of CD8+ T cells. The courses of (A) CD8+ T cells, (B) CD8+ TNAIVE, (C) CD8
+ TMEM, 
(D) CD8+ TCM within CD8
+ TMEM, (E) CD8
+ TEM within CD8
+ TMEM, (F) CD8
+ EMRA T cells within CD8+ 
TMEM, and (G) CD8
+CD28null within CD8+ T cells at T=0, T=3, and T=6 are represented. The white 
bars represent the no-infection group, and the green bars represent the infection group. The bars 
represent the medians with interquartile ranges. Absolute numbers of cells are depicted (cells/
µL) for graphs (A–C), and percentages are depicted for graphs (D–G). Significant differences were 
calculated and shown (*p<0.05, **p≤0.01, ***p≤0.001). EMRA, effector memory CD45RA+; RTx, 
renal transplantation; T=0, time of RTx; T=3, 3 months after RTx; T=6, 6 months after RTx; TCM, 
central memory T cells; TEM, effector memory T cells; TMEM, memory T cells; TNAIVE, naive T cells.
transplantation (116). The most common OI after RTx was CMV related, accounting 
for approximately half of these infections; this finding is supported by other studies 
(117-119). Urinary tract infections accounted for the majority of SIs in our study and have 
also been described by previous studies (120-122).
T-cell ageing parameters before transplant were not predictive for an infection, and 
exclusion of primary CMV infections (D+/R–) did not influence this. This indicates that 
the degree of T-cell ageing is not associated with the risk of infection after RTx in contrast 
to the association between aged T cells and a lowered risk for acute rejection (66, 67). 
The only association we found was between the development of CMV viremia/disease 
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in patients with a D+/R– configuration and the frequency of CD8+CD28null T cells before 
transplant. We found that a higher frequency of CD8+CD28null T cells is associated with 
a lower risk for the development of CMV viremia/disease. This might be related to the fact 
that these cells are preformed CMV-specific T cells in CMV-seronegative patients. A study 
by Lúcia et al. showed that CMV-specific interferon γ–producing memory T cells were 
present in CMV-seronegative patients and that high numbers of these cells provided 
clinical protection (123).
A study by Schürmann et al. showed that low counts of RTE and CD4+ T cells 
before transplant were associated with the risk of PCP after RTx (124); however, after 
a multivariate regression analysis, only the pretransplant CD4+ T lymphopenia and acute 
rejection within 3 months after RTx were associated with PCP (124). This study focused 
only on the development of PCP, whereas none of the patients in our study developed 
PCP. Furthermore, we analyzed each type of infection and did not concentrate on only one 
pathogen. Moreover, CD4+ T lymphopenia was defined as a CD4+ T-cell count of <300/
µL (124). In our study, only 12 of 188 patients had such severe CD4+ T lymphopenia, and 
they were distributed equally over both groups. In addition, the study by Schürmann et 
al. included patients experiencing an acute rejection treated with T-cell depletion therapy, 
explaining the association found between acute rejection and the risk of PCP (124). As 
expected, in this study, we also observed a strong association between T-cell depletion 
therapy and the risk of infections (14 of the 17 patients treated with T-cell depletion 
therapy developed an infection). Inclusion of these patients introduces a severe bias in 
the interpretation of the results; therefore, this group was excluded from our analyses.
Studies in the very old healthy population have identified an IRP as positively associated 
with increased morbidity and mortality (20, 112). This IRP was not predictive of an increased 
risk of infection within the first year after RTx in our cohort. The follow-up period for 
the very old healthy persons was much longer compared with our study. Furthermore, 
mortality as an end point covers all possible causes of death, not only infections. These 
differences could explain why an IRP is not a parameter for the prediction of infections in 
the first year after RTx.
Furthermore, we investigated whether the degree of premature T-cell ageing after 
transplant was associated with the risk of OIs and SIs. We did not find an association 
between the ageing parameters assessed at T=3 and infections thereafter; however, we 
observed that the infection group showed different posttransplant dynamics in T-cell 
subsets. We previously reported that the number of memory T cells decreases in the first 
months after RTx and thereafter is restored to pretransplant values between months 6 
and 12 (125). The infection group showed a similar declining trend in memory T-cell 
numbers, but these returned much more to baseline (T=0) values at T=6, particularly 
within the CD8+ compartment, compared with the group without infection. The different 
posttransplant T-cell dynamics were clearly caused by the infections. The significant rise 
in CD8+CD28null T-cell percentage in the infection group, for example, was most likely 
caused by a primary CMV infection (27, 58, 126). A study by Calarota et al. showed 
that the drop in CD4+ T cells coincided with the peak of OIs (119). Given our results, it is 
evident that a significant decrease in CD4+ T cells occurs in all patients within this period, 
in which the majority of infections occur, and is not a causal association. In contrast, 
another study showed that a low CD4+ T-cell count during the period after RTx, defined as 
a count <300/µL, predicted infection occurrence after RTx (127). Again, this observation 
might be influenced by inclusion of patients experiencing a rejection episode and treated 
with T-cell depletion therapy because low CD4+ T-cell counts were associated with a more 
aggressive immunosuppressive regimen (127).
In contrast to the results of this study, other studies have reported that low values 
of RTE and RTL and a higher frequency of late-stage differentiated T cells are associated 
with infection development (113, 114); however, those patient cohorts were much more 
heterogeneous, and the use of anti–thymocyte globulin in these studies may have been 
an important confounder.
Another factor determining the course of T-cell ageing parameters is the intensity of 
the immunosuppressive regimen during the first 3 months. Most immunosuppression 
after RTx aims to attack the most aggressive T cells, namely, memory T cells (125, 128, 
129). This probably explains the sharp decline in memory T-cell numbers in both groups 
during the first 3 months. Studies have shown that immunosuppressive drugs can 
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Figure 4. RTL and RTE after renal transplantation. The course of the RTL of (A) CD4+ and 
(B) CD8+ T cells and the course of RTE within (C) CD4+ TNAIVE and (D) CD8
+ TNAIVE at T=0, T=3, 
and T=6 are represented. The white bars represent the no-infection group, and the green bars 
represent the infection group. The bars represent the medians with interquartile ranges. For the RTE, 
percentages of cells are depicted. Significant differences were calculated and shown (*p<0.05, 
**p≤0.01, ***p≤0.001). RTE, recent thymic emigrants; RTL, relative telomere length; RTx, renal 
transplantation; T=0, time of RTx; T=3, 3 months after RTx; T=6, 6 months after RTx; TNAIVE, 
naive T cells.
U
REM
IA
 A
SSO
C
IA
TED
 PREM
A
TU
RE A
G
EIN
G
 O
F T C
ELLS A
N
D
 IN
FEC
TIO
N
S
U
REM
IA
 A
SSO
C
IA
TED
 PREM
A
TU
RE A
G
EIN
G
 O
F T C
ELLS A
N
D
 IN
FEC
TIO
N
S
44
70 71
influence T-cell memory negatively because transplant recipients show lower or defective 
vaccination responses compared with healthy persons and show reactivation of latent 
viruses (128, 129).
In summary, various measures of T-cell ageing before and at 3 months after RTx are 
not predictive for infection risk after transplant. Memory T-cell dynamics after RTx are 
changed by infections but merely as a consequence of these infections, in particular, 
CMV infection.
A possible explanation for the lack of a relationship between T-cell ageing parameters 
and infections after transplant may lie in the fact that the relatively mild effects of 
T-cell ageing are overshadowed by the use of triple immunosuppression. Even in elderly 
patients with chronic diseases, true OIs are not observed, whereas a much younger 
patient who receives immunosuppressants is susceptible to these types of infections (116, 
130). Another explanation may be found in the source of T cells that we used for our 
study. Tissue-derived resident T cells or those within secondary lymphoid organs may be 
a better representative population to gauge the immune function in ESRD patients than 
peripheral blood–derived T cells. The prematurely aged immune system in ESRD patients 
remains largely unchanged after successful RTx (125) and may become more relevant 
after a longer period in combination with immunosuppressive drugs. This could explain 
why a number of studies (127, 131, 132) have shown a relationship between persistent 
lymphopenia (not caused by T-cell depletion) after transplant and the long-term risk of 
cancer. An association with the consequences of infections >1 year after RTx will need 
further investigation.
In conclusion, this study analyzed the role of the prematurely aged T-cell system 
in ESRD patients before and after RTx in relation to the development of infections in 
a homogeneous patient population without T-cell depleting therapy. Our findings show 
that the tested T-cell parameters cannot be used to identify patients at risk for infection 
after transplantation.
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SUPPLEMENTARY FILES
Supplementary Table 1. T-cell ageing parameters prior to renal transplantation (without 
CMV viremia/disease)
RT Patients (n=188)
No Infection (n=104) 
(55%) Infection (n=59) (31%) P 
CD4 cells at T=0 (cells/µL)
CD4 naïve at T=0 (cells/µL)
CD4 memory at T=0 (cells/µL)
Naïve/memory CD4 at T=0
CD4 CM of CD4 memory at T=0 (%)
CD4 EM of CD4 memory at T=0 (%)
CD4 EMRA of CD4 memory at T=0 (%)
CD28null of CD4 at T=0 (%)
CD8 cells at T=0 (cells/µL)
CD8 naïve at T=0 (cells/µL)
CD8 memory at T=0 (cells/µL)
Naïve/memory CD8 at T=0
CD8 CM of CD8 memory at T=0 (%)
CD8 EM of CD8 memory at T=0 (%)
CD8 EMRA of CD8 memory at T=0 (%)
CD28null of CD8 at T=0 (%)
RTL CD4 at T=0
RTL CD8 at T=0
CD31 of naive CD4 at T=0 (%)
CD31 of naive CD8 at T=0 (%)
688 (524 – 887) 
207 (102 – 336)
467 (357 – 573)
0.45 (0.23 – 0.70)
61.7 (49.8 – 73.5) 
35.4 (24.5 – 45.8)
1.9 (0.7 – 4.2)
3.0 (0.5 – 8.9)
390 (254 – 503)
64 (32 – 104)
283 (189 – 405)
0.20 (0.10 – 0.53)
6.3 (3.5 – 13.5)
45.1 (29.8 – 58.5)
44.4 (27.8 – 64.9) 
43.4 (23.8 – 61.2)
12.2 (9.8 – 14.7)
11.5 (9.5 – 14.6)
65.8 (55.8 – 75.4)
97.6 (94.5 – 98.8)
714 (454 – 948) 
151 (91 – 327)
457 (297 – 648)
0.40 (0.19 – 0.69)
61.2 (52.0 – 70.5)
36.3 (28.1 – 46.6)
2.0 (1.1 – 4.0)
2.7 (0.3 – 10.9)
342 (220 – 514)
45 (24 – 100)
268 (151 – 361)
0.21 (0.09 – 0.53)
6.4 (2.7 – 12.1)
46.9 (26.0 – 59.1)
43.0 (26.3 – 64.0) 
42.1 (20.5 – 60.1)
12.3 (8.9 – 15.3)
10.4 (8.6 – 15.8)
65.4 (52.9 – 71.8)
97.9 (94.0 – 99.1)
0.871
0.622
0.858
0.515
0.876
0.638
0.645
0.944
0.281
0.162
0.542
0.611
0.599
0.947
0.922
0.901
0.755
0.604
0.303
0.551
Data are presented as medians (interquartile range). 
Supplementary Table 2. T-cell ageing parameters prior to renal transplantation for CMV D+/R+ & 
D-/R+ (moderate risk)
RT Patients (n=188)
No CMV viremia/disease 
(n=67) (36%)
CMV viremia/disease 
(n=8) (4%) P 
CD28null of CD4 at T=0 (%)
CD28null of CD8 at T=0 (%)
RTL CD4 at T=0
RTL CD8 at T=0
CD31 of naive CD4 at T=0 (%)
CD31 of naive CD8 at T=0 (%)
4.9 (2.6 – 11.4)
54.2 (36.8 – 66.9)
12.3 (9.6 – 15.4)
11.5 (9.3 – 14.4)
65.8 (56.6 – 76.3)
96.7 (93.9 – 98.7)
13.0 (4.5 – 19.7)
62.1 (46.5 – 67.2)
8.6 (6.4 – 13.7)
10.9 (8.2 – 15.8)
66.5 (47.0 – 82.7)
97.2 (96.2 – 99.2)
0.124
0.591
0.116
0.753
0.860
0.303
Data are presented as medians (interquartile range).
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Supplementary Table 3. T-cell ageing parameters prior to renal transplantation for CMV D+/R- (high risk)
RT Patients (n=188)
No CMV viremia/disease 
(n=11) (6%)
CMV viremia/disease 
(n=16) (9%) P 
CD28null of CD4 at T=0 (%)
CD28null of CD8 at T=0 (%)
RTL CD4 at T=0
RTL CD8 at T=0
CD31 of naive CD4 at T=0 (%)
CD31 of naive CD8 at T=0 (%)
0.5 (0.2 – 4.8)
27.6 (11.2 – 37.9)
11.8 (10.2 – 18.2)
14.9 (11.8 – 16.3)
69.5 (48.2 – 72.1)
97.9 (94.3 – 99.4)
0.3 (0.2 – 2.0)
17.6 (10.4 – 21.7)
11.6 (9.8 – 16.8)
14.0 (10.1 – 17.4)
67.6 (45.8 – 76.9)
99.0 (91.8 – 99.4)
0.507
0.036
0.927
0.923
0.919
0.683
Data are presented as medians (interquartile range). 
Supplementary Table 4. T-cell ageing parameters 3 months after renal transplantation 
(without CMV viremia/disease)
RT Patients (n=188)
No Infection (n=104) 
(55%)
Infection (n=26) 
(14%) P 
CD4 cells at T=3 (cells/µL)
CD4 naïve at T=3 (cells/µL)
CD4 memory at T=3 (cells/µL)
Naïve/memory CD4 at T=3
CD4 CM of CD4 memory at T=3 (%)
CD4 EM of CD4 memory at T=3 (%)
CD4 EMRA of CD4 memory at T=3 (%)
CD28null of CD4 at T=3 (%)
CD8 cells at T=3 (cells/µL)
CD8 naïve at T=3 (cells/µL)
CD8 memory at T=3 (cells/µL)
Naïve/memory CD8 at T=3
CD8 CM of CD8 memory at T=3 (%)
CD8 EM of CD8 memory at T=3 (%)
CD8 EMRA of CD8 memory at T=3 (%)
CD28null of CD8 at T=3 (%)
RTL CD4 at T=3
RTL CD8 at T=3
CD31 of naive CD4 at T=3 (%)
CD31 of naive CD8 at T=3 (%)
511 (320 – 785) 
182 (91 – 328)
312 (215 – 485)
0.59 (0.30 – 0.92)
63.6 (50.7 – 73.0) 
32.7 (24.0 – 42.9)
2.4 (1.1 – 4.7)
3.0 (1.1 – 7.6)
272 (180 – 441)
64 (27 – 126)
188 (116 – 328)
0.31 (0.14 – 0.81)
7.4 (3.7 – 12.3)
42.9 (28.8 – 54.5)
49.6 (29.7 – 65.2) 
39.2 (20.4 – 59.9)
13.3 (11.5 – 16.9)
13.0 (10.2 – 16.1)
65.0 (51.2 – 75.7)
98.0 (95.5 – 99.1)
410 (322 – 613) 
146 (94 – 300)
251 (162 – 363)
0.73 (0.27 – 1.02)
64.1 (57.1 – 73.4)
33.8 (23.6 – 40.5)
2.6 (1.4 – 3.4)
3.3 (0.6 – 10.2)
188 (122 – 364)
48 (18 – 74)
121 (70 – 293)
0.29 (0.07 – 0.68)
6.4 (3.3 – 12.8)
48.2 (31.5 – 57.4)
41.8 (29.6 – 55.1) 
35.5 (14.9 – 64.1)
11.7 (8.5 – 16.6)
12.5 (9.3 – 16.4)
65.6 (49.6 – 71.8)
97.7 (93.8 – 99.3)
0.187
0.574
0.078
0.490
0.974
0.947
0.993
0.725
0.031
0.053
0.098
0.472
0.753
0.282
0.344
0.837
0.163
0.520
0.629
0.919
Data are presented as medians (interquartile range). 
Supplementary Table 5. Correlation between T-cell parameters and infection after 3 months 
(without CMV viremia/disease)
T-cell parameter ρ P
CD4 memory at T=3 (cells/µL)
CD8 cells at T=3 (cells/µL)
CD8 naïve at T=3 (cells/µL)
-0.07
-0.11
-0.16
0.409
0.235
0.063
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ABSTRACT
Background 
Ageing is associated with changes in the peripheral T-cell immune system, which can 
be significantly influenced by latent cytomegalovirus (CMV) infection. To what extent 
changes in circulating T-cell populations correlate with T-cell composition of the lymph 
node (LN) is unclear, but is crucial for a comprehensive understanding of the T-cell system. 
Methods 
T cells from peripheral blood (PB) and LN of end-stage renal disease patients were analyzed 
for frequency of recent thymic emigrants using CD31 expression and T-cell receptor 
excision circle content, relative telomere length and expression of differentiation markers. 
Results 
Compared with PB, LN contained relatively more CD4+ than CD8+ T cells (p<0.001). 
The percentage of naïve and central memory CD4+ and CD8+ T cells and thymic output 
parameters, showed a strong linear correlation between PB and LN. Highly differentiated 
CD28null T cells, being CD27–, CD57+ or programmed death 1 (PD-1+), were found almost 
exclusively in the circulation but not in LN. An age-related decline in naïve CD4+ and 
CD8+ T-cell frequency was observed (p=0.035 and p=0.002 respectively) within LN, 
concomitant with an increase in central memory CD8+ T cells (p=0.033). Latent CMV 
infection increased dramatically the frequency of circulating terminally differentiated T 
cells, but did not alter T-cell composition and ageing parameters of LN significantly. 
Conclusion 
Overall T-cell composition and measures of thymic function in PB and LN are correlated 
strongly. However, highly differentiated CD28null T cells, which may comprise a large part 
of circulating T cells in CMV-seropositive individuals, are found almost exclusively within 
the circulation.
INTRODUCTION
One of the dominant aspects of the ageing process in the T-cell immune system, is 
a decreased thymic output of newly formed T cells, named recent thymic emigrants 
(RTE). This is evident from a decrease in circulating naive T cells expressing CD31, 
and by a decrease in T-cell receptor excision circles (TREC) content (16-18, 133, 134). 
Furthermore, an increase in age leads to a decline in the frequency of circulating naive T 
cells, while the memory T-cell compartment may contain more terminally differentiated T 
cells (20, 21). This progressive T-cell differentiation is also marked by the loss of the co-
stimulatory molecule CD28 on the surface of memory T cells (27), which enables these 
cells to become activated without the need for co-stimulation. Next to the loss of CD28, 
the loss of CD27, and the expression of CD57 and PD-1 are indicators of terminal T-cell 
differentiation (24-26). Lastly, the increased number of rounds of T-cell proliferation and 
differentiation reduces the telomere length of T cells (45, 46).
Cytomegalovirus (CMV) infection needs to be taken into account when 
the T-cell compartment is analyzed, as this infection may cause a significant imprint on 
the differentiation status of circulating T cells (27, 42). In general, it leads to an expansion 
of late-differentiated CD4+ and CD8+ T cells and an inverted CD4:CD8 T-cell ratio (43). 
Furthermore, CMV infection may lead to a reduction in telomere length of T cells (135).
The impact of an aged circulating T-cell population has been studied, for example, 
in relation to the risk for infection, decreased vaccination response and cardiovascular 
events (29, 33, 136). In addition, the presence of highly differentiated CD28null T cells 
in the peripheral blood has gained considerable interest in the field of solid organ 
transplantation as they may be instrumental in co-stimulatory blockade resistant rejection 
and long-term allograft (dys)function (29, 31, 34, 63, 137). Analysis of the T-cell population 
in lymph nodes (LNs) might prove to be of additional/higher value, as immune responses 
are initiated in secondary lymphoid organs. Until now, little is known about how changes 
in circulatory T cells relate to changes in the LN, and only a few studies have investigated 
the effect of ageing in secondary lymphoid organs (49, 50).
In this study, we investigated the relation between T-cell parameters of the LN and 
PB compartments in end-stage renal disease (ESRD) patients. More specifically, ageing 
parameters such as thymic output, relative telomere length (RTL), terminal differentiation 
markers and the influence of CMV infection on these were studied. Our results show 
that overall T-cell composition and measures of thymic function are strongly correlated 
between PB and LN. However highly differentiated CD28null T cells, which may comprise 
a large part of circulating T cells in CMV-seropositive individuals, are virtually absent 
in LNs.
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MATERIALS AND METHODS
Study population
Patients prior to kidney transplantation in the period from August 2015 to March 2016 
were eligible for participation. All patients gave written informed consent to participate 
in this study. The study was approved by the Medical Ethical Committee of the Erasmus 
MC (MEC number 2015-301) and was conducted in accordance with the Declaration of 
Helsinki and the Declaration of Istanbul.
Clinical variables were assessed as shown in Table 1, including age, gender, CMV-
seropositivity, underlying cause of renal failure, dialysis prior to transplantation and 
dialysis vintage (defined as time on dialysis since the start of any type of dialysis).
PBMC isolation
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood samples 
by using Ficoll-Paque Plus (GE healthcare, Uppsala, Sweden). Blood was obtained from 
renal transplant recipients one day prior to RT. The isolated PBMCs were stored at -150°C 
with a minimum amount of 10×106 cells per vial. The median frequency of lymphocytes 
within heparinized blood amounted to 21.9% (17.7%–26.6%) and following density 
gradient centrifugation this frequency amounted to 72.6% (64.7%–76.7%).
LNMC isolation
Iliac LNs were isolated from tissue which was obtained as waste material from renal 
transplant recipients at the time of implantation of the renal allograft. Upon arrival of 
the material at the laboratory, excessive fat tissue around the LNs was removed. Next, 
the LNs were minced and subsequently mashed through a 70 µm sieve to obtain a cell 
suspension. Then, the cell suspension was centrifuged several times to remove platelets 
and remaining fat tissue. The isolated lymph node mononuclear cells (LNMCs) were stored 
at -150°C with a minimum amount of 10×106 cells per vial. The median yield of a lymph 
node was 20×106 cells. The median frequency of lymphocytes within LNMNCs amounted 
94.8% (92.0% - 96.3%).
T-cell differentiation status
T-cell differentiation status was determined through a whole blood staining and on freshly 
isolated LNMCs, which was based upon the study by Sallusto et al. (22) as described in 
detail previously (11). These cell samples were measured on the fluorescence activated 
cell sorter (FACS)Canto II (BD Biosciences, San Jose, CA, USA) and analyzed with the FACS 
Diva software version 6.1.2 (BD Biosciences). Briefly, differential cell surface expression of 
CD45RO (pan-T cell marker for memory T cells) and CCR7 (a chemokine receptor involved 
in homing of T cells to various secondary lymphoid organs such as lymph nodes) was used 
to distinguish naive from different memory T-cell populations. Memory T cells differentiate 
into central-memory T cells (CD45RO+CCR7+ T cells, able to access the lymphoid tissue), 
effector-memory T cells (CD45RO+CCR7– T cells) and EMRA T cells (highly differentiated T 
cells re-expressing CD45RA but CCR7–) (22). A typical example of the gating strategy, is 
shown in supplementary Figure 1.
In addition to this definition of memory T cells, the expression of CD28, CD27, CD57 
and PD-1 was used to divide the T-cell compartment in early or late differentiated T cells. 
A typical example of the gating strategy, is shown in supplementary Figure 2. Essentially, 
the naive and central-memory T cells are early differentiated T cells and still express 
the costimulatory molecules CD28 and CD27. EM and EMRA T cells may progressively lose 
CD28 and subsequently CD27 expression and gain expression of CD57 and PD-1 (24-26, 
138). Next to this, examining expression of CD28 together with CD27 is of additional 
value, as the order of loss of these molecules differs between CD4+ and CD8+ T cells (i.e. 
CD4+ T cells first lose CD27 before losing CD28, while for the CD8+ T cells this is the other 
way around) (75, 139, 140). Early differentiated T cells were defined as CD28+CD27+, 
CD28+PD-1– and CD28+CD57– T cells. T cells that were CD28nullCD27–, CD28nullPD-1+ and 
CD28nullCD57+ were defined as late differentiated memory T cells. This measurement 
was performed on the Navios flow cytometer (Beckman Coulter) and the obtained data 
were analyzed with the Kaluza software version 1.3 (Beckman Coulter). The T cells were 
analyzed with DuraClone IM T-cell subsets tubes (Beckman Coulter), which were coated 
with allophycocyanin Alexa Fluor 750 (APC-A750) anti-CD3, allophycocyanin (APC) 
labeled anti-CD4, Alexa Fluor 700 (A700) labeled anti-CD8, fluorescein isothiocyanate 
(FITC) labeled anti-CD45RA, phycoerythrin (PE) labeled anti-CCR7, phycoerythrin Texas 
red (ECD) labeled anti-CD28, phycoerythrin-cyanine 7 (PE-Cy7) labeled anti-CD27, 
phycoerythrin-cyanine 5.5 (PE-Cy5.5) labeled anti-PD1, pacific blue (PacB) labeled 
anti-CD57 and krome orange (KO) labeled anti-CD45.
Relative Telomere Length
To determine the RTL of CD4+ and CD8+ T cells, flow fluorescent in situ hybridization was 
performed on thawed PBMCs and LNMCs as described in detail previously (11).
Assessment of recent thymic emigrants using CD31 and TREC content
CD31+ naive T cells were assessed by flow cytometry as a measure of recent thymic 
emigrants (RTE), as described previously (125). TREC content was determined using 1×106 
snap-frozen PBMCs and LNMCs. DNA was isolated from these snap-frozen samples and 
the TREC content, depicted by DCT (which is inversely related to the TREC content), 
was determined using quantitative polymerase chain reaction (PCR) as described 
previously (13).
Statistical analysis
All variables are presented as medians with interquartile ranges. The differences between 
paired samples (i.e. PB and LN T-cell ageing parameters of same ESRD patients) were 
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analyzed using the Wilcoxon signed-rank test. Differences between continuous variables 
from two independent groups (i.e. CMV-seropositive versus CMV-seronegative ESRD 
patients) were assessed with the Mann–Whitney U test. Correlations between PB and LN 
were calculated using the Spearman’s rank correlation. Relationships between age and 
the different T-cell ageing parameters were assessed using a linear regression analysis. 
The significance level (p-value) was two-tailed and an α of 0.05 was used for all analyses. 
Statistical analyses were performed using SPSS® version 21.0 for Windows® (SPSS Inc., 
Chicago, IL, USA) and GraphPad Prism 5 (San Diego, CA, USA). Figures were created with 
GraphPad Prism 5.
RESULTS
Patient characteristics
Patient characteristics (n=38) are shown in Table 1. The median patient age was 58 years. 
Most of the patients were CMV immunoglobulin (Ig)G+ (74%). The major cause of ESRD 
was nephrosclerosis/atherosclerosis/hypertension (29%), followed by polycystic kidney 
disease (21%), which together accounted for half of the cases.
CD4+ T-cell composition of the lymph node and peripheral blood
The median frequency of CD4+ T cells was significantly higher in LN samples compared 
with the PB (p<0.001) (Figure 1A), but the relative distribution of CD4+ naive T cells was 
similar (Figure 1B). However, compared with PB, the LN contained higher frequencies of 
CD4+ CM T cells (p<0.001) (Figure 1C) and lower frequencies of CD4+ EM T cells and 
effector memory CD45RA+ (EMRA) T cells (p<0.001 and p=0.026 respectively) (Figures 
1D-E). Except for the frequency of CD4+ EMRA T cells, frequencies of CD4+ T cells, CD4+ 
naive T cells, CD4+ CM T cells and CD4+ EM T cells showed a remarkable good correlation 
between PB and LN (Figure 1).
Next, the early versus late T-cell differentiation was analyzed by measuring the expression 
of CD27, PD-1 and CD57 on CD28+ and CD28null T cells (Table 2). Within the CD4+ T-cell 
population, the frequency of CD28null T cells was significantly lower in LN compared 
with PB (1.0%, range 0.6%-1.6% vs 1.8%, range 0.7-8.8; p=0.001) and late memory 
T cells subpopulations, either defined as CD28nullCD27– T cells, CD28nullPD-1+ T cells or 
CD28nullCD57+ T cells, were virtually absent in LN (p<0.001 for all comparisons). Instead, 
the percentage of CD4+ T cells with full expression of CD28 and CD27 (CD28+CD27+) was 
significantly higher in the LN (Table 2). 
In summary, the composition of the CD4+ T-cell compartment in PB and LN are highly 
interrelated, except for the absence of late differentiated T cells, which almost exclusively 
appear in PB.
Table 1. Patient characteristics
RT Patients (n=38)
Age 58 (45 – 65) 
Male 24 (63%)
CMV-seropositivity 28 (74%)
Underlying disease
 Nephrosclerosis/atherosclerosis/hypertension 11 (29%)
 Primary glomerulopathies 5 (13%)
 Diabetes 7 (18%)
 Urinary tract infections/stones 0 (0%)
 Reflux nephropathy 0 (0%)
 Polycystic Kidney Disease 8 (21%)
 Other 3 (8%)
 Unknown 4 (11%)
Dialysis prior to transplantation 24 (63%)
Data are presented as median (interquartile range) or as number (percentage). RT indicates renal 
transplantation; and CMV, cytomegalovirus.
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Figure 1. CD4+ T-cell subsets in the peripheral blood (PB) and the lymph node (LN) and 
the correlation between PB and LN. The frequencies and correlations of (A) CD4+ T cells within 
CD3+ T cells, (B) CD4+ naive T cells within CD4+ T cells, (C) CD4+ central memory (CM) T cells within 
CD4+ T cells, (D) CD4+ effector memory (EM) T cells within CD4+ T cells and (E) CD4+ effector memory 
CD45RA+ (EMRA) T cells within CD4+ T cells are represented. Frequencies of cells are depicted as 
individual percentages as well as median and interquartile range (left plots). A Spearman’s rho was 
shown only when a significant correlation was present; n=38 for peripheral blood and n=38/37 
for lymph node samples. Significant differences were calculated and shown (*p<0.05, **p≤0.01, 
***p≤0.001).
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CD8+ T-cell composition of the lymph node and peripheral blood
The frequency of CD8+ T cells was significantly lower in LN than in PB with a relative 
higher proportion of naive T cells (p<0.001 for both variables) (Figure 2A-B). The CD8+ 
memory T-cell population in LN contained relatively more CM T cells (p<0.001) (Figure 2C) 
and less highly differentiated CD8+ EMRA T cells (p<0.001) (Figure 2E). 
All CD8+ T cell subsets, except for EM T cells, were positively correlated between 
the two different compartments (Figure 2). Specifically, the frequency of total CD8+ T 
cells, CD8+ naive T cells and CD8+ CM T cells showed a very close correlation.
Differentiated CD8+CD28null T cells were significantly less frequent in LN than in PB 
(10.6%, range 7.5%–15.0% vs 41.5%, range 23.8%–64.0%; p<0.001). 
The expression of CD27, PD-1 and CD57 in relation to CD28 expression showed 
similar results within the CD8+ T-cell population as obtained for the CD4+ T cells (Table 2). 
The frequencies of late differentiated T cells (CD8+CD28null T cells lacking CD27, expressing 
PD-1 or CD57) were high in PB, but few of these cells were found in LN (p<0.001). In 
contrast, LN contained significantly more T cells expressing CD28 and CD27. 
In summary, similar to the CD4+ T cells, the composition of the CD8+ T-cell compartment 
of PB and LN was highly interrelated, but late differentiated CD8+CD28null T cells were 
confined to the circulating CD8+ T-cell pool. 
Recent thymic emigrants and RTL in the lymph node and peripheral blood
Frequencies of CD31+ naive T cells were significantly lower in LN than in PB for both CD4+ 
and CD8+ T cells (p<0.001 and p=0.008, respectively) (Figure 3A and B). Frequencies of 
CD31+ CD4+ and CD31+ CD8+ naive T cells in PB and LN were highly correlated (p<0.001 
for both variables) (Figure 3A and B). Furthermore, the TREC content in the lymphocyte 
population, which is another measure of the number of RTE, was significantly higher (i.e. 
lower ΔCT) in the LN (p=0.002) (Figure 3C) compared with PB. The TREC content also 
showed a significant positive correlation between PB and LN (Figure 3C). Combining both 
parameters, a significant negative correlation between the frequency of CD31+ CD4+ 
and CD8+ naive T cells and ΔCT in both the PB and LN was observed (Supplementary 
Figure 3). Interestingly, the RTL of both CD4+ as well as CD8+ T cells was similar between 
PB and LN (Figure 3D and E).
Age-related changes of T-cell characteristics in the lymph node
Figure 4 shows the T-cell characteristics that were significantly associated with age. 
A negative association between age and frequency of CD4+ naive T cells was observed 
(B= –0.42, p=0.035) (Figure 4A), while the frequencies of CD4+ memory T cells increased 
Table 2. CD27, PD-1 and CD57 expression on CD28null T cells in the peripheral blood and lymph node
PB (n=38) LN (n=33) p
CD4+ T cells
 CD28+CD27+ (%) 87.4 (81.5 – 94.3) 93.8 (91.6 – 96.1) <0.001
 CD28nullCD27– (%) 1.1 (0.2 – 7.5) 0.3 (0.1 – 0.6) <0.001
 CD28+PD–1– (%) 78.5 (71.0 – 84.0) 74.2 (65.8 – 81.6) 0.077
 CD28nullPD–1+ (%) 1.0 (0.3 – 7.3) 0.4 (0.3 – 0.9) 0.004
 CD28+CD57– (%) 96.7 (90.1 – 98.7) 97.4 (96.0 – 98.2) 0.063
 CD28nullCD57+ (%) 0.8 (0.1 – 5.9) 0.1 (0.0 – 0.2) <0.001
CD8+ T cells
 CD28+CD27+ (%) 54.8 (36.7 – 73.7) 89.8 (84.1 – 92.6) <0.001
 CD28nullCD27– (%) 28.7 (10.8 – 49.3) 1.9 (1.0 – 2.6) <0.001
 CD28+PD–1– (%) 43.1 (25.9 – 57.5) 63.2 (49.5 – 75.1) <0.001
 CD28nullPD–1+ (%) 12.4 (6.9 – 18.4) 2.4 (1.6 – 5.1) <0.001
 CD28+CD57– (%) 56.2 (37.5 – 73.9) 87.3 (80.2 – 89.7) <0.001
 CD28nullCD57+ (%) 26.6 (13.4 – 39.1) 1.5 (1.0 – 2.3) <0.001
Data are presented as medians (interquartile range). PB indicates peripheral blood; and LN, lymph node.
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Figure 2. CD8+ T-cell subsets in the peripheral blood (PB) and the lymph node (LN) and 
the correlation between PB and LN. The frequencies and correlations of (A) CD8+ T cells within 
CD3+ T cells, (B) CD8+ naive T cells within CD8+ T cells, (C) CD8+ central memory (CM) T cells within 
CD8+ T cells, (D) CD8+ effector memory (EM) T cells within CD8+ T cells and (E) CD8+ effector memory 
CD45RA+ (EMRA) T cells within CD8+ T cells are represented. Frequencies of cells are depicted as 
individual percentages as well as median and interquartile range (left plots). A Spearman’s rho was 
shown only when a significant correlation was present; n=38 for peripheral blood and n=38/37 
for lymph node samples. Significant differences were calculated and shown (*p<0.05, **p≤0.01, 
***p≤0.001).
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with age (B=0.42, p=0.035) (Figure 4B). The expression of CD27, PD-1 and CD57 in 
combination with CD28 expression within the CD4+ T-cell population did not show any 
associations with age (data not shown). 
Similarly, frequencies of naive CD8+ T cells were negatively associated with age 
(B= –0.82, p=0.002) (Figure 4C), whereas those of CD8+ memory T cells revealed a positive 
association with age (B=0.59, p=0.023) (Figure 4D). Next to this, also the frequency of 
CD8+ CM T cells was positively associated with age (B=0.40, p=0.033) (Figure 4E). Within 
the CD8+ T-cell population, frequencies of early differentiated T cells, i.e. CD28+CD27+ 
and CD28+PD1– T cells were decreased with increasing age (B= –0.20, p=0.028 and 
B= –0.50, p=0.043 respectively).
Assessment of thymic output also revealed age-associated changes within the LN. 
Frequencies of CD4+ RTE decreased with age (B= –0.62, p=0.004) (Figure 4F) as did 
the TREC content (i.e. higher ΔCT) (B=0.09, p=0.003) (Figure 4G). Conversely, the RTL 
of both the CD4+ and the CD8+ T cells in the LN showed no association with age 
(data not shown). 
CMV infection does not change lymph node T-cell characteristics
In accordance with previous studies (27, 42, 43), CMV infection altered the peripheral 
T-cell compartment leading to relatively more CD8+ T cells, as well as increased frequencies 
of CD4+CD28null and CD8+CD28null T cells showing decreased expression of CD27 and 
increased expression of PD-1 and CD57 (Table 3 & Table 4). 
However, CMV infection did not affect the composition of CD4+ (Table 3) and CD8+ T 
cells (Table 4) within LN.
In addition, no association was seen between CMV infection and thymic output 
parameters in LN, with the frequencies of CD4+CD31+ and CD8+CD31+ naive T cells and 
the TREC content being similar between CMV+ and CMV– patients (data not shown). 
Similarly, no effect of CMV on RTL of CD4+ and CD8+ T cells within LN was observed (data 
not shown). 
In summary, despite a major effect of CMV infection on peripheral blood T-cell 
composition, this was not paralleled by similar effects within LN.
DISCUSSION
In this study we investigated, whether the ageing parameters of the circulating T-cell 
population, correlates with the T-cell characteristics of LN and the effect of CMV on PB 
and LN composition. Our main conclusions are that the T-cell composition and measures 
of thymic function in PB and LN are interrelated, but that the highly differentiated 
CD28null T cells, which may comprise a large part of circulating T cells in CMV-seropositive 
individuals, are almost exclusively found within the circulation. This study is the first in 
which a pairwise and a more in depth comparison was performed between PB and LN for 
different T-cell ageing parameters in ESRD patients. Next to the different T-cell subsets, 
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Figure 3. CD31+ naive T cell frequency, T cell receptor excision circles (TREC) content and 
relative telomere length (RTL) in the peripheral blood (PB) and lymph node (LN) with 
correlations. The frequencies and correlations of (A) CD4+CD31+ naive T cells, (B) CD8+CD31+ 
naive T cells, (C) TREC content, (D) CD4+ RTL and (E) CD8+ RTL for both the peripheral blood and 
the lymph node are represented. Frequencies of CD4+ and CD8+CD31+ naive T cells and RTL are 
depicted as percentages as well as median and interquartile range. The ΔCT is related inversely 
to the TREC content; n=38 for peripheral blood and n=37 for lymph node samples with regard 
to the analysis of CD4+CD31+ naive T cells and CD8+CD31+ naive T cells; n=22 for analysis of 
the TREC content and n=24 for the analysis of RTL in both T cell subsets.. Significant differences 
were calculated and shown (*p<0.05, **p≤0.01, ***p≤0.001). 
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Figure 4. Effect of age on T-cell ageing parameters in the lymph node (LN). Linear regression 
analysis between age and (A) CD4+ naive T cells, (B) CD4+ memory T cells, (C) CD8+ naive T cells, (D) 
CD8+ memory T cells, (E) CD8+ central memory (CM) T cells and (F) CD4+CD31+ naive T cells and (G) 
T-cell receptor excision circles (TREC) content are represented. Frequencies of cells are depicted with 
percentages and the TREC content is depicted with ΔCT. Only significant associations are shown.
Table 3. CD4+ T-cell differentiation status in lymph node and peripheral blood for CMV+ and CMV– 
patients
n CMV+ n CMV– p
Lymph node
 CD4+ T cells (%) 28 74.3 (62.5 – 80.1) 10 83.0 (68.6 – 87.0) 0.094
 CD4+ naive T cells (%) 27 30.2 (13.6 – 43.7) 10 18.9 (12.3 – 30.7) 0.313
 CD4+ memory T cells (%) 27 69.8 (56.3 – 86.4) 10 81.1 (69.3 – 87.7) 0.313
 CD4+ CM T cells (%) 27 54.8 (43.1 – 68.3) 10 63.8 (49.5 – 76.5) 0.383
 CD4+ EM T cells (%) 27 10.5 (4.6 – 17.8) 10 4.7 (1.9 – 22.4) 0.494
 CD4+ EMRA T cells (%) 27 1.1 (0.8 – 1.9) 10 1.8 (0.6 – 2.6) 0.620
 CD4+CD28null T cells (%) 27 1.1 (0.7 – 1.8) 10 0.7 (0.3 – 1.1) 0.078
 CD4+CD28+CD27+ (%) 23 93.9 (92.2 – 97.3) 10 92.4 (89.9 – 96.0) 0.248
 CD4+CD28nullCD27– (%) 23 0.3 (0.1 – 0.6) 10 0.4 (0.1 – 0.5) 0.739
 CD4+CD28+PD–1– (%) 23 73.9 (66.8 – 78.2) 10 79.7 (64.4 – 84.6) 0.281
 CD4+CD28nullPD–1+ (%) 23 0.4 (0.3 – 1.0) 10 0.6 (0.3 – 0.9) 0.681
 CD4+CD28+CD57– (%) 23 97.1 (96.6 – 98.3) 10 97.6 (93.4 – 98.2) 0.652
 CD4+CD28nullCD57+ (%) 23 0.1 (0.0 – 0.2) 10 0.0 (0.0 – 0.2) 0.246
Peripheral blood
 CD4+ T cells (%) 28 60.3 (48.8 – 64.8) 10 76.7 (68.5 – 83.7) <0.001
 CD4+ naive T cells (%) 28 28.9 (13.1 – 42.2) 10 32.4 (19.9 – 42.8) 0.703
 CD4+ memory T cells (%) 28 71.1 (57.8 – 86.9) 10 67.6 (57.2 – 80.2) 0.703
 CD4+ CM T cells (%) 28 39.5 (35.3 – 50.9) 10 44.0 (33.8 – 54.8) 0.655
 CD4+ EM T cells (%) 28 22.5 (15.7 – 30.1) 10 17.3 (13.8 – 25.1) 0.380
 CD4+ EMRA T cells (%) 28 2.0 (1.3 – 4.9) 10 2.1 (1.4 – 3.3) 0.934
 CD4+CD28null T cells (%) 28 5.6 (1.3 – 11.5) 10 0.6 (0.3 – 0.8) <0.001
 CD4+CD28+CD27+ (%) 28 83.9 (77.8 – 92.7) 10 94.2 (89.7 – 9.5) 0.012
 CD4+CD28nullCD27– (%) 28 3.9 (0.7 – 9.2) 10 0.1 (0.0 – 0.2) <0.001
 CD4+CD28+PD–1– (%) 28 77.7 (71.0 – 82.8) 10 81.4 (71.1 – 89.0) 0.214
 CD4+CD28nullPD–1+ (%) 28 2.3 (0.6 – 9.0) 10 0.1 (0.0 – 0.3) <0.001
 CD4+CD28+CD57– (%) 28 93.9 (88.7 – 97.4) 10 98.9 (97.8 – 99.4) <0.001
 CD4+CD28nullCD57+ (%) 28 2.7 (0.6 – 6.5) 10 0.0 (0.0 – 0.2) <0.001
Data are presented as medians (interquartile range). CMV indicates cytomegalovirus; CM, central 
memory, EM, effector memory; and EMRA, effector memory CD45RA+.
we included analyses of other differentiation markers such as CD27, PD-1 and CD57 in 
combination with CD28. Furthermore, we also analyzed the TREC content and RTL of 
the T cells in both the lymph node and the peripheral blood. 
In previous studies it was shown that the PB compartment of ESRD patients displayed 
distinct changes that resemble the T-cell ageing process in elderly healthy individuals. It is 
associated with loss of naive T cells, an inverted CD4:CD8 ratio and an increase in highly 
differentiated T cells, lacking the co-stimulatory molecule CD28 (11, 13, 30, 56, 141). 
The T-cell composition of LNs of the same patients, showed a higher frequency of CD4+ 
T cells and a lower frequency of CD8+ T cells compared with PB. The high frequency of 
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CD4+ T cells was also found in the lymphoid tissues of deceased pediatric and young adult 
organ donors in a study by Thome et al. (142). Furthermore, there was a lower frequency 
of highly differentiated T cells within LN samples in contrast to PB. This finding was 
further supported by the other T-cell memory differentiation markers (CD28, CD27, PD-1 
and CD57). It is known that CD4+CD28null are more differentiated than CD8+CD28null, as 
the latter can still contain CD27 in contrast to the CD4+ T-cell fraction (75, 139, 140). 
However, both the CD8+CD28null T cells as well as the CD8+CD28nullCD27– T cells were more 
frequent in PB. Even though a positive correlation existed between LN and PB samples for 
the majority of the different T-cell subset frequencies, the highly differentiated T cells (i.e. 
CD28null T cells) were far more abundant in PB. The low number of highly differentiated T 
cells in LN might be explained by the lack of co-expression of CCR7, which T cells use for 
homing to secondary lymphoid organs (31). 
The parameters for thymic output showed similar results for both the CD31 and 
the TREC assay. The results indicate a remarkably high correlation between the data 
obtained in the circulation and within LN. In addition, CD31+ T cells and TREC content in 
LN T-cell population showed a relation with the age of the individual as we and others 
have described before for circulating T cells (11, 13, 18, 134, 143). Taken together it 
can be concluded that the loss of thymic function with increasing age is also reflected in 
the secondary lymphoid tissue. Primary immune responses (e.g. vaccination) are initiated 
within LN. The intricate relation between the amount of naive T cells in PB and LN 
therefore probably explains why the number of circulating naive T cells is associated with 
the response to vaccination (144). 
In this study we did not find any differences regarding the RTL between PB and LN. 
This could be explained by the depth of the analysis of RTL. We took the CD4+ and CD8+ 
T cell-population as a whole instead of focusing on the different T-cell subsets. Because of 
this, differences in RTL due to differences in frequencies of subsets might be overlooked. 
Furthermore, we cannot fully exclude that the isolation procedure resulted in a shift in 
T-cell subsets, possibly influencing the analysis of the RTL. 
Age-related changes were observed in both CD4+ and CD8+ T-cell compartments 
within the lymph node. The frequency of naive T cells declined, while the frequency of 
memory T cells increased. Other studies also showed an age-related decline in naive T 
cells within LNs of healthy individuals and from deceased organ donors (49, 142, 145). 
Furthermore, a study by Thome et al. found that EM T cells were less abundant in pediatric 
lymphoid tissues, while these were more frequent in young adult lymphoid tissues (142). 
Next to this, the TREC content also decreased with increasing age in the LN, supporting 
the T-cell ageing process in LN. These results indicate that age-related changes in T-cell 
composition are similar for PB and LN with the exception of the late differentiated T cells, 
which appear to remain outside the LN. 
CMV infection dramatically changes the composition of circulating T cells and almost 
doubles the total number of CD8+ T cells, in particular with a late differentiation phenotype 
(27, 42, 43). However, the T-cell differentiation status within the LNs did not differ 
between CMV+ and CMV– patients. In a study of Remmerswaal et al., the frequency of 
CMV-specific CD8+ T cells was significantly lower in the LN compared with the PB, which 
is in line with our findings (146). Next to this, a study by Havenith et al. also showed 
the absence of highly differentiated CD4+CD28nullCD27– T cells in the lymph node, which 
can appear due to a CMV infection (147). These findings suggest that a latent CMV 
infection does not have a significant impact on T cells within LN, while the opposite is 
true for PB T cells. 
In conclusion, the T-cell composition in PB is strongly related to T-cell composition 
of the LN, while the presence of highly differentiated CD28null T cells is more exclusive 
Table 4. CD8+ T-cell differentiation status in lymph node and peripheral blood for CMV+ and 
CMV– patients
n CMV+ n CMV– p
Lymph node
 CD8+ T cells (%) 28 19.0 (13.2 – 29.5) 10 13.0 (8.7 – 22.9) 0.159
 CD8+ naive T cells (%) 27 39.5 (20.5 – 51.6) 10 28.5 (11.0 – 58.4) 0.281
 CD8+ memory T cells (%) 27 60.5 (48.4 – 79.6) 10 71.5 (41.6 – 89.1) 0.281
 CD8+ CM T cells (%) 27 12.0 (5.6 – 36.5) 10 11.3 (4.6 – 44.2) 0.959
 CD8+ EM T cells (%) 27 21.9 (9.9 – 36.1) 10 26.5 (14.3 – 53.7) 0.442
 CD8+ EMRA T cells (%) 27 8.8 (5.0 – 17.7) 10 12.7 (7.4 – 19.2) 0.330
 CD8+CD28null T cells (%) 27 10.7 (7.4 – 16.7) 10 9.1 (6.8 – 13.4) 0.365
 CD8+CD28+CD27+ (%) 23 90.9 (83.3 – 92.7) 10 86.5 (84.1 – 91.4) 0.357
 CD8+CD28nullCD27– (%) 23 1.9 (1.2 – 3.4) 10 1.4 (0.8 – 2.5) 0.240
 CD8+CD28+PD–1– (%) 23 63.2 (50.2 – 74.8) 10 63.7 (46.4 – 76.0) 0.953
 CD8+CD28nullPD–1+ (%) 23 2.2 (1.5 – 5.4) 10 3.5 (2.1 – 5.3) 0.240
 CD8+CD28+CD57– (%) 23 87.3 (81.6 – 90.1) 10 87.4 (73.6 – 89.3) 0.681
 CD8+CD28nullCD57+ (%) 23 1.6 (1.1 – 2.7) 10 1.3 (1.0 – 1.8) 0.248
Peripheral blood
 CD8+ T cells (%) 28 35.5 (27.9 – 41.4) 10 18.3 (13.1 – 27.3) 0.002
 CD8+ naive T cells (%) 27 18.7 (7.7 – 25.8) 10 32.5 (14.2 – 49.0) 0.123
 CD8+ memory T cells (%) 27 81.3 (74.2 – 92.2) 10 67.5 (51.0 – 85.8) 0.123
 CD8+ CM T cells (%) 27 5.9 (2.6 – 9.4) 10 14.7 (7.5 – 19.7) 0.006
 CD8+ EM T cells (%) 27 27.0 (16.3 – 37.5) 10 27.9 (24.8 – 49.2) 0.159
 CD8+ EMRA T cells (%) 27 42.2 (29.6 – 57.1) 10 19.7 (12.8 – 26.4) <0.001
 CD8+CD28null T cells (%) 27 47.0 (35.8 – 69.1) 10 22.2 (15.1 – 32.2) <0.001
 CD8+CD28+CD27+ (%) 28 47.9 (29.5 – 62.1) 10 76.1 (70.3 – 85.0) <0.001
 CD8+CD28nullCD27– (%) 28 35.6 (26.6 – 57.9) 10 7.4 (3.7 – 11.0) <0.001
 CD8+CD28+PD–1– (%) 28 38.7 (24.8 – 49.2) 10 57.8 (40.6 – 69.9) 0.026
 CD8+CD28nullPD–1+ (%) 28 13.1 (6.9 – 18.7) 10 10.3 (6.9 – 19.5) 0.804
 CD8+CD28+CD57– (%) 28 49.7 (30.6 – 63.2) 10 77.3 (66.9 – 84.0) <0.001
 CD8+CD28nullCD57+ (%) 28 30.5 (21.3 – 49.1) 10 11.6 (7.9 – 14.9) <0.001
Data are presented as medians (interquartile range). CMV indicates cytomegalovirus; CM, central 
memory, EM, effector memory; and EMRA, effector memory CD45RA+.
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to the PB compartment. In addition, CMV changed the T-cell differentiation status in 
PB drastically, while no significant alterations were observed within LN with regard to 
T-cell differentiation and ageing parameters. This study provides a new perspective on 
the T-cell immune system, especially of those with ESRD. PB seems to harbor the majority 
of terminally differentiated T cells, while LNs do not harbor this specific subset of T 
cells. These findings suggest that during an immune response the late differentiated T 
cells directly access the tissue and exert their immune function. This is consistent with 
the observation that many of these cells carry the chemokine receptor CX3CR1 for 
the endothelium-derived chemokine fractalkine (146). Fractalkine is considered a major 
player in inflammatory responses, recruiting leukocytes into the inflamed tissue (148-
150). These late differentiated T cells then can respond to IL-15 produced by the inflamed 
parenchym, proliferate and exert their cytotoxic function (94, 95, 151). Whether the T-cell 
characteristics in the LN might provide a better predictive model for clinical outcomes, 
such as the development of (co-stimulatory blockade resistant) rejection and infection 
after e.g. kidney transplantation is subject to further investigation.
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Supplementary Figure 1. Gating strategy of the T-cell subsets. First, lymphocytes were selected 
based on the forward- and sidescatter, and CD3+ T cells were selected from these lymphocytes. 
The CD3+ T cells were then divided further into CD4+ and CD8+ T-cell fractions. Each population 
was dissected into different subsets using CCR7 and CD45RO. After this division, CD4+ (only this 
is shown) and CD8+ naive T cells were analyzed for CD31 expression. Besides this, total CD4+ (only 
this is shown) and total CD8+ T cells were analyzed for frequencies of cells lacking CD28 expression.
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Supplementary Figure 2. Gating strategy of the T-cell differentiation markers. First, CD45+ 
leucocytes were gated. From these cells, lymphocytes were selected based on the forward and 
side-scatter; CD3+ T cells were selected from these lymphocytes. The CD3+ T cells were then divided 
further into CD4+ and CD8+ T-cell fractions. Each fraction was analyzed further for the expression 
of CD27, programmed death 1 (PD-1) or CD57 in combination with CD28 (only the CD8+ T cell 
fraction is shown). From these analyses only the least (CD28+CD27+, CD28+PD-1– and CD28+CD57–) 
and most differentiated (CD28nullCD27–, CD28nullPD-1+ and CD28nullCD57+) T cells were selected 
(indicated within the black frames).
0 6
0
20
40
60
80
100
8 10 12 14
Spearman r: -0.540
p < 0.01
TREC content PB (DCT)
CD
4+
CD
31
+
na
iv
e
T
ce
lls
PB
(%
)
0 6
0
60
60
70
80
90
100
8 10 12 14
Spearman r: -0.548
p < 0.01
TREC content PB (DCT)
CD
8+
CD
31
+
na
iv
e
T
ce
lls
PB
(%
)
0 6
0
20
40
60
80
100
8 10 12 14
Spearman r: -0.575
p < 0.01
TREC content LN (DCT)
CD
4+
CD
31
+
na
iv
e
T
ce
lls
LN
(%
)
0 6
0
60
8 10 12 14
60
70
80
90
100
Spearman r: -0.569
p < 0.01
TREC content LN (DCT)
CD
8+
CD
31
+
na
iv
e
T
ce
lls
LN
(%
)
A
C D
B
Supplementary Figure 3. Correlation between CD31+ naive T cells and the T-cell receptor 
excision circles (TREC) content in peripheral blood (PB) and the lymph node (LN). 
The Spearman’s rho correlation analysis is shown between CD4+CD31+ naïve T cells within the PB 
and the TREC content within the PB (A), between CD8+CD31+ naive T cells within the PB and 
the TREC content within the PB (B), between CD4+CD31+ naive T cells within the LN and the TREC 
content within the LN (C) and between CD8+CD31+ naive T cells within the LN and the TREC content 
within the LN (D). Frequencies of cells are depicted on the y-axis, and the ΔCT which is related 
inversely to the TREC content is depicted on the x-axis.
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ABSTRACT
Background 
The T-cell composition within the lymph node (LN) of end-stage renal disease (ESRD) 
patients differs from the composition within the circulation. Activation of the alloreactive 
T-cell response within secondary lymphoid organs is important after organ transplantation. 
However, to date no data are present on lymph node T cell subsets and the risk for acute 
rejection after kidney transplantation.
Methods 
T cells from LNs of ESRD patients were analyzed for frequency of recent thymic emigrants, 
relative telomere length, expression of differentiation markers, and were related to 
the development of early acute rejection (EAR), occurring within three months after renal 
transplantation (RT). Furthermore, the alloreactive potential of mononuclear cells isolated 
from the LN and peripheral blood of 10 patients was analyzed. Measures of alloreactive 
potential included proliferation, cytokine production, frequencies of IFN-γ producing cells 
and the presence of cytotoxic molecules.
Results 
Patients with EAR were younger (p=0.019), CMV-seropositive (p=0.037) and usually 
received dialysis prior to RT (p=0.030). Next to this, patients with EAR showed a lower 
CD4:CD8 ratio (p=0.027) within the LN. T cells from the LN were similar with regard 
to alloreactive capacity compared to those within the circulation. Univariate regression 
analysis showed that the CD4:CD8 ratio (OR: 0.67, p=0.039), patient age (OR: 0.93, 
p=0.024) and preemptive RT (OR: 0.11, p=0.046) were associated with EAR. After 
a multivariate analysis only the CD4:CD8 ratio (OR: 0.58, p=0.019) and preemptive RT 
(OR:0.05, p=0.012) were associated with EAR.
Conclusion 
A lower CD4:CD8 ratio in the LN is associated with a higher risk for the development of 
rejection within three months after RT.
INTRODUCTION
The composition and function of the T-cell compartment in patients prior to renal 
transplantation (RT) may affect the risk for subsequent acute rejection and infection after 
transplantation (10, 35, 36, 66, 124, 141, 152). For instance, ageing-related expansion of 
highly differentiated T cells within PB, such as CD8+ EMRA T cells or CD4+CD28null T cells, 
is associated with a lower risk for early acute rejection after RT (36, 66). 
However, T cells within PB are only one of the cell populations that play a role in allograft 
rejection. Another compartment which may have a significant role in the development 
of acute rejection is the lymph nodes (LNs). Early after organ transplantation, the direct 
pathway of alloantigen recognition plays the most important part in the initiation of 
the alloreactive response (153). One of the key events for this response is migration 
of donor-derived dendritic cells to LNs of the host, which is followed by activation of 
alloreactive T cells (153, 154). Next to this, a semi-direct pathway is also being described 
(153, 155), which involves transfer of intact MHC:peptide complexes from donor antigen 
presenting cells (APCs) to host APCs, and simultaneous presentation of the processed 
antigens to CD4+ T cells in an indirect manner and the intact complexes to CD8+ T 
cells in a direct manner (155, 156). These pathways show the importance of the T-cell 
composition within LNs with regard to development of rejection. 
The T-cell composition of LN differs substantially from peripheral blood (PB) as T-cell 
subsets may or may not be able to migrate to LNs. We and others have studied the T-cell 
composition of the LN of ESRD patients and found that highly differentiated T cells were 
virtually absent from LNs, while they were present within PB (146, 157). Whether the LN 
T-cell composition and alloreactivity is associated with development of acute rejection 
after RT has not been studied thus far. 
Therefore, in this study we investigated whether phenotypical T-cell characteristics 
within LNs showed an association with development of rejection within 3 months after 
RT. Next to this, we have also investigated functional differences between LN and PB, to 
assess whether there were variations with regard to alloreactive potential between these 
two compartments. These possible functional differences were studied by performing 
mixed lymphocyte reactions (MLRs) and analyzing proliferation, cytokine production and 
presence of cytotoxic molecules within supernatants. 
MATERIALS AND METHODS
Study population
Patients prior to RT in the period from August 2015 to March 2016 were suitable for 
participation. Each patient gave written informed consent to take part in this study. 
The study was approved by the Medical Ethical Committee of the Erasmus MC (MEC 
number 2015-301) and was conducted in accordance with the Declaration of Helsinki 
and the Declaration of Istanbul.
Clinical variables were assessed as shown in Table 1, including age of the recipient 
and donor, gender, CMV-seropositivity, human leukocyte antigen (HLA) class I and 
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class II mismatches, current and historical panel reactive antibody (PRA) scores, number 
of RTs, warm ischemia time, number of living donor transplants, cause of chronic 
kidney disease, preemptive RT (defined as receiving a kidney before initiation of renal 
replacement therapy), number of related RT (receiving a kidney from a genetically related 
donor) and type of rejection. The HLA-typing was assessed according to international 
standards (American Society for Histocompatibility and Immunogenetics/the European 
Federation for Immunogenetics) using serologic and DNA-based techniques. The PRAs 
were determined at the laboratory of the blood bank in Leiden, the Netherlands. 
Early acute rejection (EAR) was defined as development of biopsy-proven acute 
allograft rejection according to the Banff criteria (158, 159) within 3 months after RT.
PBMC and LNMC isolation
Peripheral blood mononuclear cells (PBMCs) and lymph node mononuclear cells (LNMCs) 
were isolated as described previously (157). The isolated PBMCs and LNMCs were stored 
at -150°C with a minimum amount of 10×106 cells/vial. Median yield of the lymph node 
amounted to 20×106 cells. 
T-cell differentiation status
Whole blood and freshly isolated LNMCs were used to assess T-cell differentiation status 
by flowcytometry. Differentiation status was based upon the study by Sallusto et al. (22), 
as described in detail previously (11). Briefly, expression of CD45RO and CCR7 was used 
to determine naive and memory T-cell populations. Memory T-cell subsets were further 
defined as central memory (CM) T cells (CD45RO+CCR7+ T cells), effector memory (EM) T 
cells (CD45RO+CCR7– T cells) and EMRA T cells (CD45RA+CCR7– effector memory T cells) 
(22). In addition, CD28 expression was analyzed as this is lost upon T-cell differentiation 
(20, 23, 27, 29). Cells were stained as described previously (36), and were measured on 
the FACSCanto II (BD) and analyzed with the FACS Diva software version 6.1.2 (BD). 
To dissect T cells into early and late differentiated cells, expression of CD28, CD27, 
CD57 and PD-1 was also analyzed. Naive and central memory T cells express CD28 and 
CD27. Effector memory and EMRA T cells progressively lose expression of these molecules 
(CD4+ T cells first lose CD27 and then CD28, while the opposite is true for CD8+ T cells 
(75, 139, 140)) and express CD57 and PD-1 (24-26, 138). Thus, early differentiated T cells 
were defined as CD28+CD27+, CD28+PD-1– and CD28+CD57– T cells, while CD28nullCD27–, 
CD28nullPD-1+ and CD28nullCD57+ T cells were defined as late differentiated T cells. This 
measurement was performed on the Navios flow cytometer (Beckman Coulter) and 
collected data were evaluated with the Kaluza software version 1.3 (Beckman Coulter). 
T cells were analyzed with DuraClone IM T-cell subsets tubes (Beckman Coulter) as 
described previously (157).
Relative Telomere Length 
Relative telomere length (RTL) of CD4+ and CD8+ T cells was determined by using flow 
fluorescent in situ hybridization on thawed PBMCs and LNMCs, as described in detail 
previously (11). 
Assessment of recent thymic emigrants using CD31 and TREC content
Recent thymic emigrants (RTEs) were defined as naive T cells expressing CD31 and were 
assessed by flow cytometry, as described previously (125). T-cell receptor excision circles 
(TREC) content was determined using 1×106 snap-frozen PBMCs and LNMCs. DNA 
was isolated from these snap-frozen samples and TREC content was detected using 
quantitative PCR as described previously (13). The TREC content is depicted as 1/DCT.
Allogeneic stimulation
PBMCs and LNMCs from renal transplant recipients (responders) were thawed and rested 
overnight. Then PBMCs and LNMCs were labeled with CFSE (Molecular Probes®, Leiden, 
the Netherlands) according to manufacturer’s instructions and stimulated in triplicate at 
5x104/well with irradiated PBMCs (40 Gy) of their corresponding donor, at a 1:1 ratio 
for 6 days. As a negative control, responders were stimulated with their own irradiated 
PBMCs or LNMCs (autologous stimulation). Responder cells were stimulated with 
phytohaemagglutinin (PHA) 5 µg/ml to examine their maximum proliferative potential. 
On day 6, wells of the same condition were pooled and supernatant stored at -80oC. 
Proliferation was analyzed by measuring CFSE dilution and determining the frequency 
of CFSE– cells. For this purpose, cells were stained using the following antibodies; 
AmCyan-labeled anti-CD3 (BD), pacific blue (PacB)-labeled anti-CD4 (BD), APC-Cy7-
labeled anti-CD8 (BD), phycoerythrin (PE)-Cy7-labeled anti-CCR7 (BD Pharmigen), APC-
labeled anti-CD45RO (BD), PE-labeled anti-CD28 (BD). A dump-channel was applied to 
exclude unwanted cells from the analysis, by co-staining cells for the live-dead marker 
7-AAD, peridin chlorophyll protein (PerCP)-labeled anti-CD19 (BD), PerCP-Cy5.5-labeled 
anti-CD56 (Biolegend) and PerCP-labeled anti-CD14 (BD) (Supplemental figure 1). 
Samples were measured on the FACSCanto II (BD) and analyzed using FACS Diva software 
version 6.1.2 (BD).
Analysis of cytokine and granzyme B production
Concentrations of interferon (IFN)-γ, tumor necrosis factor (TNF)-α and granzyme B were 
determined from collected supernatants. These supernatants were analyzed with the human 
cytometric bead array (CBA) flex set (BD) according to manufacturer’s instructions. Briefly, 
a standard curve for each analyte using a 4-parameter logistic regression analysis was 
created. This curve was based upon standards with fixed concentrations of each analyte 
and their corresponding median fluorescence intensities (MFIs). Then, MFI of the various 
analytes within the samples were converted to concentrations (pg/mL). Samples were 
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measured on the FACS Canto II (BD) and concentrations were determined with GraphPad 
Prism 5 (CA, USA).
IFN-γ ELISPOT assay
Frequencies of IFN-γ producing cells (spots/100.000 cells) following autologous, allogeneic 
or PHA stimulation were measured with an Enzyme-Linked ImmunoSpot (ELISPOT) assay 
(U-CyTech, Utrecht, The Netherlands). During the first day, the ELISPOT plate was coated 
with the antibody and incubated overnight. The same day cells were thawed and rested 
overnight. The following day, the assay plate was blocked using a blocking buffer and 
incubated for 1 hour at 37oC. After the plate was washed with phosphate buffered saline 
(PBS), cells were pipetted into wells and stimulated in triplicate, as described earlier, for 
1 day. Thereafter, plates were washed first with PBS and then with PBS-Tween. Spots 
were made visible according to manufacturer’s instructions. Spots were analyzed using 
the ELISpot reader (Bioreader®-600V, BIO-SYS GmbH, Karben, Germany).
Statistical analysis
Variables are presented as medians with interquartile ranges. Differences between paired 
samples (PB and LN from the same patient) were analyzed using the Wilcoxon signed-
rank test. Differences between continuous variables from two independent groups were 
assessed with the Mann–Whitney U test. Differences between categorical variables 
were analyzed either with the Pearson’s chi-squared test or with the Fisher’s exact test 
depending on the expected values in any of the cells of a contingency table. Associations 
between rejection and the assessed parameters were analyzed using a binary logistic 
regression analysis. The significance level (p-value) was two-tailed and an α of 0.05 
was used. Statistical analyses were performed using SPSS® version 21.0 for Windows® 
(SPSS Inc., IL, USA) and GraphPad Prism 5 (CA, USA). Figures were created with GraphPad 
Prism 5 (CA, USA).
RESULTS
Patient characteristics
Patient characteristics (n=38) are shown in Table 1. Median patient age was 58 years 
and median donor age was 55 years. Most of the patients underwent an RT for the first 
time (82%), while 18% underwent a transplantation for the second time. Most common 
cause of ESRD was nephrosclerosis/atherosclerosis/hypertension (29%) followed by 
polycystic kidney disease (21%), together accounting for half of the cases. Overall, 24 
(63%) patients received dialysis treatment prior to RT. Eleven of the 38 patients (29%) 
developed an EAR. Majority of the rejections were classified as cellular rejection (64%) 
and the remaining as antibody-mediated rejection. Median patient age was significantly 
younger within the rejectors compared with the non-rejectors (47 vs 60, p<0.019). All 
patients who developed an EAR were CMV-seropositive, while 63% of the non-rejectors 
was CMV-seropositive (p=0.037). Median warm ischemia time was longer for the rejectors 
compared with the non-rejectors (23 minutes vs 17 minutes, p=0.045). Majority of 
the rejectors had dialysis prior to RT (91%), while 52% of the non-rejectors received 
this therapy (p=0.030). Immunological risk factors like PRA score, HLA mismatches or 
unrelated donor transplantation were not different between the two groups.
Table 1. Patient Characteristics
RT Patients (n=38)
No Rejection 
(n=27) (71%)
Rejection  
(n=11) (29%) p
Age recipient 60 (51 – 66) 47 (37 – 58) 0.019
Age Donor 51 (42 – 61) 63 (50 – 69) 0.129
Male gender recipient 17 (63%) 7 (64%) >0.999
CMV-seropositivity recipient 17 (63%) 11 (100%) 0.037
CMV-serostatus donor/recipient
 -/- 6 (29%) 0 (0%) 0.154
 -/+ 7 (26%) 7 (64%) 0.061
 +/- 4 (15%) 0 (0%) 0.303
 +/+ 10 (37%) 4 (36%) >0.999
Mismatch HLA class I 3 (2 – 4) 3 (2 – 4) 0.727
Mismatch HLA class II 1 (1 – 2) 1 (1 – 2) 0.824
Mismatch HLA class I and II 4 (4 – 5) 5 (3 – 5) 0.949
PRA current (%) 0 (0 – 4) 0 (0 – 33) 0.446
PRA historic (%) 4 (0 – 29) 6 (0 – 73) 0.727
Number of RT 1 (1 – 1) 1 (1 – 1) >0.999
Warm ischemia time (minutes) 17 (13 – 22) 23 (20 – 27) 0.045
Living donor transplant 22 (81%) 8 (73%) 0.667
Cause of CKD
 Nephrosclerosis/atherosclerosis/
hypertension
6 (22%) 5 (45%) 0.238
 Primary glomerulopathies 3 (11%) 2 (13%) 0.615
 Diabetes 7 (26%) 0 (0%) 0.084
 Polycystic Kidney Disease 6 (22%) 2 (18%) >0.999
 Other 2 (7%) 1 (9%) >0.999
 Unknown 3 (11%) 1 (9%) >0.999
Pre-emptive RT 13 (48%) 1 (9%) 0.030
Genetically-related RT 1 (4%) 1 (9%) 0.501
Acute Rejection type
 Cellular rejection 7 (64%)
 Antibody-mediated rejection 4 (36%)
Data are presented as medians (interquartile range) or as numbers (percentages). CKD indicates chronic 
kidney disease; CMV, cytomegalovirus; HLA, human leukocyte antigen; PRA, panel reactive antibody; RT, 
renal transplantation. 
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T-cell composition of the LN prior to RT shows an association with EAR
Figures 1 and 2 show the T-cell differentiation status of CD4+ and CD8+ T cells within 
the LNs of the rejectors and non-rejectors. Median frequency of CD4+ T cells prior to 
RT is significantly lower (p=0.014) and median frequency of CD8+ T cells is significantly 
higher (p=0.019) within the rejectors (Figures 1A and 1B). This led to a significantly lower 
CD4:CD8 ratio in LNs of patients with EAR (3.4 vs 5.7, p=0.027) (Figure 1C). Furthermore, 
median frequencies of CD4+ EM T cells and CD4+CD28null T cells were significantly higher 
within the rejectors (p=0.044 and p=0.008, respectively) (Figures 2C and 2G). But overall, 
median percentage of CD4+CD28null T cells remained low in both groups (0.8% vs 1.5%). 
No other significant differences were observed for the other CD4+ or CD8+ T-cell subsets.
Assessment of T-cell differentiation status can be further refined by differential 
expression levels of CD27, CD57 and PD-1 in combination with CD28. However, this 
approach did not show any differences between the two groups (Table 2).
In summary, a lower CD4:CD8 ratio was associated with rejection.
RTL, RTEs and TREC content in the LN are not associated with rejection
The telomere length is indicative of T cell replicative history, while CD31 expression on 
naïve T cells and TREC content are a measure of thymic output of naïve T cells. These 
parameters are strongly associated with the age and therefore a measure of the biological 
age of the T-cell system (16-18, 45, 46, 133). Figure 3 demonstrates the RTL of T cells, 
RTE frequency and the TREC content in LNs between the rejectors and non-rejectors. RTL 
of CD4+ and CD8+ T cells was similar between the two groups (Figures 3A and 3B). Also, 
no differences were observed for CD4+ and CD8+ RTEs between rejection and no rejection 
(Figures 3C and 3D). Finally, the TREC content was also not associated with development 
of rejection (Figures 3E).
A lower CD4:CD8 ratio within the LN and dialysis prior transplantation 
are associated with rejection
Table 3 shows a univariate regression analysis of the significant clinical and immunological 
parameters with development of EAR. This univariate analysis showed that a higher 
CD4:CD8 ratio was associated with a lower risk for EAR (OR=0.67, p=0.039). Next to this, 
an older patient age and preemptive RT were also associated with a lower risk for rejection 
(OR=0.93, p=0.024; OR=0.11, p=0.046, respectively). Then these parameters were put 
into a multivariate regression analysis for a first model (Table 4). This showed that age 
was not associated with development of EAR. On the other hand, a higher CD4:CD8 ratio 
showed a tendency for a lower risk for rejection (OR=0.63, p=0.053), while preemptive 
RT still showed a significant association with development of EAR (OR=0.06, p=0.023). 
Taking the parameter ‘age’ out of the equation, showed a second model with significant 
associations (Table 4). A higher CD4:CD8 ratio and preemptive RT were both associated 
with a lower risk for EAR (OR=0.58, p=0.019; OR=0.05, p=0.012, respectively). 
Figure 1. CD4+ and CD8+ T-cell subsets in the lymph node between rejection and no rejection 
groups. (A) Frequencies of CD4+ T cells and (B) CD8+ T cells, (C) CD4:CD8 ratio, (D) frequencies 
of CD4+ naïve T cells, (E) CD8+ naïve T cells, (F) CD4+ memory T cells and (G) CD8+ memory T 
cells within the lymph nodes are shown between the no rejection and rejection groups. Data are 
presented with individual percentages and medians or bars and medians. Significant differences 
were calculated and shown (*p<0.05, **p≤0.01, ***p≤0.001).
T-C
ELL C
O
M
PO
SITIO
N
 O
F TH
E LY
M
PH
 N
O
D
E A
N
D
 TH
E RISK
 FO
R EA
RLY
 REJEC
TIO
N
T-C
ELL C
O
M
PO
SITIO
N
 O
F TH
E LY
M
PH
 N
O
D
E A
N
D
 TH
E RISK
 FO
R EA
RLY
 REJEC
TIO
N
66
104 105
0
20
40
60
80
100
No Rejection Rejection
C
D
4+
C
M
T
ce
lls
w
ith
in
th
e
ly
m
ph
no
de
(%
)
0
20
40
60
80
100
No Rejection Rejection
C
D
8+
C
M
T
ce
lls
w
ith
in
th
e
ly
m
ph
no
de
(%
)
0
20
40
60
80
100
No Rejection Rejection
*
C
D
4+
EM
T
ce
lls
w
ith
in
th
e
ly
m
ph
no
de
(%
)
0
20
40
60
80
100
No Rejection Rejection
C
D
8+
EM
T
ce
lls
w
ith
in
th
e
ly
m
ph
no
de
(%
)
0
20
40
60
80
100
No Rejection Rejection
C
D
4+
EM
R
A
T
ce
lls
w
ith
in
th
e
ly
m
ph
no
de
(%
)
0
20
40
60
80
100
No Rejection Rejection
C
D
8+
EM
R
A
T
ce
lls
w
ith
in
th
e
ly
m
ph
no
de
(%
)
0
10
20
30
40
50
No Rejection Rejection
*
C
D
4+
C
D
28
nu
ll
T
ce
lls
w
ith
in
th
e
ly
m
ph
no
de
(%
)
0
20
40
60
80
100
No Rejection Rejection
C
D
8+
C
D
28
nu
ll
T
ce
lls
w
ith
in
th
e
ly
m
ph
no
de
(%
)
A B
C D
E F
G H
Thus, a lower CD4:CD8 ratio in the LN and receiving dialysis prior to transplantation 
increases the risk for the development of rejection after transplantation.
T cells from the LN and PB proliferate similarly upon allogeneic 
stimulation
Median frequency of proliferating CD4+ T cells from the LN rose significantly from 2.4% to 
45.0% (p=0.002) upon allogeneic stimulation (Figure 4A), and that of CD4+ T cells from 
the PB increased from 2.1% to 39.3% (p=0.004) (Figure 4B). Within the proliferating 
CD4+ T cells, majority of the cells were memory T cells (mainly CM) (Figures 4A and 4B). 
The CD28+ T-cell fraction was the main proliferating fraction within proliferating CD4+ 
T cells in PB and LN (>99.0% proliferation in both compartments) (Figures 4A and 4B).
The CD8+ T cells showed similar results compared to the CD4+ T cells. Median frequency 
of proliferating CD8+ T cells from the LN rose significantly from 1.4% to 22.9% (p=0.004) 
upon allogeneic stimulation (Figure 4C) and median frequency of CD8+ T cells from PB 
increased from 0.6% to 29.9% (p=0.002) (Figure 4D). CD8+ memory T cells comprised 
the largest fraction within proliferating CD8+ T cells in both LN and PB, with CM T cells 
also being the major contributor within this fraction (Figures 4C and 4D). The CD28+ T-cell 
fraction was again the main proliferating fraction within proliferating CD8+ T cells in LN 
and PB (Figures 4C and 4D).
Comparing the frequency of proliferating T cells upon alloreactive stimulation between 
LN and PB, showed no differences except for CD8+CD28null T cells within proliferating 
CD8+ T cells. Median frequency of these cells within LN amounted to 0.3% while this was 
2.9% within PB (p=0.037), which is probably due to the higher presence of these cells 
within PB compared with LN.
Figure 2. Memory CD4+ and CD8+ T-cell subsets and CD28 expression in the lymph node 
between rejection and no rejection groups. (A) Frequencies of CD4+ central memory (CM) T 
cells, (B) CD8+ CM T cells, (C) CD4+ effector memory (EM) T cells, (D) CD8+ EM T cells, (E) CD4+ 
effector memory CD45RA+ (EMRA) T cells, (F) CD8+ EMRA T cells, (G) CD4+CD28null T cells and (H) 
CD8+CD28null T cells within the lymph nodes are shown between the no rejection and rejection 
groups. Data are presented with individual percentages and medians. Significant differences were 
calculated and shown (*p<0.05, **p≤0.01, ***p≤0.001).
Table 2. CD4+ & CD8+ T-cell differentiation status in lymph node with regard to the development 
of rejection
n No Rejection n Rejection p
CD4+ 
 CD4+CD28+CD27+ (%) 25 93.8 (91.6 – 96.6) 8 93.8 (81.1 – 94.7) 0.578
 CD4+CD28nullCD27– (%) 25 0.3 (0.1 – 0.6) 8 0.2 (0.1 – 0.8) 0.951
 CD4+CD28+PD–1– (%) 25 73.5 (64.0 – 82.0) 8 76.3 (72.0 – 80.4) 0.665
 CD4+CD28nullPD–1+ (%) 25 0.4 (0.2 – 0.9) 8 0.5 (0.3 – 1.2) 0.578
 CD4+CD28+CD57– (%) 25 97.6 (95.3 – 98.6) 8 97.0 (96.5 – 97.7) 0.272
 CD4+CD28nullCD57+ (%) 25 0.1 (0.0 – 0.2) 8 0.1 (0.0 – 0.2) 0.885
CD8+
 CD8+CD28+CD27+ (%) 25 89.6 (84.1 – 93.3) 8 90.4 (78.8 – 92.2) 0.789
 CD8+CD28nullCD27– (%) 25 1.9 (1.0 – 2.6) 8 1.7 (1.0 – 6.5) 0.789
 CD8+CD28+PD–1– (%) 25 62.2 (49.5 – 75.1) 8 66.9 (45.8 – 75.1) 0.853
 CD8+CD28nullPD–1+ (%) 25 2.4 (1.6 – 5.2) 8 2.6 (1.6 – 4.8) 0.951
 CD8+CD28+CD57– (%) 25 87.4 (80.2 – 91.0) 8 86.3 (75.5 – 88.8) 0.374
 CD8+CD28nullCD57+ (%) 25 1.5 (1.0 – 2.3) 8 1.5 (0.9 – 4.3) 0.757
Data are presented as medians (interquartile range). CM indicates central memory; EM, effector memory; 
and EMRA, effector memory CD45RA+.
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Polyclonal stimulation with PHA induced >95% proliferation of CD4+ T cells and CD8+ 
T cells from both compartments, although, this response was significantly higher in CD4+ 
and CD8+ T cells from LN (p=0.037 for both subsets). The functional assays could not 
be performed in all patients as the yield of cells from the LN was not sufficient enough 
in some cases. For this reason the number of patients with EAR included in this part of 
the study was too low (n=3) for adequate comparison with patients without EAR.
In conclusion, the alloreactive potential is not different between T cells from LN and 
PB, but T cells from LN show a slightly higher proliferative potential in response to PHA.
IFN-γ ELISPOT shows no differences between LN and PB, but IFN-γ and 
granzyme B production by LNMCs is lower than PBMCs after 6 days of 
allogeneic stimulation
Frequency of IFN-γ producing LNMCs increased significantly after allogeneic stimulation 
(p=0.034), while a similar tendency was seen for PBMCs (p=0.083). However, median 
amount of spots remained low after allogeneic stimulation (3.5/1×105 for the LN and 
6/1×105 for the PB). Furthermore, there were no significant differences between the two 
different compartments after allogeneic stimulation (Figure 5A). Stimulation with PHA, 
showed a significantly higher IFN-γ secretion by PBMCs compared with T cells within 
LNMCs (256/1×105 vs 126/1×105, p=0.047). 
After allogeneic stimulation of LNMCs and PBMCs for 6 days, concentrations of 
TNF-α, IFN-γ and granzyme B in the supernatants were significantly increased. LNMCs 
had a lower production of TNF-α (p=0.065) (Figure 5B), IFN-γ and granzyme B compared 
with PBMCs (p=0.020 and p=0.049, respectively) (Figures 5C and 5D). Interestingly, 
amount of IFN-γ spots after allogeneic stimulation for 1 day correlated significantly with 
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Figure 3. Relative telomere length, recent thymic emigrant frequency and T-cell receptor 
excision circle content in the lymph node between rejection and no rejection groups. 
The relative telomere length (RTL) of (A) CD4+ T cells and (B) CD8+ (T cells) within the lymph nodes 
between the no rejection and rejection groups are shown. Frequencies of (C) CD4+ and (D) CD8+ 
recent thymic emigrants (RTEs) within the lymph nodes between the no rejection and rejection group 
are shown. (E) The TREC content (1/ΔCT) within the lymph nodes between the no rejection and 
rejection group is shown. Data are shown as individual points and medians. Significant differences 
were calculated and shown (*p<0.05, **p≤0.01, ***p≤0.001).
Table 3. Univariate regression analysis between rejection and immunological and clinical parameters
OR 95% CI p
CD4+ T cells (%) 0.95 0.90 – 1.00 0.062
CD4+ EM T cells (%) 1.02 0.98 – 1.06 0.314
CD4+CD28null T cells (%) 1.30 0.86 – 1.95 0.216
CD4:CD8 ratio 0.67 0.45 – 0.98 0.039
CD8+ T cells (%) 1.08 1.00 – 1.16 0.057
Age recipient 0.93 0.88 – 0.99 0.024
CMV-seropositivity recipient 0.00 0.00 – N/A 0.999
Warm ischemia time (minutes) 1.06 0.96 – 1.16 0.241
Pre-emptive RT 0.11 0.01 – 0.96 0.046
EM indicates effector memory; RT, renal transplantation; and N/A, not available. 
Table 4. Multivariate regression analysis between rejection and immunological and clinical parameters
OR 95% CI p
Model 1
 CD4:CD8 ratio 0.63 0.39 – 1.01 0.053
 Age recipient 0.97 0.90 – 1.04 0.393
 Pre-emptive RT 0.06 0.01 – 0.68 0.023
Model 2
 CD4:CD8 ratio 0.58 0.36 – 0.92 0.019
 Pre-emptive RT 0.05 0.00 – 0.51 0.012
EM indicates effector memory; RT, renal transplantation; and N/A, not available. 
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production of IFN-γ by LNMCs as well as PBMCs after 6 days (ρ=0.88, p=0.001 and 
ρ=0.64, p=0.048, respectively).
Thus, production of TNF-α, IFN-γ and granzyme B by LNMCs and PBMCs increases 
after allogeneic stimulation. However, generation of these products is lower by LNMCs 
than by PBMCs.
DISCUSSION
This study has investigated for the first time the relation between T-cell characteristics of 
the lymph node and acute rejection after RT. Surprisingly, a lower CD4:CD8 ratio in the LN 
was significantly associated with a higher risk for rejection. Studies have shown that CD8+ 
T cells play an important role in allograft rejection (160, 161). Antigen presenting cells 
can present the alloantigen to CD4+ and CD8+ T cells that are present within the lymph 
node, which will lead to the activation of these cells. Having a lower CD4:CD8 ratio might 
tip the balance towards a more cytotoxic profile, which could promote allograft rejection. 
A study by Ford et al. has shown in a murine skin graft model that, a high initial 
frequency of antigen-specific CD8+ T cells resulted in the development of CD8+ T cells 
which were able to produce multiple cytokines and were more prone to escape co-
stimulation blockade (162). Next to this, a study by Shenoy et al. showed that a lower 
CD4:CD8 ratio in bronchus-associated lymphoid tissue was associated with a higher 
frequency of acute rejections within one year after lung transplantation (163). Thus, 
having a high initial frequency of CD8+ T cells in lymph nodes, could lead to a higher 
chance for the presence of alloreactive CD8+ T cells, increasing the risk for rejection. 
It is known that alloantigen recognition can occur via direct or indirect pathways (153), 
but next to this a semi-direct pathway is also being described (153, 155). This semi-direct 
pathway involves the transfer of intact MHC:peptide complexes from donor APCs to host 
APCs and also the processing of antigens by the host APCs (155). The host APCs can 
then simultaneously present the processed antigens to CD4+ T cells in an indirect manner, 
while they present the intact complexes to CD8+ T cells in a direct manner (155, 156). 
At the same time, the CD4+ T cells can provide help to the CD8+ T cells to activate them 
Figure 4. Proliferation of CD4+ and CD8+ T cells from the lymph node and peripheral blood 
after allogeneic stimulation. Frequencies of proliferating CD4+ T cells within (A) the lymph node 
and (B) the peripheral blood are shown after allogeneic stimulation. Frequencies of proliferating 
CD8+ T cells within (C) the lymph node and (D) the peripheral blood are shown after allogeneic 
stimulation. Each graph is divided into 4 parts marked with the dotted lines. From left to right; 
the total proliferating T-cell population is shown, which then is subdivided into naïve and memory T 
cells in the second portion, the third portion shows the subdivision of the memory T-cell population 
into central memory (CM), effector memory (EM) and effector memory CD45RA+ (EMRA) T cells, 
the fourth portion shows the subdivision of the total T-cell population into CD28+ and CD28null T 
cells. Frequencies are presented with bars and medians.
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Figure 5. IFN-γ, TNF-a and Granzyme B production after allogeneic stimulation. (A) The number 
of IFN-γ spots per 100.000 cells by lymph node mononuclear cells (LNMCs) and peripheral blood 
mononuclear cells (PBMCs) after allogeneic stimulation for 1 day is shown. The production of (B) 
TNF-α, (C) IFN-γ and (D) granzyme B (pg/ml) by LNMCs and PBMCs after allogeneic stimulation for 
6 days is shown. Data are shown as individual points and medians. Significant differences were 
calculated and shown (*p<0.05, **p≤0.01, ***p≤0.001).
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(155). It has been shown that CD4+ T cells which are activated by the indirect pathway, can 
successfully enhance direct pathway CD8+ T-cell responses (164). As the direct pathway 
is the most important pathway in the initiation of alloreactive responses (153), a higher 
frequency of CD8+ T cells within the lymph nodes prior to transplantation will increase 
the possibility for allorecognition by the direct and also by the semi-direct pathway.
 Next to this, we have found that younger patients have a higher risk for EAR. 
Even though this finding was not significant after a multivariate analysis, it still showed 
an important difference between the rejection and no rejection groups after a univariate 
analysis. This association between a younger age and an increased risk for rejection has 
also been found by previous studies (165, 166). An aged immune system in the older 
patients may underlie the reduced risk for rejection. In addition, ESRD patients undergo 
uremia-associated premature ageing of their T-cell system (11, 13, 125), which further 
impairs the alloreactivity of their immune system. For this reason we have studied in detail 
the relation between several immune parameters of T-cell ageing and clinical outcome 
after RT. In particular, the increased presence of highly differentiated CD8+ EMRA T cells 
or CD4+CD28null T cells in the circulation, was associated with a decreased risk for acute 
rejection but no other parameters such as telomere length and thymic output of naïve 
T cells (36, 66). In this study we did not find an association between all tested immune 
parameters of T cell ageing and acute rejection. The absence of highly differentiated T 
cells within the LN is most likely the reason that we also could not relate the presence of 
these cells to acute rejection (157). 
Furthermore, we analyzed differences in IFN-γ production by mononuclear cells 
isolated from the LN and PB using the ELISPOT assay. Previous studies have shown that 
this assay shows important correlations with regard to rejection and graft function after 
RT (167-170). However, we saw no differences with regard to IFN-γ producing cells 
from both compartments. On the other hand, we saw that the production of IFN-γ and 
granzyme B was higher by PBMCs after 6 days of stimulation. Again, this is probably 
due to the higher presence of more differentiated cells within the PB compared with 
the LN (157). Next to this, proliferation of T cells upon stimulation with alloantigens 
was also similar between the two compartments. This means that LNMCs have a similar 
alloreactive potential, with the LNMCs showing a lower production of cytokines and 
cytotoxic molecules, due to the presence of less differentiated T cells within the LNs.
This study is the first which shows an association between the T-cell CD4:CD8 ratio 
of the lymph node and the development of early acute rejection after RT. Although this 
finding is of considerable interest, it needs to be validated in a study with a larger cohort. 
However, the results show that the LN should be considered as a different compartment 
with its own contribution to the risk for the development of rejection. Although 
speculative, one of the implications of our finding could be that highly differentiated 
memory T cells in the peripheral blood are relevant for and associated with acute rejection 
as they can directly enter peripheral tissues such as the renal transplant. In contrast, these 
cells cannot enter the LN and alloreactivity in this environment is stimulated by donor-
derived APC interacting with naïve and central memory T cells. The relative contribution 
of both pathways needs to be further elucidated. 
In conclusion, a lower CD4:CD8 ratio within LN is associated with a higher risk for 
the development of rejection within three months after RT.
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Supplementary Figure 1. Analysis of proliferation after allogeneic stimulation of PBMCs and LNMCs. An example 
of the gating strategy is shown. The left column represents the analysis of LNMCs while the right column shows the 
analysis of PBMCs after allogeneic stimulation. From top to bottom; first, lymphocytes were selected based on the 
forward and  sideward  scatter. Then,  living CD3+ T  cells were  selected  from  these  lymphocytes. The CD3+ T cells 
were  then  further divided  into CD4+ and CD8+ T cells. Each population was  then  further dissected  into different 
subsets using CCR7 and CD45RO. Only CD4+ T cells are shown, but the same analysis was applied on CD8+ T cells. 
The bottom graphs show an example of the analysis of proliferation after allogeneic stimulation with CFSE dilution. 
 
Supplementary Figure 1. Analysis of proliferation after allogeneic stimulation of PBMCs 
and LNMCs. An example of the gating strategy is shown. The left column represents the analysis 
of LNMCs while the right column shows the analysis of PBMCs after allogeneic stimulation. From 
top to bottom; first, lymphocytes were selected based on the forward and sideward scatter. Then, 
living CD3+ T cells were selected from these lymphocytes. The CD3+ T cells were then further divided 
into CD4+ and CD8+ T cells. Each population was then further dissected into different subsets using 
CCR7 and CD45RO. Only CD4+ T cells are shown, but the same analysis was applied on CD8+ T cells. 
The bottom graphs show an example of the analysis of proliferation after allogeneic stimulation 
with CFSE dilution.
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SUMMARY
The kidneys play an important role in several essential processes within the body. They 
regulate the osmolality and the volume of the extracellular fluid. This is achieved by 
the excretion of water, electrolytes and waste products. Next to this, the kidneys are also 
involved in the production of several hormones such as erythropoietin (production of 
erythrocytes), calcitriol/active vitamin D (bone metabolism) and renin (vasoconstriction 
and increase in blood pressure). Thus, a loss of renal function will have a negative impact 
on all the aforementioned processes.
Besides these processes, the loss of renal function also influences the immune 
system. Previous studies have shown that patients with end-stage renal disease undergo 
premature ageing of their T-cell immunity. A discrepancy of 20 to 30 years was noted 
between then immunological age of these patients and their calendar age. This enhanced 
ageing is probably initiated by the presence of uremia, which creates a proinflammatory 
environment. This will lead to a continuous activation of the immune system, which 
also involves the T cells. This process might play a part in the decreased vaccination 
responses and the increased susceptibility for infections, seen in end-stage renal disease 
patients. Thus, these changes of the immune system will also influence clinical outcomes 
in the setting of renal transplantation. Renal transplantation is the best option with 
regard to renal replacement therapy, but this also requires the use of immunosuppressive 
medication. These agents will reduce the risk for rejection, while on the other hand 
increasing the risk for infections. In patients with end-stage renal disease, who already 
have an impaired immune system, the use of these drugs could have a deleterious 
effect. Thus, predictive immunological parameters are needed to determine the risk 
for the development of rejection and infections after renal transplantation. This will 
aid in the development of personalized approaches with regard to immunosuppressive 
medication in renal transplantation.
In chapter 1 the process of premature T-cell ageing in end-stage renal disease 
patients and the available T-cell ageing parameters are introduced. These parameters are 
the frequency and absolute numbers of recent thymic emigrants within naive T cells and 
the T-cell receptor excision circle (TREC) content, which are both measures for thymic 
output. Furthermore, the differentiation status of T cells and the relative telomere length 
of T cells, can also be used as T-cell ageing parameters. These parameters can be assessed 
within different compartments such as the peripheral blood and the lymph nodes.
In chapter 2 the association between circulatory T-cell ageing parameters prior 
to transplantation and the risk for early acute rejection (within 3 months) after renal 
transplantation is discussed. Patients without an early rejection after transplantation had 
more CD4+CD28null T cells prior to transplantation. A similar trend was also observed 
for the CD8+CD28null T cells. None of the other parameters such as relative telomere 
length or the frequency of recent thymic emigrants did show an association with the risk 
for rejection. 
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In chapter 3 the CD4+CD28null are further analyzed with regard to their alloreactive 
potential. CD4+CD28null T cells did not show any significant increase in proliferation, 
degranulation, cytotoxicity or cytokine production upon allogeneic stimulation without 
cytokines. However, addition of IL-15 (with/without IL-21) significantly increased 
alloreactivity. Thus, CD4+CD28null T cells can become alloreactive when the optimal 
conditions are met.
In chapter 4 the relationship between the development of opportunistic and/or 
serious infections after renal transplantation and circulatory T-cell ageing parameters 
prior to, and 3 and 6 months after transplantation is analyzed. None of the analyzed 
T-cell ageing parameters were predictive for the development of infections after 
transplantation. However, the T-cell kinetics at 3 and 6 months after transplantation 
rather reflected the exposure to infections. This suggests that the current circulatory T-cell 
ageing parameters are not predictive for infections after renal transplantation.
In chapter 5 T-cell ageing parameters within the lymph node are analyzed to assess 
whether the changes observed in the peripheral blood of end-stage renal disease 
patients also occur in the lymph nodes. T-cell ageing parameters such as the frequency 
of recent thymic emigrants, the TREC content and the different subsets of T cells showed 
significant correlations between the lymph node and the peripheral blood. The effect 
of age could also be observed within the lymph nodes. A decline in naive T cells and an 
increase in memory T cells was seen with increasing age. On the other hand, the highly 
differentiated T cells were close to absent in the lymph node. Next to this, the effect of 
CMV on T-cell differentiation could not be observed within the lymph node in contrast 
to the peripheral blood. Thus, T-cell ageing parameters in the lymph node are strongly 
correlated with the peripheral blood, while the highly differentiated T cells mainly reside 
within the peripheral blood.
In chapter 6 the association between T-cell composition of the lymph node and 
the development of rejection within 3 months after transplantation was analyzed. Patients 
that developed rejection within three months after transplantation, had a lower frequency 
of CD4+ T cells and a higher frequency of CD8+ T cells leading to a lower CD4:CD8 ratio 
within the lymph nodes. Furthermore, there were no functional differences with regard to 
alloreactivity between T cells from the lymph node and T cells from the peripheral blood. 
DISCUSSION
This thesis describes the different aspects of premature T-cell ageing with regard to 
the predictive value of this ageing process with regard to clinical outcomes and its 
effect in different compartments of the body. Previous studies have shown that patients 
with ESRD have a prematurely aged circulatory T-cell immune system (11, 13, 125). It is 
shown that their circulatory immunological age can be 20 to 30 years older than their 
calendar age (11). This uremia associated premature ageing process is comparable with 
the physiological ageing that can be observed in elderly healthy individuals (20, 58). 
Furthermore, this premature circulatory T-cell ageing in ESRD patients is irreversible, even 
after renal transplantation (125). 
In the setting of renal transplantation, a highly differentiated T-cell system can lead to 
prevention of early acute rejection (36). We showed that a high number of CD4+CD28null 
T cells prior to renal transplantation is associated with a lower risk for the development 
of acute rejection within three months after transplantation (36). However, other studies 
showed that these cells can also be associated with a higher risk for the development of 
rejection (29, 34). This paradox can be explained by the alloreactive potential of these 
cells. We hypothesize that these cells have a low alloreactive capacity, which can only be 
upregulated under optimal conditions, such as the presence of the cytokines IL-15 and IL-21 
(article submitted). This could also be the explanation for the improved transplant survival 
and function seen in patients receiving the co-stimulatory blockade therapy belatacept 
(106). Blocking of CD80/86 on an antigen presenting cell will prevent this molecule from 
binding to CD28 on the T cell, which will lead to anergy of the CD28+ T cells (106). This 
blockade will lead to an overall low risk for alloreactivity when the low alloresponsive 
profile of CD4+CD28null T cells is also taken into account. But when CD86+ antigen 
presenting cells escape such blockades, this could induce the activation of the highly 
cytotoxic CD28null T cells through the production of IL-15 by for example monocytes and 
renal tubular epithelial cells. The presence of increased gene expression of IL-15, perforin 
and granzyme B has been shown in rejecting renal allograft specimens (171, 172). Also, 
the existence of CD86+ monocytes has been demonstrated in the rejected allograft under 
belatacept treatment (109). These co-stimulatory blockade resistant rejections are also 
more severe (92, 108, 109), suggesting the activation of these highly cytotoxic CD28null T 
cells. Furthermore, in a murine islet transplantation model, an IL-15 antagonist has been 
shown to reduce CD8+ T-cell infiltration, which was not achieved with co-stimulatory 
blockade (CTLA4/Fc) therapy alone (173).
Next to this, the low alloreactive capacity of these CD4+CD28null T cells might be 
due to their impairment with regard to their T-cell receptor (TCR) diversity. Studies have 
shown that continuous antigenic stimulation under chronic inflammatory conditions can 
promote T cells to differentiate into memory T cells with a low TCR diversity (23, 174). 
Next to this, CMV latency also plays a significant role in the expansion of terminally 
differentiated T cells (42, 43, 58). These mechanisms together can create a terminally 
differentiated T-cell pool that is able to recognize only a small group of antigens, which 
then leads to a reduced ability to recognize new antigens. But when they are able to 
recognize these antigens, they will require additional stimulation from cytokines such as 
IL-15 and IL-21 to properly respond and exert possible cytotoxic functions.
In this thesis, the predictive value of T-cell ageing parameters with regard to 
the development of infections was also investigated. None of these T-cell ageing 
parameters was able to predict the development of infections after renal transplantation 
(175). The T-cell kinetics rather represented the consequence of an infectious episode 
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after renal transplantation (175). This lack of an association between the T-cell 
ageing parameters and the development of infections might be due to the usage of 
immunosuppressive drugs which could have influenced these ageing parameters. This 
might be due to the follow-up period of one year. After this period, the influence of 
immunosuppression might be less and the effects of an aged immune system might 
therefore become more prominent. 
We also investigated the extent of this premature ageing process in different 
compartments of the body. Our results showed that the majority of the T-cell ageing 
parameters were strongly correlated between the peripheral blood and the lymph 
node (157). However, highly differentiated T cells were virtually absent from the lymph 
nodes, while the frequency of naive T cells and recent thymic emigrants (RTEs) were 
higher within the lymph nodes (157). The absence of highly differentiated T cells within 
the lymph nodes, might be caused by the lack of CCR7 on their surface, impairing them 
from homing to secondary lymphoid organs. Next to this, the effect of CMV was also not 
detectable within the lymph nodes, while it has a profound effect on circulatory T cells 
(157). The absence of highly differentiated T cells and the low frequency of CMV-specific 
CD8+ T cells within the lymph nodes have also been supported by other studies (145-147). 
Interestingly the effect of age itself was present within the lymph nodes; frequencies of 
RTEs and naive T cells declined over increasing age (157). This age-dependent decrease 
of naive T cells within the lymph nodes have also been observed by other studies (49, 
145). The lymph nodes, important for the initiation of immune reactions, could play 
a role for the development of infections and rejection after transplantation. As a first step 
to correlate lymph node T-cell composition and functionality with clinical outcomes, we 
showed that ESRD patients with a high CD8+ T-cell frequency and thus a lower CD4:CD8 
ratio within the lymph nodes, were more prone to develop rejection within three months 
after renal transplantation (in preparation). Our functional analyses showed no differences 
between the alloreactive capacity of T cells isolated from the lymph node compared to 
the peripheral blood. 
These findings show that immunological ageing can be assessed with the parameters 
used in this thesis. However, whether these T-cell parameters can be used as predictors 
for clinical outcomes requires more in depth analysis. For true personalized medicine, 
a better immunological model is essential, which incorporates the different aspects of 
this process. For example, molecular mechanisms that are involved in immunosenescence 
can be a part of this model. Studies have shown that CD28 gene expression declines 
with increasing age (176, 177). Furthermore, raised levels of transcription factors that 
are associated with increased cytotoxicity, such as T-bet and eomesodermin were also 
observed in CD8+CD28null memory T cells (177). This can be accompanied by investigating 
microRNA regulation. It has been shown that miR-181a declined with increasing age, 
leading to an impaired TCR sensitivity in CD4+ T cells (178). Furthermore, other cells of 
the immune system, such as B cells, are also affected by ageing (179). This means that 
research regarding interaction between different cells of the immune system will give 
a better reflection of the true extent of this ageing process. How all these mechanisms 
together contribute to premature ageing in ESRD is unknown, but needs to be 
elucidated for a proper model which defines appropriate parameters that can be used for 
personalized medicine.
Our results show the relationship between T-cell ageing parameters and clinical 
outcomes as well as the extensiveness of uremia associated T-cell ageing throughout 
the different compartments of the body. These studies demonstrate that these ageing 
parameters are not equally contributing to the prediction of different clinical outcomes. 
Next to that, the lymph nodes seem to be have a different T-cell composition, while age 
itself does have an effect on this configuration. 
CONCLUSION
This research describes the relationship between premature T-cell ageing in patients 
with end-stage renal disease and the development of rejection and infections after renal 
transplantation. A highly differentiated T-cell system is protective for the development of 
rejection after transplantation, probably due to the low alloresponsive character of these 
cells. On the other hand, T-cell ageing parameters are not a tool to predict the development 
of infections within one year after transplantation. Next to that, the range of this 
premature ageing process throughout the body is also evaluated. Although T-cell ageing 
parameters were strongly correlated between the peripheral blood and lymph nodes, 
highly differentiated T cells were virtually absent from the lymph nodes.
For a complete understanding of the ageing process in ESRD patients, further research 
is needed with regard to the interaction between the different cells of the immune 
system, combined with the molecular changes that occur during this ageing process. 
This research should include studies integrating these parameters and associate them 
with clinical outcomes such as rejection and infections. Furthermore, a more in depth 
analysis of functional impairments of the different immune cells after allogeneic challenge 
should be performed. These impairments can be at the antigen presentation level and/
or at the level of antibody production by B cells. These comparisons can be made by 
studying the immune cells from an ESRD patient and cells from a healthy individual. 
The clinically relevant parameters could then be transformed to an algorithm. This 
algorithm can be used as a more proper tool for a more solid risk assessment with regard 
to clinical outcomes. This then will provide a more personalized approach for the use 
of immunosuppression. Thus, this thesis describes only the T-cell aspect of the affected 
immune system in end-stage renal disease patients.
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NEDERLANDSE SAMENVATTING
De nieren spelen een belangrijke rol bij een aantal essentiële processen in het lichaam. 
Ze zorgen voor een balans in de osmolaliteit en het volume van de extracellulaire 
vloeistof. Dit resultaat wordt bereikt door het uitscheiden van water, elektrolyten 
en afvalstoffen. Daarnaast zijn de nieren betrokken bij de productie van een aantal 
hormonen zoals erytropoëtine (productie van rode bloedcellen), calcitriol/actief vitamine 
D (botmetabolisme) en renine (vaatvernauwing en verhoging van de bloeddruk). Wanneer 
de nieren hun functie verliezen, zal dit dus effect hebben op alle voorgaande processen. 
Naast al het bovengenoemde, heeft het verlies van nierfunctie ook invloed op het 
afweersysteem. Eerder is aangetoond dat deze patiënten een verouderd T-cel afweersysteem 
hebben. De immunologische leeftijd van deze patiënten kan 20-30 jaar ouder zijn dan 
hun kalenderleeftijd. Deze versnelde veroudering wordt waarschijnlijk geïnitieerd door 
de aanwezige uremie, die een pro-inflammatoir milieu creëert. Dit milieu zal tot een 
continue activatie leiden van het immuunsysteem, waaronder dus ook de T-cellen. Dit 
proces kan mede ten grondslag liggen aan het feit dat patiënten met eindstadium 
nierfalen minder reageren op vaccinaties en een verhoogde kans hebben op infecties. 
Dit betekent dat deze veranderingen in het afweersysteem ook een rol zullen spelen 
bij niertransplantatie. Een transplantatie is de beste optie in het kader van nierfunctie 
vervangende therapie, maar aan de andere kant brengt een dergelijke ingreep het 
gebruik van afweer onderdrukkende middelen met zich mee. Deze middelen verminderen 
weliswaar de kans op afstoting na transplantatie, maar verhogen aan de andere kant 
de kans op infecties. Bij patiënten met eindstadium nierfalen, waarvan het afweersysteem 
al is aangedaan door nierfunctie verlies, zal het gebruik van afweer onderdrukkende 
middelen dus een ernstiger effect kunnen hebben. Dit maakt het definiëren van 
immunologisch voorspellende parameters voor het ontwikkelen van afstoting en infecties 
na transplantatie noodzakelijk, om een zo individueel mogelijke benadering voor afweer 
onderdrukkende therapiekeuze te kunnen bewerkstelligen.
In hoofdstuk 1 wordt de versnelde veroudering van het T-cel afweersysteem bij 
patiënten met eindstadium nierfalen en de verschillende T-cel parameters die bepaald 
kunnen worden uit bloed en lymfeklieren uiteengezet. De parameters die gebruikt 
kunnen worden, zijn: frequentie van naïeve T-cellen die afkomstig zijn uit de thymus, 
de differentiatiestatus van de T-cellen en de telomeerlengte van de T-cellen.
In hoofdstuk 2 worden de verschillende T-cel parameters vanuit het bloed voorafgaand 
aan transplantatie in relatie gebracht met het risico op afstoting kort (tot 3 maanden) na 
niertransplantatie. Hieruit bleek dat een hoog aantal CD4+CD28nul T-cellen met name 
voorkwam bij patiënten zonder afstoting na niertransplantatie. Een vergelijkbare trend 
werd ook waargenomen voor de CD8+CD28nul T-cellen. De toegenomen aanwezigheid 
van deze doorgedifferentieerde cellen is dus geassocieerd met een lager risico op vroege 
afstoting na niertransplantatie.
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In hoofdstuk 3 wordt verder ingegaan op de CD4+CD28nul T-cellen met betrekking 
tot hun alloreactief potentieel. Hierbij is onderzocht hoe deze cellen reageren op allogene 
stimulatie en wat de invloed is van exogene cytokines. Hieruit kwam naar voren dat zonder 
cytokines, de CD4+CD28nul T-cellen niet in staat waren tot proliferatie, degranulatie, 
cytotoxicitieit of cytokine productie na allogene stimulatie. Toevoegen van IL-15 
(met/zonder IL-21) verhoogde de alloreactiviteit. Deze bevindingen laten dus zien, dat 
het milieu waar deze cellen zich in bevinden van invloed is op hun alloreactief potentieel.
In hoofdstuk 4 worden de verschillende T-cel parameters vanuit het bloed 
voorafgaand, en 3 en 6 maanden na transplantatie in relatie gebracht met het 
ontwikkelen van opportunistische en/of serieuze infecties. Hieruit bleek dat geen van 
de onderzochte T-cel parameters een voorspellende waarde had voor het optreden van 
infecties na niertransplantatie. De kinetiek van de parameters na transplantatie was 
een weerspiegeling van de opgetreden infecties. Dit suggereert dat de huidige T-cel 
parameters niet geschikt zijn voor het voorspellen van infecties na transplantatie. 
In hoofdstuk 5 wordt verder onderzocht of de waargenomen T-cel veranderingen in 
het bloed ook kunnen worden waargenomen in de lymfeklieren. Hieruit kwam naar voren 
dat de verschillende parameters tussen de twee compartimenten sterk aan elkaar waren 
gecorreleerd. Daarnaast werd er een effect van veroudering gezien in de lymfeklieren, 
waarbij een afname van naïeve T-cellen en een toename van geheugen T-cellen werden 
waargenomen. Daartegenover werd geconstateerd dat de doorgedifferentieerde cellen 
in hoge frequenties aanwezig waren in het bloed, terwijl deze cellen nagenoeg afwezig 
waren in de lymfeklier. Hiernaast werden ook de effecten van CMV niet waargenomen 
in de lymfeklier, terwijl deze wel duidelijk te observeren waren in het bloed van dezelfde 
patiënt. Hieruit kan geconcludeerd worden dat de T-cel parameters in bloed en lymfeklier 
sterk met elkaar zijn gecorreleerd, maar dat de doorgedifferentieerde cellen zich 
voornamelijk in het bloed bevinden.
In hoofdstuk 6 wordt verder ingegaan op de functionele eigenschappen van 
de cellen geïsoleerd uit de lymfklier vergeleken met de cellen verkregen uit het bloed. 
In dit hoofdstuk werd geobserveerd dat een lagere frequentie aan CD4+ T-cellen en een 
hogere frequentie aan CD8+ T-cellen, dus een lagere CD4:CD8 ratio in de lymfeklier, 
geassocieerd was met het ontwikkelen van rejectie binnen 3 maanden na transplantatie. 
Daarnaast werd geobserveerd dat er functioneel geen verschillen waren m.b.t. 
alloreactiviteit tussen T-cellen vanuit de lymfeklier en T-cellen vanuit het perifere bloed. 
Concluderend laten de resultaten in dit proefschrift zien dat een meer gedifferentieerd 
T-cel immuunsysteem wellicht een gunstiger prognose biedt in het kader van afstoting na 
niertransplantatie. Hierbij gaat het voornamelijk om een relatie met de aanwezigheid van 
veel CD4+CD28nul T-cellen. Deze cellen lijken beperkt in hun alloreactiviteit, maar of deze 
cellen de bepalende factor zijn in het voorkomen van rejectie is nog niet met zekerheid 
te zeggen. Hoogstwaarschijnlijk maken deze cellen meer een deel uit van een aangedaan 
immuunsysteem, dat minder in staat is om nieuwe antigenen te herkennen en hierop 
adequaat te reageren. Daarnaast zijn er belangrijke intra-individuele verschillen, omdat 
niet alle compartimenten in het lichaam even sterk zijn aangedaan door nierfunctieverlies. 
Hieruit volgt logischerwijs dat er meer diepgaand onderzoek nodig is op het gebied van 
veroudering bij patiënten met eindstadium nierfalen. In de bovenstaande onderzoeken 
lag de nadruk op de T-cellen. In vervolgonderzoeken zou de focus meer moeten liggen 
op de interactie van T-cellen met de B-cellen en/of de antigeen presenterende cellen 
in de verschillende compartimenten van het lichaam. Voor een completer beeld, is 
onderzoek op moleculair niveau, zoals transcriptiefactoren en micro-RNA, noodzakelijk, 
waarbij epigenetica een belangrijke rol kan spelen om in te grijpen in deze processen.
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Ronella, je was één van de eersten die mij de fijne technieken van het ficollen moest 
aanleren. Je ontspannen en geduldige werkwijze hebben ervoor gezorgd dat ik het snel 
onder de knie kreeg. Bedankt voor al je hulp.
Joke, ook jij was één van de eersten die mij aan de routinewerkzaamheden moest 
introduceren. Daarnaast was jij degene die wist waar alles stond, maar dan ook echt 
alles. Bedankt voor je hulp tijdens mijn promotie.
Marjolein, fijn om te weten dat er altijd iemand is waar je op kan terugvallen. Je hebt 
de nodige hulp aangeboden voor zowel routinewerkzaamheden als mijn experimenten. 
Bedankt dat je altijd klaar stond om te helpen.
Sander, we hebben zeker veel gelachen aan de lunchtafel dan wel in het lab. Dit werd 
voornamelijk veroorzaakt door je bijzondere gevoel voor humor. Daarnaast was je ook 
altijd erg behulpzaam. Bedankt hiervoor.
Annemiek, met jou kon ik over van alles praten. We hadden het dan over je huis of over 
je dochters, maar ook over onderzoek. Ook jij stond altijd klaar voor hulp. Bedankt voor 
de gezelligheid.
Mandy, de stagiaire die toch ook een tijdje (p’ongeluk) echt heeft gewerkt. Je bijzondere 
dansmoves en je goede gevoel voor humor zullen zeker niet vergeten worden. Bedankt 
voor de gezelligheid.
Elly, Ruben, Tanja, Thea and Frieda, thank you all for the nice times in the lab and also 
for your tips with regard to techniques in the lab and how to draw blood in the most 
comfortable way.
De nefrologen, Dennis, bedankt voor al je hulp en input die hebben bijgedragen aan mijn 
eerste twee publicaties van mijn promotieonderzoek. Annelies, bedankt voor de fijne en 
precieze samenwerking die heeft meegeholpen aan het ontstaan van twee hoofdstukken 
van dit proefschrift. Verder wil ik alle nefrologen bedanken die hebben meegeholpen aan 
de inclusie van patiënten en voor al hun input tijdens de verschillende meetings. 
De transplantatiechirurgen, Frank, bedankt voor je nauwe betrokkenheid bij een deel 
van mijn onderzoek en je bijdrage aan twee hoofdstukken van dit proefschrift. Verder 
wil ik alle transplantatiechirurgen bedanken voor hun medewerking aan het includeren 
van patiënten.
Brothers en sister, met jullie heb ik al veel meegemaakt sinds de 2e jaar van de studie. 
De verscheidenheid aan jullie persoonlijkheden heeft voor de nodige verfrissing gezorgd 
tijdens dit traject. De ontspannen (Caribische) houding van Tony (ook al heb je eigenlijk 
twee andere namen) gecombineerd met de kritische blikken van Sharif en de precisie van 
Cath, die weer aangevuld werden door Carlo’s boerenverstand vond ik heel waardevol. 
Daarnaast betekende het veel voor me wanneer we tijdens belangrijke momenten in ons 
leven altijd voor elkaar klaar stonden. Verder hebben de poolavonden, de etentjes en 
de movie nights voldoende afleiding gegeven. Bedankt voor de leuke afwisseling.
De co-groep, wat heb ik veel geluk gehad met zo een leuke co-groep die ik nog 
regelmatig zie. Het begon met Rob, Titia, Floor, Sahar, Debbie en Fatma, maar werd 
op een gegeven moment gezellig uitgebreid met de vriendjes en de vriendinnetjes die 
zelfs tot prachtige afkortingen hebben geleid (Florijn en T&T). De barbecues in het park, 
de weekendjes in Zeeland en alle andere gelegenheden die tevens de smikkelstand op 
hoge toeren lieten draaien, hebben zeker voor de nodige ontspanning gezorgd. Biggity 
bedankt jullie voor al deze leuke momenten.
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Lieve familie en kennissen, het maakt niet uit wanneer we bij elkaar komen, er zal altijd 
een oppasverhaal komen met een bijzondere herinnering eraan. Bedankt voor al jullie 
inzet tijdens mijn opvoeding en voor alle leuke momenten die voor de nodige afwisseling 
hebben gezorgd. Emekleriniz için hepinize tek tek tesekkür ederim.
Lieve mama, papa en Övgü, Sevgili annem, babam ve kardesim, bedankt voor al jullie 
steun, motivatie en vertrouwen die mij heel erg geholpen om dit traject te kunnen 
voltooien. Dankzij jullie ligt dit boekje nu in jullie handen. Babam, bedankt voor 
de discipline en de structuur die je me van kleins af aan al hebt aangeleerd. Annem, 
bedankt voor je heldere en praktische blik, die mij hielp om alles overzichtelijk te houden. 
Övgücügüm, bedankt voor al je vertrouwen en steun wat ervoor heeft gezorgd dat ik 
alles met je kon delen en bespreken. Size ne kadar tesekkür etsem azdır. Sizi biraz olsun 
gururlandırabildiysem ne mutlu bana.
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